Note: Descriptions are shown in the official language in which they were submitted.
s
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTS PART~E DE CETTE DEMANDS OU CE BREVET
COMPREND PLUS DUN TOME.
CECI EST LE TOME ~ DE
NOTE: Pour !es tomes additionels, veuillez contacter !e Bureau canadien des
brevets
JUMBO APPLICATIONSIPATENTS
THIS SECT10N OF THE APP~ICATION/PATENT CONTAINS MORE
THAN ONE VOLUME
THIS IS VOLUME ~_ OF
NOTE: For additional vo~umes.pi~ase~contact the Canadian Patent Office' . ,-
_ ____.~r_ .~...,___ _. _~.~.~..
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
186 Human Secreted Proteins
Field of the Invention
This invention relates to newly identified polynucleotides and the
polypeptides
encoded by these polynucleotides, uses of such polynucleotides and
polypeptides, and
their production.
Background of the Invention
Unlike bacterium, which exist as a single compartment surrounded by a
membrane, human cells and other eucaryotes are subdivided by membranes into
many
functionally distinct compartments. Each membrane-bounded compartment, or
organelle, contains different proteins essential for the function of the
organelle. The cell
uses "sorting signals," which are amino acid motifs located within the
protein, to target
proteins to particular cellular organelles.
One type of sorting signal, called a signal sequence, a signal peptide, or a
leader
sequence, directs a class of proteins to an organelle called the endoplasmic
reticulum
(ER). The ER separates the membrane-bounded proteins from all other types of
proteins. Once localized to the ER, both groups of proteins can be further
directed to
another organelle called the Golgi apparatus. Here, the Golgi distributes the
proteins to
vesicles, including secretory vesicles, the cell membrane, lysosomes, and the
other
organelles.
Proteins targeted to the ER by a signal sequence can be released into the
extracellular space as a secreted protein. For example, vesicles containing
secreted
proteins can fuse with the cell membrane and release their contents into the
extracellular
space - a process called exocytosis. Exocytosis can occur constitutively or
after receipt
of a triggering signal. In the latter case, the proteins are stored in
secretory vesicles {or
secretory granules) until exocytosis is triggered. Similarly, proteins
residing on the cell
membrane can also be secreted into the extracellular space by proteolytic
cleavage of a
"linker" holding the protein to the membrane.
Despite the great progress made in recent years, only a small number of genes
encoding human secreted proteins have been identified. These secreted proteins
include
the commercially valuable human insulin, interferon, Factor VIII, human growth
hormone, tissue plasminogen activator, and erythropoeitin. Thus, in light of
the
pervasive role of secreted proteins in human physiology, a need exists for
identifying
and characterizing novel human secreted proteins and the genes that encode
them. This
knowledge will allow one to detect, to treat, and to prevent medical disorders
by using
secreted proteins or the genes that encode them.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
2
Summary of the Invention
The present invention relates to novel polynucleotides and the encoded
polypeptides. Moreover, the present invention relates to vectors, host cells,
antibodies,
and recombinant methods for producing the polypeptides and polynucleotides.
Also
provided are diagnostic methods for detecting disorders related to the
polypeptides, and
therapeutic methods for treating such disorders. The invention further relates
to
screening methods for identifying binding partners of the polypeptides.
l0 Detailed Description
Definitions
The following definitions are provided to facilitate understanding of certain
terms used throughout this specification.
In the present invention, "isolated" refers to material removed from its
original
environment (e.g., the natural environment if it is naturally occurring), and
thus is
altered "by the hand of man" from its natural state. For example, an isolated
polynucleotide could be part of a vector or a composition of matter, or could
be
contained within a cell, and still be "isolated" because that vector,
composition of
matter, or particular cell is not the original environment of the
polynucleotide.
In the present invention, a "secreted" protein refers to those proteins
capable of
being directed to the ER, secretory vesicles, or the extracellular space as a
result of a
signal sequence, as well as those proteins released into the extracellular
space without
necessarily containing a signal sequence. If the secreted protein is released
into the
extracellular space, the secreted protein can undergo extracellular processing
to produce
a "mature" protein. Release into the extracellular space can occur by many
mechanisms, including exocytosis and proteolytic cleavage.
As used herein , a "polynucleotide" refers to a molecule having a nucleic acid
sequence contained in SEQ ID NO:X or the cDNA contained within the clone
deposited
with the ATCC. For example, the polynucleotide can contain the nucleotide
sequence
of the full length cDNA sequence, including the 5' and 3' untranslated
sequences, the
coding region, with or without the signal sequence, the secreted protein
coding region,
as well as fragments, epitopes, domains, and variants of the nucleic acid
sequence.
Moreover, as used herein, a "polypeptide" refers to a molecule having the
translated
amino acid sequence generated from the polynucleotide as broadly defined.
In the present invention, the full length sequence identified as SEQ ID NO:X
was often generated by overlapping sequences contained in multiple clones
(contig
T r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
analysis). A representative clone containing all or most of the sequence for
SEQ ID
NO:X was deposited with the American Type Culture Collection ("ATCC"). As
shown in Table l, each clone is identified by a cDNA Clone ID (Identifier) and
the
ATCC Deposit Number. The ATCC is located at 12301 Park Lawn Drive, Rockville,
Maryland 20852, USA. The ATCC deposit was made pursuant to the terms of the
Budapest Treaty on the international recognition of the deposit of
microorganisms for
purposes of patent procedure.
A "polynucleotide" of the present invention also includes those
polynucleotides
capable of hybridizing, under stringent hybridization conditions, to sequences
contained
in SEQ ID NO:X, the complement thereof, or the cDNA contained within the clone
deposited with the ATCC. "Stringent hybridization conditions" refers to an
overnight
incubation at 42° C in a solution comprising 50% formamide, Sx SSC (750
mM NaCI,
75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), Sx Denhardt's
solution,
10% dextran sulfate, and 20 ~tg/ml denatured, sheared salmon sperm DNA,
followed
by washing the filters in O.lx SSC at about 65°C.
Also contemplated are nucleic acid molecules that hybridize to the
polynucleotides of the present invention at lower stringency hybridization
conditions.
Changes in the stringency of hybridization and signal detection are primarily
accomplished through the manipulation of formamide concentration (lower
percentages
of formamide result in lowered stringency); salt conditions, or temperature.
For
example, lower stringency conditions include an overnight incubation at
37°C in a
solution comprising 6X SSPE (20X SSPE = 3M NaCI; 0.2M NaH2P04; 0.02M EDTA,
pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA;
followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to
achieve even
lower stringency, washes performed following stringent hybridization can be
done at
higher salt concentrations (e.g. SX SSC).
Note that variations in the above conditions may be accomplished through the
inclusion and/or substitution of alternate blocking reagents used to suppress
background in hybridization experiments. Typical blocking reagents include
Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and
commercially available proprietary formulations. The inclusion of specific
blocking
reagents may require modification of the hybridization conditions described
above, due
to problems with compatibility.
Of course, a polynucleotide which hybridizes only to polyA+ sequences (such
as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or
to a
CA 02283299 1999-09-02
WO 98/39448 PCT/LJS98I04493
4
complementary stretch of T (or U) residues, would not be included in the
definition of
"polynucleotide," since such a polynucleotide would hybridize to any nucleic
acid
molecule containing a poly (A) stretch or the complement thereof (e.g.,
practically any
double-stranded cDNA clone).
The polynucleotide of the present invention can be composed of any
polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or
DNA
or modified RNA or DNA. For example, polynucleotides can be composed of single-
and double-stranded DNA, DNA that is a mixture of single- and double-stranded
regions, single- and double-stranded RNA, and RNA that is mixture of single-
and
double-stranded regions, hybrid molecules comprising DNA and RNA that may be
single-stranded or, more typically, double-stranded or a mixture of single-
and double-
stranded regions. In addition, the polynucleotide can be composed of triple-
stranded
regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also
contain one or more modified bases or DNA or RNA backbones modified for
stability
or for other reasons. "Modified" bases include, for example, tritylated bases
and
unusual bases such as inosine. A variety of modifications can be made to DNA
and
RNA; thus, "polynucleotide" embraces chemically, enzymatically, or
metabolically
modified forms.
The polypeptide of the present invention can be composed of amino acids joined
to each other by peptide bonds or modified peptide bonds, i.e., peptide
isosteres, and
may contain amino acids other than the 20 gene-encoded amino acids. The
polypeptides may be modified by either natural processes, such as
posttranslational
processing, or by chemical modification techniques which are well known in the
art.
Such modifications are well described in basic texts and in more detailed
monographs,
as well as in a voluminous research literature. Modifications can occur
anywhere in a
polypeptide, including the peptide backbone, the amino acid side-chains and
the amino
or carboxyl termini. It will be appreciated that the same type of modification
may be
present in the same or varying degrees at several sites in a given
polypeptide. Also, a
given polypeptide may contain many types of modifications. Polypeptides may be
branched , for example, as a result of ubiquitination, and they may be cyclic,
with or
without branching. Cyclic, branched, and branched cyclic polypeptides may
result
from posttranslation natural processes or may be made by synthetic methods.
Modifications include acetylation, acylation, ADP-ribosylation, amidation,
covalent
attachment of flavin, covalent attachment of a heme moiety, covalent
attachment of a
nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid
derivative,
covalent attachment of phosphotidylinositol, cross-linking, cyclization,
disulfide bond
formation, demethylation, formation of covalent cross-links, formation of
cysteine,
r ._ T _w.._...._
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation,
GPI
anchor formation, hydroxylation, iodination, methylation, myristoylation,
oxidation,
pegylation, proteolytic processing, phosphorylation, prenylation,
racemization,
selenoylation, sulfation, transfer-RNA mediated addition of amino acids to
proteins
5 such as arginylation, and ubiquitination. (See, for instance, PROTEINS -
STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W.
H. Freeman and Company, New York (1993); POSTTRANSLATIONAL
COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic
Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646
(1990);
Rattan et al., Ann NY Acad Sci 663:48-62 ( 1992).)
"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y"
refers to a polypeptide sequence, both sequences identified by an integer
specified in
Table 1.
"A polypeptide having biological activity" refers to polypeptides exhibiting
activity similar, but not necessarily identical to, an activity of a
polypeptide of the
present invention, including mature forms, as measured in a particular
biological assay,
with or without dose dependency. In the case where dose dependency does exist,
it
need not be identical to that of the polypeptide, but rather substantially
similar to the
dose-dependence in a given activity as compared to the polypeptide of the
present
invention (i.e., the candidate polypeptide will exhibit greater activity or
not more than
about 25-fold less and, preferably, not more than about tenfold less activity,
and most
preferably, not more than about three-fold less activity relative to the
polypeptide of the
present invention.)
Polynucleotides and Polyp~tides of the Invention
FEATURES OF PROTEIN ENCODED BY GENE NO: 1
This gene is expressed primarily in testes tumor and to a lesser extent in
fetal
brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue{s) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to, cancer particularly of the testes, and defects of the central
nervous system
such as seizure and neurodegenerative disorders. Similarly, polypeptides and
antibodies
directed to these polypeptides are useful in providing immunological probes
for
differential identification of the tissues) or cell type(s). For a number of
disorders of
the above tissues or cells, particularly cancer of the testes and central
nervous system,
CA 02283299 1999-09-02
WO 98/39448 PCT/LJS98/04493
6
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., testes and other reproductive tissue,
brain and
other tissue of the nervous system, and blood cells, and spleen, and cancerous
and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
S fluid) or another tissue or cell sample taken from an individual having such
a disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment/diagnosis of testicular
cancer and
treatment of central nervous system disorders since this gene is primarily
expressed in
the testes tumor and developing brain.
FEATURES OF PROTEIN ENCODED BY GENE NO: 2
This gene is expressed primarily in cancer tissues, such as breast cancer and
IS Wilm's tumor, and to a lesser extent in fetal tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to, and/or tumors, particularly, those found in the breast, and
developmental
abnormalities or disorders. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the glandular tissues, expression of this gene at
significantly higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., mammary
2S tissue, and fetal tissue and, cancerous and wounded tissues) or bodily
fluids (e.g.,
serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or
cell sample
taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder. Preferred epitopes include those
comprising a
sequence shown in SEQ ID NO. 314 as residues: Pro-11 to Thr-18, Leu-43 to Pro-
S0,
Gly-64 to Leu-72, and Leu-81 to Lys-86.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment/diagnosis of cancers
and/or tumors,
particularly, those found in the breast since expression is mainly in
cancer/tumor
3S tissues. May serve as therapeutic proteins for
proliferation/differentiation of fetal
tissues.
r ~
CA 02283299 1999-09-02
WO 98!39448 PCT/US98/04493
7
FEATURES OF PROTEIN ENCODED BY GENE NO: 3
This gene is expressed primarily in CD34 depleted huffy coat and to a lesser
extent in spleen, chronic lymphocytic leukemia.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: blood
disorders or
leukemias, diseases of the immune system. Similarly, polypeptides and
antibodies
directed to these polypeptides are useful in providing immunological probes
for
differential identification of the tissues) or cell type(s). For a number of
disorders of
the above tissues or cells, particularly of the immune system, expression of
this gene at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., blood cells, and spleen, and cancerous and wounded tissues) or
bodily
fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment/diagnosis of blood
disorders or
leukemias, diseases of the immune system since expression is in tissues
related to
immune function.
FEATURES OF PROTEIN ENCODED BY GENE NO: 4
This gene is expressed primarily in CD34 depleted huffy coat.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: blood
disorders or
lymphocytic diseases. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the immune system, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., blood
cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma, urine,
synovial fluid or spinal fluid] or another tissue or cell sample taken from an
individual
having such a disorder, relative to the standard gene expression level, i.e.,
the
expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
H
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment/diagnosis of blood
disorders since
expression is in tissues related to immune function.
FEATURES OF PROTEIN ENCODED BY GENE NO: 5
This gene is expressed primarily in CD34 depleted huffy coat.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: blood or
immune
diseases. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the immune system, expression of this gene at significantly higher or lower
levels may
be routinely detected in certain tissues and cell types (e.g., blood cells,
and cancerous
and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid or
spinal fluid) or another tissue or cell sample taken from an individual having
such a
disorder, relative to the standard gene expression level, i.e., the expression
level in
healthy tissue or bodily fluid from an individual not having the disorder.
Preferred
epitopes include those comprising a sequence shown in SEQ ID NO. 317 as
residues:
Pro-13 to Lys-21.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment/diagnosis of blood
disorders since
expression is in tissues related to immune function.
FEATURES OF PROTEIN ENCODED BY GENE NO: 6
This gene is expressed primarily in CD34 depleted huffy coat.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: blood or
immune
diseases. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the immune system, expression of this gene at significantly higher or lower
levels may
be routinely detected in certain tissues and cell types (e.g., and blood
cells, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
9
in healthy tissue or bodily fluid from an individual not having the disorder.
Preferred
epitopes include those comprising a sequence shown in SEQ ID NO. 31$ as
residues:
Lys-31 to Lys-39.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment/diagnosis of blood
diseases since it
is expressed in tissues related to immune function.
FEATURES OF PROTEIN ENCODED BY GENE NO: 7
This gene is expressed primarily in CD34 depleted buffy coat and to a lesser
extent in pineal gland.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: diseases of
the immune
system and brain associated diseases. Similarly, polypeptides and antibodies
directed to
these polypeptides are useful in providing immunological probes for
differential
identification of the tissues) or cell type(s). For a number of disorders of
the above
tissues or cells, particularly of the immune system, expression of this gene
at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., blood cells, and pineal gland, and cancerous and wounded tissues)
or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment/diagnosis of blood
disorders,
immune diseases or brain associated diseases (specifically of the pineal
gland) since
expression is in tissues related to immune function.
FEATURES OF PROTEIN ENCODED BY GENE NO: 8
The translation product of this gene shares sequence homology with an organic
cation transporter which is thought to be important in organic cation uptake
in the
kidney and liver. (See Accession No. 2343059.) Preferred polypeptide fragments
comprise the amino acid sequence ITIAIQMICLVNXELYPT'FVRNXGVMVCSSLCDIGGIITP
FIVFRLREVWQALPLILFAVLGLLAAGVTLLLPETKGVALPETMKDAENLGRKAKPKENTIYLK
VQTSEPSGT (SEQ ID NO: 615) or TMKDAENLGRKAKPKENT (SEQ ID NO: 616) as well
as N-terminal and C-terminal deletions of these fragments. Also preferred are
polynucleotide fragments encoding these polypeptide fragments.
CA 02283299 1999-09-02
WO 98/39448 PCT/IJS98/04493
This gene is expressed primarily in liver.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: hepatic and
renal
5 diseases where drug elimination/cation exchange (organic cation uptake) in
the liver and
kidney are problematic. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the hepatic or renal system, expression of this gene at
significantly higher
10 or lower levels may be routinely detected in certain tissues and cell types
(e.g., kidney
and liver, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma,
urine, synovial fluid or spinal fluid) or another tissue or cell sample taken
from an
individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder. Preferred epitopes include those comprising a sequence shown in SEQ
ID
NO. 320 as residues: Asn-64 to Asn-74, and Gln-81 to Gly-87.
The tissue distribution and homology to organic canon transporter indicate
that
polynucleotides and polypeptides corresponding to this gene are useful as a
polyspecific
transporter that is important for drug elimination in the liver (and possibly
kidney) since
expression is found in the liver.
FEATURES OF PROTEIN ENCODED BY GENE NO: 9
This gene is expressed primarily in eosinophil induced with IL-5 and to a
lesser
extent in fetal liver and spleen. This gene also maps to chromosome 15, and
therefore
can be used in linkage analysis as a marker for chromosome 15.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: diseases of
the immune
system, particularly allergies or asthma. Similarly, polypeptides and
antibodies directed
to these polypeptides are useful in providing immunological probes for
differential
identification of the tissues) or cell type(s). For a number of disorders of
the above
tissues or cells, particularly of the immune system, expression of this gene
at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., blood cells, liver, and spleen, and cancerous and wounded
tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
CA 02283299 1999-09-02
WO 98/39448 PCT/US98104493
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treating/diagnosis of diseases
involving
esosinphil reactions since expression seems to be concentrated in eosinophils
and other
tissues involved in immunity such as the liver and spleen.
FEATURES OF PROTEIN ENCODED BY GENE NO: 10
This gene is expressed primarily in tissues of hematopoietic lineage and to a
lesser extent in Hodgkins lymphoma. Any frame shifts in this sequence can
easily be
clarified using known molecular biology techniques.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to, and immune deficiency or dysfunction. Similarly, polypeptides
and
antibodies directed to these polypeptides are useful in providing
immunological probes
for differential identification of the tissues) or cell type(s). For a number
of disorders
of the above tissues or cells, particularly of the immune system, expression
of this gene
at significantly higher or lower levels may be routinely detected in certain
tissues and
cell types (e.g., hematopoietic cells, lymphoid and reticuloendothelial
tissues, and
cancerous tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment/ diagnosis for lymphomas
or
immune dysfuction or as a therapeutic protein useful in immune modulation
based on
expression in anergic T-cells and lymphomas.
FEATURES OF PROTEIN ENCODED BY GENE NO: 11
This gene is expressed primarily in neutrophils and to a lesser extent in
activated
lymphoid cells.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the cell type present in a
biological sample and
for diagnosis of diseases and conditions: inflamation. Similarly, polypeptides
and
antibodies directed to these polypeptides are useful in providing
immunological probes
for differential identification of the tissues) or cell type(s). For a number
of disorders
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
12
of the above tissues or cells, particularly of the immune system, expression
of this gene
at significantly higher or lower levels may be routinely detected in certain
tissues and
cell types (e.g., blood cells and lymphoid tissue, and cancerous and wounded
tissues)
or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid)
or another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder. Preferred epitopes include
those
comprising a sequence shown in SEQ ID NO. 323 as residues: Glu-40 to Lys-46.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for modulation of an immune reaction or
as a
growth factor for the differentiation or proliferation of neutrphils for the
treatment of
neutropenia.
FEATURES OF PROTEIN ENCODED BY GENE NO: 12
This gene is expressed primarily in brain and to a lesser extent in activated
T-
cells. It is likely that the open reading frame containing the predicted
signal peptide
continues in the 5' direction. Preferred polypeptide fragments comprise the
amino acid
sequence PRVRNSPEDLGLSLTGDSCKL (SEQ ID N0:617).
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions:
neurodegenerative
disorders including ischemic shock, alzheimers and cognitive disorders.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the central
nervous
system, expression of this gene at significantly higher or lower levels may be
routinely
detected in certain tissues and cell types (e.g., blood cells, and brain, and
other tissue of
the nervous system and cancerous and wounded tissues) or bodily fluids (e.g.,
serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder. Preferred epitopes include those comprising a sequence shown in SEQ
ID
NO. 324 as residues: Ser-5 to Glu-14, Ile-21 to Pro-35, Ser-65 to Asp-81, Cys-
89 to
Val-96, Lys-136 to Ser-145, Ile-152 to Met-169, and Arg-189 to Lys-196.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnostic/treatment for cancers of
the given
tissue or in the treatment of neurological disorders of the CNS.
~ ...~...
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
t3
FEATURES OF PROTEIN ENCODED BY GENE NO: 13
This gene was also recently cloned by other groups, naming this calcium-
activated
potassium channel gene, hKCa4. (See Accession No. AF033021, see also,
Accession
No. 2584866.) This gene is mapped to human chromosome 19q13.2. A second signal
sequence likely exists upstream from the predicted signal sequence as
described in
Table 1. Preferred polypeptide fragments comprise: QADDLQATVAALCVLRGGGPWAG
SWLSPKTPGAMGGDLVLGLGALRRRKRLL (SEQ NO: 618); or EQEKSLAGWALVLAXXGIGL
MVLHAEMLWFGGCSAVNATGHLSDTLWLIPITFLTIGYGDVVPGTMWGKIVCLCTGVMGVCC
TALLVAVVARKLEFNKAEKHVHNFMMDIQYTKEMKESAARVLQEAWMFYKHTRRKESHAAR
XHQRXLLAAINAFRQV RLKHRKLREQVNSM VDIS KMHMILYDLQQNLSSSHRALEKQIDTLAG
KLDALTELLSTALGPRQLPEPSQQSK (SEQ ID NO: 619), as well as N-terminal and C-
terminal deletions. Also preferred are polynulcleotide fragments encoding
these
polypeptide fragments.
I S This gene is expressed primarily in breast lymph node and T-cells, and to
a
lesser extent in placenta.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: hematologic
and
immune disorders. Similarly, polypeptides and antibodies directed to these
polypeptides
are useful in providing immunological probes for differential identification
of the
tissues) or cell type(s). For a number of disorders of the above tissues or
cells,
particularly of the immune system, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., lymphoid
tissue, blood cells and placenta, and cancerous and wounded tissues) or bodily
fluids
(e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue
or cell
sample taken from an individual having such a disorder, relative to the
standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder. Preferred epitopes include those
comprising a
sequence shown in SEQ ID NO. 325 as residues: Arg-13 to Lys-23.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the treatment/diagnosis of
hematologic and
diseases involving immune modulation based or distribution in the lymph node
and T-
cells.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
14
FEATURES OF PROTEIN ENCODED BY GENE NO: 14
This gene was recently cloned by another group, calling it PAPS synethase.
(See Accession No. e1204135.) Preferred polypeptide fragments comprise the
amino
acid sequence YQAHHVSRNKRGQVVGTRGGFRGCTVWLTGLSGAGK (SEQ ID NO: 620).
Also preferred are the polynucleotide fragments encoding this polypeptide
fragment.
It has been discovered that this gene is expressed primarily in benign
prostate
hyperplasia, Human Umbilical Vein Endothelial Cells and to a lesser extent in
smooth
muscle and Human endometrial stromal cells-treated with estradiol.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: inflamation,
ischemia,
and restenosis, based on endothelial cell and smooth muscle cell expression,
and
prostate diseases such as benign prostate hyperplasia or prostate cancer.
Similarly,
polypeptides and antibodies directed to these poiypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the
prostate or vessels
of the circulatory system, expression of this gene at significantly higher or
lower levels
may be routinely detected in certain tissues and cell types (e.g., prostate,
endothelial
cells, smooth muscle, and endometrium, and cancerous and wounded tissues) or
bodily
fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder. Preferred epitopes include those
comprising a
sequence shown in SEQ ID NO. 326 as residues: Arg-21 to Asp-26, Lys-35 to Lys-
44,
Glu-49 to Asn-58.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treating/diagnosing diseases or
conditions
where the endothelial cell lining of the veins and arteries of underlying
smooth muscle
are involved.
FEATURES OF PROTEIN ENCODED BY GENE NO: 15
This gene is expressed primarily in human 6 week embryo and to a lesser extent
in placenta.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: developmental
anomalies or fetal deficiencies. Similarly, polypeptides and antibodies
directed to these
T ,. r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98104493
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly developmental in nature, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., embryonic
5 tissue, and placenta, and cancerous and wounded tissues) or bodily fluids
(e.g., serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder. Preferred epitopes include those comprising a sequence shown in SEQ
ID
10 NO. 327 as residues Lys-50 to Glu-57.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for detection of developmental
abnormalities.
FEATURES OF PROTEIN ENCODED BY GENE NO: 16
15 This gene is expressed primarily in kidney and amygdala and to a lesser
extent
in fetal tissues. This gene is mapped to chromosome 14, and therefore is
useful in
linkage analysis as a marker for chromosome 14.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) present in a
biological sample and
for diagnosis of diseases and conditions: kidney diseases, neurological
disorders and
developmental abnormalities. Similarly, polypeptides and antibodies directed
to these
polypeptides are useful in providing immunological probes for differential
identification
of the tissue(s). For a number of disorders of the above tissues, particularly
of the renal
system or developing fetal tissues, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., kidney,
amygdala, and fetal tissues, and cancerous and wounded tissues) or bodily
fluids (e.g.,
serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or
cell sample
taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment or diagnosis of conditions
affecting
the brain, kidneys and fetal development.
FEATURES OF PROTEIN ENCODED BY GENE NO: 17
This gene is expressed primarily in ovarian cancer.
CA 02283299 1999-09-02
WO 98139448 PCT/US98/04493
16
Therefore, polynucleotides and polypeptides of the invention are usefizl as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: solid tumors
similar to
ovarian cancer Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the reproductive system. expression of this gene at significantly higher or
lower levels
may be routinely detected in certain tissues and cell types (e.g., ovarian and
other
reproductive tissue, and cancerous and wounded tissues) or bodily fluids
(e.g., serum,
IO plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder. Preferred epitopes include those comprising a sequence shown in SEQ
ID
NO. 329 as residues Ser-51 to Val-56.
I S The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the treatment of solid tumors of the
reproductive system such as ovarian cancer.
FEATURES OF PROTEIN ENCODED BY GENE NO: 18
This gene is expressed primarily in brain medulloblastoma._ Preferred
polypeptide
fragments comprise the amino acid sequence: IRHEQHPNFSLEMHSKGSSLLLFLPQL
ILILPVCAHLHEELNC (SEQ ID NO: 643) and SFFISEEKGHLLLQAERHPWVAGALVGVSG
GLTLTTCSGPTEKPATKNYFL,KRLLQEMHIRAN (SEQ ID NO: 644), as well as N-terminal
and C-terminal deletions. Also preferred are polynucleotide fragments encoding
these
polypeptide fragments.
20 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: tumors
particularly of
the CNS or Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
25 or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the Central nervous system, expression of this gene at significantly higher or
lower
levels may be routinely detected in certain tissues and cell types (e.g.,
brain and other
tissue of the nervous system, and cancerous and wounded tissues) or bodily
fluids
(e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue
or cell
30 sample taken from an individual having such a disorder, relative to the
standard gene
~ T
CA 02283299 1999-09-02
WO 98/39448 PCT/CJS98/04493
17
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treating medulloblastoma or similar
tumors.
FEATURES OF PROTEIN ENCODED BY GENE NO: 19
This gene is expressed primarily in adipocytes.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: obesity.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the adipose
tissues
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., adipocytes and cancerous and wounded
tissues)
or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid)
or another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treating obesity by regulating the
function and
number of adipocytes
FEATURES OF PROTEIN ENCODED BY GENE NO: 20
This gene is expressed primarily in B cell lymphoma.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to, of the immune system with an emphasis on B cell lymphoma.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the tumors
of the
immune system, expression of this gene at significantly higher or lower levels
may be
routinely detected in certain tissues and cell types (e.g., blood cells, and
lymphoid
tissue, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma,
urine, synovial fluid or spinal fluid) or another tissue or cell sample taken
from an
individual having such a disorder, relative to the standard gene expression
level, i.e.,
CA 02283299 1999-09-02
WO 98/39448 PCT/ITS98104493
18
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of B cell
derived
tumors based on its expression in b cell lymphomas
FEATURES OF PROTEIN ENCODED BY GENE NO: 21
This gene is expressed primarily in immune cells and to a lesser extent in
fetal
tissues
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: inflammatory
diseases
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
immune expression of this gene at significantly higher or lower levels may be
routinely
detected in certain tissues and cell types (e.g., cells of the immune system,
and fetal
tissues, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma,
urine, synovial fluid or spinal fluid) or another tissue or cell sample taken
from an
individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder. Preferred epitopes include those comprising a sequence shown in SEQ
ID
N0:333 as residues Asp-10 to Pro-19, Ser-74 to Tyr-79, Glu-95 to Lys-110.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment of diseases involving
alterations in T
cell activity.
FEATURES OF PROTEIN ENCODED BY GENE NO: 22
It has been discovered that this gene is expressed primarily in ovarian tumor.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: tumors
particularly of
the ovary. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
tumors of the reproductive organs. expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., ovarian
T ,r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
19
and other reproductive tissue and cancerous and wounded tissues) or bodily
fluids
(e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue
or cell
sample taken from an individual having such a disorder, relative to the
standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder. Preferred epitopes include those
comprising a
sequence shown in SEQ ID NO. 334 as residues: Leu-22 to Gln-27.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of ovarian
tumors as it
has only been identified in ovarian tumors.
FEATURES OF PROTEIN ENCODED BY GENE NO: 23
It has been discovered that this gene is expressed primarily in fetal tissues
and to
a lesser extent in osteoclastoma cell line
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues} or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: osteoporosis
or arthritis
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
skeletal expression of this gene at significantly higher or lower levels may
be routinely
detected in certain tissues and cell types (e.g., bone cells, and fetal
tissue, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment of conditions of abnormal
bone
remodeling due to enhanced activity of osteoclasts. This may be useful as a
specific
marker for malignancies derived from osteoclasts or their precursors.
FEATURES OF PROTEIN ENCODED BY GENE NO: 24
The translation product of this gene shares sequence homology with a
periplasmic ribonuclease which is thought to be important in degrading
extracellular
polynucleotides
It has been discovered that this gene is expressed primarily in serum treated
smooth muscle cells
CA 02283299 1999-09-02
WO 98!39448 PCT/US98/04493
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: vascular
disease such as
restenosis. Similarly, polypeptides and antibodies directed to these
polypeptides are
5 useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the vasculature expression of this gene at significantly higher or lower
levels may be
routinely detected in certain tissues and cell types (e.g.> smooth muscle, and
cancerous
and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid or
10 spinal fluid) or another tissue or cell sample taken from an individual
having such a
disorder, relative to the standard gene expression level, i.e., the expression
level in
healthy tissue or bodily fluid from an individual not having the disorder.
Preferred
epitopes include those comprising a sequence shown in SEQ ID NO: 336 as
residues:
Gln-30 to Lys-36, and Pro-41 to Arg-48.
15 The tissue distribution and homology to ribonucleases indicate that
polynucleotides and polypeptides corresponding to this gene are useful for
treatment of
pathological conditions of smooth muscle associated with bacterial or viral
infiltration
FEATURES OF PROTEIN ENCODED BY GENE NO: 25
20 This gene is expressed primarily in Early Stage Human Brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: human brain
development and related diseases. Similarly, polypeptides and antibodies
directed to
these polypeptides are useful in providing immunological probes for
differential
identification of the tissues) or cell type(s). For a number of disorders of
the above
tissues or cells, particularly of the human brain development and related
diseases,
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., brain and other tissue of the nervous
system, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to this gene indicate that
polynucleotides
and polypeptides corresponding to this gene are useful for diagnosis and
treatment of
diseases affecting human brain development and related diseases.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
21
FEATURES OF PROTEIN ENCODED BY GENE NO: 26
It has been discovered that this gene is expressed primarily in human brain
tissue.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: human brain
diseases
and other diseases related to brain diseases, which may be caused by brain
diseases.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
human brain diseases, expression of this gene at significantly higher or lower
levels
may be routinely detected in certain tissues and cell types (e.g., brain and
other tissue of
the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g.,
serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution and homology to the gene indicate that polynucleotides
and polypeptides corresponding to this gene are useful for diagnosis and
treatment of
human brain diseases and other diseases related.
FEATURES OF PROTEIN ENCODED BY GENE NO: 27
It has been discovered that this gene is expressed primarily in Anergic T-
cells.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: immune
diseases,
inflammatory diseases and diseases related to T lymph cells. Similarly,
polypeptides
and antibodies directed to these polypeptides are useful in providing
immunological
probes for differential identification of the tissues) or cell type(s). For a
number of
disorders of the above tissues or cells, particularly of the immune diseases,
inflammatory diseases and diseases related to T lymph cells, expression of
this gene at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types {e.g., blood cells, and cancerous and wounded tissues) or bodily fluids
(e.g.,
serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or
cell sample
taken from an individual having such a disorder, relative to the standard gene
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
22
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution and homology to the gene indicate that polynucleotides
and polypeptides corresponding to this gene are useful for immune diseases,
inflammatory diseases and diseases related to T lymph cells.
FEATURES OF PROTEIN ENCODED BY GENE NO: 28
The translation product of this gene shares sequence homology with Shigella
flexneri positive transcriptional regulator CriR (criR) gene which is thought
to be
important in regulation of gene expression.
This gene is expressed primarily in human synovial sarcoma and normal human
brawn tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: human brain
diseases
particularly sarcomas of the synovium. Similarly, polypeptides and antibodies
directed
to these polypeptides are useful in providing immunological probes for
differential
identification of the tissues) or cell type(s). For a number of disorders of
the above
tissues or cells, particularly of the human brain and synovium and other
related human
brain diseases, expression of this gene at significantly higher or lower
levels may be
routinely detected in certain (e.g., synovial tissue, and brain and other
tissue of the
nervous system, and cancerous and wounded tissues) or bodily fluids (e.g.,
serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of human
synovial
sarcoma and other related human brain diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 29
This gene is expressed in bone marrow, infant brain, fetal liver and spleen,
prostate and to a lesser extent in pineal gland, adipose tissue, kidney,
adrenal gland,
umbilical vein endothelial cells, and T cells.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for identification of the tissues) or cell types) present in a
biological sample
and for diagnosis of diseases and conditions: diseases related to bone marrow
or
r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
23
hematoplastic tissues, prostate, kidney, adrenal gland, and cardiovascular
tissue or
organs. Similarly, polypeptides and antibodies directed to these polypeptides
are useful
in providing immunological probes for identification of the tissues) or cell
type(s). For
a number of disorders of the above tissues or cells, particularly of the
diseases related to
hematoplastic tissues, immune system, prostate, kidney, adrenal gland, and
cardiovascular tissue or organs, expression of this gene at significantly
higher or lower
levels may be routinely detected in certain tissues and cell types (e.g., bone
marrow,
hematopoietic cells, pineal gland, adipose tissue, kidney, adrenal gland,
endothelial
cells, and blood cells, and cancerous and wounded tissues) or bodily fluids
(e.g.,
serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or
cell sample
taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution and homology to the gene indicate that polynucleotides
and polypeptides corresponding to this gene are useful for diagnosis and
treatment of
diseases related to hematoplastic tissues, immune system, prostate, kidney,
adrenal
gland, and cardiovascular tissue or organs.
FEATURES OF PROTEIN ENCODED BY GENE NO: 30
This gene is expressed primarily in meningea and to a lesser extent in breast
and
adult brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: Diseases of
the
meningea and related brain diseases. Similarly, polypeptides and antibodies
directed to
these polypeptides are useful in providing immunological probes for
differential
identification of the tissues) or cell type(s). For a number of disorders of
the above
tissues or cells, particularly of the meningea and related brain diseases,
expression of
this gene at significantly higher or lower levels may be routinely detected in
certain
tissues and cell types (e.g., miningea, mammary tissue, and brain and other
tissue of
the nervous system, and cancerous and wounded tissues) or bodily fluids (e.g.,
serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
24
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of diseases
of the
meningea and related brain diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 31
This gene is expressed in meningea, fetal spleen, osteoblast and to a lesser
extent in activated T-cells, endometrial stromal cells, fetal lung, HL-60,
thymus, testis
and endothelial cells.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: meningeal
disease,
osteoporosis, immune diseases, and hematoplastic diseases. Similarly,
polypeptides
and antibodies directed to these polypeptides are useful in providing
immunological
probes for identification of the tissues) or cell type(s). For a number of
disorders of the
above tissues or cells, particularly of the meningeal diseases, osteoporosis,
immune
diseases, and hematoplastic diseases, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., blood
cells, endometrium, lung, thymus, testis, and endothelial cells, and cancerous
and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to gene indicate that polynucleotides and
polypeptides corresponding to this gene are useful for diagnosis and treatment
of
meningeal, osteoporosis, immune diseases, hematoplastic diseases, testis
diseases and
lung diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 32
This gene is expressed primarily in human thymus and to a much lesser extent
in infant brain, T-cells, smooth muscle, endothelial cells, bone marrow, human
ovarian
tumor and keratinocytes testes, osteoclastoma, breast, and tonsils.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: Diseases
involving the
thymus, particularly thymic cancer and diseases involving T-cell maturation.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). Far a
r. fi
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
number of disorders of the above tissues or cells, particularly of the thymus,
expression
of this gene at significantly higher or lower levels may be routinely detected
in certain
tissues and cell types (e.g., thymus, brain, and other tissue of the nervous
system,
blood cells, bone marrow, ovaries, and testes, and other reproductive tissue,
mammary
5 tissue, tonsils, melanocytes and cancerous and wounded tissues) or bodily
fluids (e.g.,
serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or
cell sample
taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
10 The tissue distribution and homology to gene indicate that polynucleotides
and
polypeptides corresponding to this gene are useful for diagnosis and treatment
of
diseases of the thymus particularly thymic cancer and diseases involving T-
cell
maturation.
15 FEATURES OF PROTEIN ENCODED BY GENE NO: 33
This gene is expressed primarily in human tonsils, and placenta, and to a
lesser
extent in adipocytes, melanocyte, and infant brain.
Therefore, poiynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
20 biological sample and for diagnosis of diseases and conditions:
inflammatory diseases,
immune diseases, and obesity. Similarly, polypeptides and antibodies directed
to these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the inflammatory diseases, immune diseases, and obesity,
expression of
25 this gene at significantly higher or lower levels may be routinely detected
in certain
tissues and cell types (e.g., tonsils, placenta, adipocytes, melanocytes, and
brain and
other tissue of the nervous system, and cancerous and wounded tissues) or
bodily
fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
The tissue distribution and homology to this gene indicate that
polynucleotides
and polypeptides corresponding to this gene are useful for diagnosis and
treatment of
diseases such as inflammation, immune diseases, and obesity.
CA 02283299 1999-09-02
WO 98/39448 PCT/LJS98/04493
26
FEATURES OF PROTEIN ENCODED BY GENE NO: 34
This gene is expressed in activated T cells, and to a lesser extent in
pituitary,
testis, and breast lymph node.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: diseases
relating to T
cells. Similarly, polypeptides and antibodies directed to these polypeptides
are useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
disorders of the immune system, expression of this gene at significantly
higher or lower
levels may be routinely detected in certain tissues and cell types (e.g.,
pituitary, testes
and other reproductive tissue, mammary tissue, and lymphoid tissue, and
cancerous
and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid or
spinal fluid) or another tissue or cell sample taken from an individual having
such a
disorder, relative to the standard gene expression level, i.e., the expression
level in
healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment of immune disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 35
This gene is expressed primarily in infant brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: neurological
disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
diseases relating to neurological disorders, expression of this gene at
significantly
higher or lower levels may be routinely detected in certain tissues and cell
types (e.g.,
brain, and other tissue of the nervous system, and cancerous and wounded
tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of
neurological
disorders.
~. r
CA 02283299 1999-09-02
WO 98139448 PCT/US98/04493
27
FEATURES OF PROTEIN ENCODED BY GENE NO: 36
This gene is expressed primarily in infant brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: neurological
disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
diseases relating to neurological disorders, expression of this gene at
significantly
higher or lower levels may be routinely detected in certain tissues and cell
types (e.g.,
brain and other tissue of the nervous system, and cancerous and wounded
tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of
neurological
disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 37
This gene is expressed primarily in human ovary.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: ovarian
cancer.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
ovarian disorders such as those involving germ cells, ovarian follicles,
stromal cells,
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., ovary and other reproductive tissue,
and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of
ovariopathy.
CA 02283299 1999-09-02
WO 98/39448 PCT/C1S98/04493
28
FEATURES OF PROTEIN ENCODED BY GENE NO: 38
This gene is expressed primarily in lymph node breast cancer.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: breast cancer.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the breast
cancer,
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., mammary tissue and lymphoid tissue,
and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for used as a diagnostic marker for
breast cancer.
FEATURES OF PROTEIN ENCODED BY GENE NO: 39
This gene is expressed primarily in brain and to a lesser extent in other
tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: neuronal
disorders such
as trauma, brain degeneration, and brain tumor. Similarly, polypeptides and
antibodies
directed to these polypeptides are useful in providing immunological probes
for
differential identification of the tissues) or cell type(s). For a number of
disorders of
the above tissues or cells, particularly of the brain, expression of this gene
at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., brain and other tissue of the nervous system, and cancerous and
wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and therapeutic treatment
of
neuronal disorders.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
29
FEATURES OF PROTEIN ENCODED BY GENE NO: 40
This gene is expressed in early stage human embryo, adrenal gland tumor, and
immune tissues such as fetal liver, fetal spleen, T-cell, and myoloid
progenitor cell line
and to a lesser extent in ovary, colon cancer, and a few orther tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: tumorigenesis
including
adrenal gland tumor, colon cancer and various other tumors, developmental and
immune disorders. Similarly, polypeptides and antibodies directed to these
polypeptides
are useful in providing immunological probes for differential identification
of the
tissues) or cell type(s). For a number of disorders of the above tissues or
cells,
particularly of the cancer tissues, early stage human tissues, and immune
system,
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., liver, spleen, blood cells, bone
marrow, ovary
and other reproductive tissue, and colon, and cancerous and wounded tissues)
or bodily
fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and therapeutic treatment
of immune
and developmental disorders, and tumorigenesis.
FEATURES OF PROTEIN ENCODED BY GENE NO: 41
This gene is expressed primarily in fetal lung, endothelial cells, liver,
thymus
and a few other immune tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: immune
disorders such
as immune deficiency and autoimmune diseases, pulmonary diseases, liver
diseases,
and tumor matasis. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the fetal lung, liver, endothelial cells, and immune tissues,
expression of
this gene at significantly higher or lower levels may be routinely detected in
certain
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
tissues and cell types (e.g., lung, endothelial cells, liver, thymus, and
other tissue of
the immune system, and cancerous and wounded tissues) or bodily fluids (e.g.,
serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
5 the expression level in healthy tissue or bodily fluid from an individual
not having the
disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis of immune disorders and
pulmonary
and hepatic diseases. Its promoter may also be used for immune system and lung-
10 specific gene therapies. The expression of this gene in endothelial cells
indicates that it
may also involve in angiogenesis which therefore may play role in tumor
matasis.
FEATURES OF PROTEIN ENCODED BY GENE NO: 42
This gene is expressed primarily in liver, thyroid, parathyroid and to a
lesser
I S extent in fetal lung, stomach and early embryos.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: metabolic
regulation,
obesity, heptic failure, heptacellular tumors or thyroiditis and thyroid
tumors. Similarly,
20 polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the
digestive/endocrine
system expression of this gene at significantly higher or lower levels may be
routinely
detected in certain tissues and cell types (e.g., liver, thyroid, parathyroid,
lung,
25 stomach, and embryonic tissue, and cancerous and wounded tissues) or bodily
fluids
(e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue
or cell
sample taken from an individual having such a disorder, relative to the
standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
30 The tissue distribution and the extracellular locations indicates that
polynucleotides and polypeptides corresponding to this gene are useful for the
detection
and treatment of digestivelendocrine disorders, including metabolic
regulation, heptic
failure, malabsortion, gastritis and neoplasrns.
r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
31
FEATURES OF PROTEIN ENCODED BY GENE NO: 43
This gene is expressed primarily in Schizophrenic adult brain, pituitary,
front
cortex, hypothalmus and to a lesser extent in retina, adipose and stomach
cancer and
placenta.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: schizophrenia
and other
neurological disorders. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the central nerve system, expression of this gene at
significantly higher
or lower levels may be routinely detected in certain tissues and cell types
(e.g., retinal
tissue, adipose, stomach, and placenta, and cancerous and wounded tissues) or
bodily
fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful in treatmentldetection of disorders in
the nerve
system, including schizophrenia, neurodegeneration, and neoplasia.
Additionally, a
secreted protein in brain may serve as an endocrine.
FEATURES OF PROTEIN ENCODED BY GENE NO: 44
The translation product of this gene shares sequence homology with GTP
binding proteins which are thought to be important in signal transduction and
protein
transport.
This gene is expressed primarily in umbilical vein and microvascular
endothelial
cells, GM-CSF treated macrophage, anergic T cells, osteoblast, osteoclast,
CD34+ cells
and to a lesser extent in gall bladder.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: bone formation
and
growth, osteonecrosis, osteoporosis, angiogenesis and/or hematopoeisis.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the
skeletal and
hematopoeisis systems, expression of this gene at significantly higher or
lower levels
CA 02283299 1999-09-02
WO 98/39448 PCT/US98104493
32
may be routinely detected in certain tissues and cell types (e.g., endothelial
cells, blood
cells, bone, and gall bladder, and cancerous and wounded tissues) or bodily
fluids
(e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue
or cell
sample taken from an individual having such a disorder, relative to the
standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution and homology to GTP binding proteins indicate that
polynucleotides and polypeptides corresponding to this gene are useful for
treatment/detection of bone formation and growth, osteonecrosis, osteoporosis,
and/or
hematopoeisis because its involvement in the growth signaling or angiogenesis.
FEATURES OF PROTEIN ENCODED BY GENE NO: 45
The translation product of this gene shares sequence homology with signal
sequence receptor gamma subunit which is thought to be important in protein
translocation on endoplasmic reticulum.
This gene is expressed primarily in adrenal gland, salivary gland, prostate,
and
to a lesser extent in endothelial cells and smooth muscle.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: protein
secretion.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
secretory organs, expression of this gene at significantly higher or lower
levels may be
routinely detected in certain tissues and cell types (e.g., adrenal gland,
salivary gland,
prostate, endothelial cells, and smooth muscle, and cancerous and wounded
tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution and homology to SSR gamma subunit indicate that
polynucleotides and polypeptides corresponding to this gene are useful for
endocrine
disorders, prostate cancer, xerostomia or sialorrhea.
FEATURES OF PROTEIN ENCODED BY GENE NO: 46
This gene is expressed primarily in osteoclastoma cells and to a lesser extent
in
melanocyte, amygdala, brain, and stomach.
r i
CA 02283299 1999-09-02
WO 98/39448 PCT/US98104493
33
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: ossification,
- osteoporosis, fracture, osteonecrosis, osteosarcoma. Similarly, polypeptides
and
antibodies directed to these polypeptides are useful in providing
immunological probes
for differential identification of the tissues) or cell type(s). For a number
of disorders
of the above tissues or cells, particularly of the skeletal systems,
expression of this gene
at significantly higher or lower levels may be routinely detected in certain
tissues and
cell types (e.g., melanocytes, amygdala, brain and other tissue of the nervous
system,
and stomach, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful in intervention of ossification,
osteoporosis,
fracture, osteonecrosis and osteosarcoma.
FEATURES OF PROTEIN ENCODED BY GENE NO: 48
The translation product of this gene shares sequence homology with proline
rich
proteins which is thought to be important in protein-protein interaction.
This gene is expressed primarily in brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: neurological
and
psychological disorders. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the central nerve system and endocrine system, expression of
this gene at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., brain and other tissue of the nervous system, and cancerous and
wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
fluid from an individual not having the disorder.
The tissue distribution and homology to proline-rich proteins indicate that
polynucleotides and polypeptides corresponding to this gene are useful in
intervention
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
34
and detection of neurological diseases, including trauma, neoplasia,
degenerative or
metabolic conditions in the central nerve system. Additionally, the gene
product may be
a secreted by the brain as an endocrine.
FEATURES OF PROTEIN ENCODED BY GENE NO: 49
The translation product of this gene shares sequence homology with the AOCB
gene from Aspergillus nidulans which is important in asexual development.
This gene is expressed primarily in infant brain and to a lesser extent in the
developing embryo, trachea tumors, B-cell lymphoma and synovial sarcoma.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions:
neurodegenerative
diseases, leukemia and sarcoma's. Similarly, polypeptides and antibodies
directed to
these polypeptides are useful in providing immunological probes for
differential
1 S identification of the tissues) or cell type(s). For a number of disorders
of the above
tissues or cells, particularly of the brain and immune system, expression of
this gene at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., embryonic tissue, blood cells, trachea, and synovial tissue, and
cancerous
and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid or
spinal fluid) or another tissue or cell sample taken from an individual having
such a
disorder, relative to the standard gene expression level, i.e., the expression
level in
healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution in infant brain and sarcoma's and homology to a gene
involved in a key step of eukaryotivc development (fungal spore formation)
indicates
that the protein product of this clone could play a role in neurological
diseases such as
schizophrenia, particularly in infants. The existence of the gene in a B-cell
lymphoma
indicates the gene may be used in the treatment and detection of leukemia.
FEATURES OF PROTEIN ENCODED BY GENE NO: 50
This gene is expressed primarily in fetal lung.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: pulmonary
disorders
including lung cancer. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the pulmonary system, expression of this gene at significantly
higher or
r r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
lower levels may be routinely detected in certain tissues and cell types
(e.g., lung, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
5 in healthy tissue or bodily fluid from an individual not having the
disorder.
The tissue distribution of this gene only in fetal lung indicates that it
plays a key
role in development of the pulmonary system. This would suggest that
misregulation of
the expression of this protein product in the adult could lead to lymphoma or
sarcoma
formation, particularly in the lung. It may also be involved in predisposition
to certain
10 pulmonary defects such as pulmonary edema and embolism, bronchitis and
cystic
fibrosis.
FEATURES OF PROTEIN ENCODED BY GENE NO: 51
This gene is expressed primarily in hernatopoietic cell types and fetal cells
and to
15 a lesser extent in all tissue types.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: defects in the
immune
system and hematopoeisis. Similarly, polypeptides and antibodies directed to
these
20 polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the immune and hematopoietic systems, expression of this gene
at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., hematopoietic cells, and fetal tissue, and cancerous and wounded
tissues)
25 or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal
fluid) or another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution of this gene predominantly in hematopoeitic cells and
in
30 the developing embryo indicates that polynucleotides and polypeptides
corresponding to
this gene are useful for detection and treatment of lymphomas and disease
states
affecting the immune system or hematopoeisis disorders such as leukemia, AIDS,
arthritis and asthma..
35 FEATURES OF PROTEIN ENCODED BY GENE NO: 52
This gene is expressed primarily in prostate and to a lesser extent in fetal
spleen,
fetal liver, infant brain and T cell leukemias.
CA 02283299 1999-09-02
WO 98/39448 PCT/ITS98/04493
36
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: prostate
disorders,
prostate cancer, leukemia. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the immune system, and/or prostate gland expression of this
gene at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., thymus, spleen, liver, brain and other tissue of the nervous
system, and
blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma,
urine, synovial fluid or spinal fluid) or another tissue or cell sample taken
from an
individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution of this gene in prostate indicates that
polynucleotides and
polypeptides corresponding to this gene are useful for detection or treatment
of prostate
disorders or prostate cancer. Its distribution in fetal liver and fetal spleen
indicates it
may play a role in the immune system and its misregulation could lead to
immune
disorders such as leukemia, arthritis and asthma.
FEATURES OF PROTEIN ENCODED BY GENE NO: 53
The translation product of this gene shares sequence homology with dynein.
This gene is expressed primarily in brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: neuro-
degenerative
diseases of the brain. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly neuro-degenerative diseases expression of this gene at
significantly higher
or lower levels may be routinely detected in certain tissues and cell types
(e.g., brain
and other tissue of the nervous system, and cancerous and wounded tissues) or
bodily
fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
r r
CA 02283299 1999-09-02
WO 98/39448 PCT/L1S98/04493
37
The predominant tissue distribution in the brain and homology to dynein, a
microtubule motor protein involved in the positioning of cellular organelles
and
molecules indicates that polynucleotides and polypeptides corresponding to
this gene
are useful for detection/treatment of neurodegenerative diseases, such as
Alzheimers,
Huntigtons, Parkinsons diseases and shizophrenia.
FEATURES OF PROTEIN ENCODED BY GENE NO: 54
The translation product of this gene shares sequence homology with ubiquitin-
conjugation protein, an enzyme which is thought to be important in the
processing of
the Huntingtons Disease causing gene.
This gene is expressed primarily in brain and to a lesser extent in activated
macrophages.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
I S biological sample and for diagnosis of diseases and conditions:
neurodegenerative
disease states including Huntington's disease. Similarly, polypeptides and
antibodies
directed to these polypeptides are useful in providing immunological probes
for
differential identification of brain tissues. For a number of disorders of the
above
tissues or cells, particularly of the neurological systems expression of this
gene at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types {e.g., brain and other tissue of the nervous system, and blood cells,
and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The predominant tissue distribution of this gene in the brain and its homology
to
a Huntington interacting protein indicates that polynucleotides and
polypeptides
corresponding to this gene are useful for the regulation of the expression of
the
Huntington disease gene and other neurodegenerative diseases including
spinocerebullar ataxia types I and III, dentatorubropallidoluysian and spinal
bulbar
muscular atrophy. In addition, the existence of elevated levels of free
ubiquitin pools in
Alzheimer's disease, Parkinson's disease and amylotrophic lateral sclerosis
indicates
that the ubiquitin pathway of protein degradation plays a role in these
disease states.
Thus, considering the gene described here is homologous to a ubiquitin-
conjugation
protein it may play a general role in neurodegenarative conditions.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
38
FEATURES OF PROTEIN ENCODED BY GENE NO: 56
This gene is expressed primarily in T-cells (anergic T-cells, resting T-Cells,
apoptotic T-cells) and lymph node (breast), as well as brain (hypothalamus,
hippocampus, pituitary, infant brain, early-stage brain).
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: immune (e.g.
immunodeficiencies, autoimmunities, inflammation, leukemias & lymphomas) and
neurological (e.g. Alzheimer's disease, dementia, schizophrenia) disorders.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the central
nervous,
hematopoietic and immune systems, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., blood
cells, lymphoid tissue, and brain and other tissue of the nervous system, and
cancerous
and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid or
spinal fluid) or another tissue or cell sample taken from an individual having
such a
disorder, relative to the standard gene expression level, i.e., the expression
level in
healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful in the intervention or detection of
pathologies
associated with the hematopoietic and immune systems, such as anemias
(leukemias).
In addition, the expression in brain (including fetal) might suggest a role in
developmental brain defects, neuro-degenerative diseases or behavioral
abnomalities
(e.g. schizophrenia, Alzheimer's, dementia, depression, etc.).
FEATURES OF PROTEIN ENCODED BY GENE NO: 57
This gene is expressed primarily in lung, and to a lesser extent in a variety
of
other hematological cell types (e.g. Raji cells, bone marrow cell line,
activated
monocytes).
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: pulmonary
and/or
hematological disfunction. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the vasculo-pulmonary and hematopoietic systems, expression of
this
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
39
gene at significantly higher or lower levels may be routinely detected in
certain tissues
and cell types (e.g., lung and blood cells, and cancerous and wounded tissues)
or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful in the intervention and detection of
pathologies
associated with the vasculo-pulmonary system. In addition the expression of
this gene
in a variety of leukocytic cell types and a bone marrow cell line might
suggest a role in
hematopoietic and immune system disorders, such as leukemias & lymphomas,
inflammation, immunodeficiencies and autoimmunities.
FEATURES OF PROTEIN ENCODED BY GENE NO: 58
The translation product of this gene shares sequence homology with adenylate
kinase isozyme 3 (gi1163528 GTP:AMP phosphotransferase {EC 2.7.4.10) [Bos
taurus]), which is thought to be important in catalyzing the phosphorylation
of AMP to
ADP in the presence of ATP or inorganic triphosphate.
This gene is expressed primarily in fetal liver, heart and placenta, and to a
lesser
extent in many other tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: hepatic,
cardiovascular
or reproductive disorders. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the hepatic, cardiovascular and reproductive systems,
expression of this
gene at significantly higher or lower levels may be routinely detected in
certain tissues
and cell types (e.g., liver, heart, and placenta, and cancerous and wounded
tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the treatment and diagnosis of
conditions
related to hepatic function and pathogenesis, in particular, those dealing
with liver
development and the differentiation of hepatocyte progenitor cells.
CA 02283299 1999-09-02
WO 98/39448 PCT/LTS98/04493
FEATURES OF PROTEIN ENCODED BY GENE NO: 59
This gene is expressed primarily in CD34 positive cells (Cord Blood).
Therefore, polynucleotides and polypeptides of the invention are useful as
5 reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: hematopoietic
differentiation and immune disorders. Similarly, polypeptides and antibodies
directed to
these polypeptides are useful in providing immunological probes for
differential
identification of the tissues) or cell type(s). For a number of disorders of
the above
10 tissues or cells, particularly of hematopoietic and immune systems,
expression of this
gene at significantly higher or lower levels may be routinely detected in
certain tissues
and cell types (e.g., hematopoietic cells, and blood cells, and cancerous and
wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
15 the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful in the detection and treatment of
conditions
associated with CD34-positive cells, and therefore as a marker for cell
differentiation in
20 hematapoiesis, as well as immunological disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 60
The translation product of the predicted open reading frame of this contig has
sequence identity to the murine gene designated Insulin-Like Growth Factor-
Binding
25 Protein (IGFBP)-1 as described by Lee and colleagues (Hepatology 19 (3),
656-665
( 1994)).
This gene is expressed exclusively in hemangiopericytoma.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
30 biological sample and for diagnosis of hemangiopericytoma and other
pericyte or
endothelial cell proliferative disorders. Similarly, polypeptides and
antibodies directed
to these polypeptides are useful in providing immunological probes for
differential
identification of the tissues) or cell type(s). For a number of disorders of
the above
tissues or cells, particularly of the circulatory and immune systems,
expression of this
35 gene at significantly higher or lower levels may routinely be detected in
certain tissues
and cell types (e.g., pericyte or endothelial cells, and liver, and cancerous
and wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or
t
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
4t
another tissue or cell sample taken from an individual having such a disorder,
relative to
the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
fluid from an individual not having the disorder.
Polynucleotides and polypeptides corresponding to this gene are useful as cell
growth regulators since IGFBP-1-like molecules function as modulators of
insulin-like
growth factor activity. In addition, since IGFBP-1 is expressed at high levels
following hepatectomy and during fetal liver development, polynucleotides of
the
present invention may also be used for the diagnosis of developmental
disorders.
Further, polypeptides of the present invention may be used therapeutically to
treat
developmental liver disorders as well as to regulate hepatocyte and supporting
cell
growth following hepatectomy or to treat liver disorders.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of
hemangiopericytoma and liver disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: bl
This gene is expressed primarily in schizophrenic frontal cortex.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: nervous system
and
cognitive disorders. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the frontal cortex and CNS expression of this gene at
significantly higher
or lower levels may be routinely detected in certain tissues and cell types
(e.g., brain
and other tissue of the nervous system, and cancerous and wounded tissues) or
bodily
fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for study, treatment and diagnosis of
frontal
cortex, neuro-degenerative and CNS disorders
FEATURES OF PROTEIN ENCODED BY GENE NO: 62
This gene is expressed primarily in human adrenal gland tumor, and to a lesser
extent in human kidney, medulla and adult pulmonary tissue.
CA 02283299 1999-09-02
WO 98/39448 PCT/C1S98/04493
42
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: metabolic,
endocrine
disorders. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the endocrine and nervous system disorders and neoplasia, expression of this
gene at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., adrenal gland, kidney, brain and other tissue of the nervous
system,
pulmonary tissue, and cancerous and wounded tissues) or bodily fluids (e.g.,
serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for study, treatment and diagnosis of
neurological
and endocrine disorders including neoplasia.
FEATURES OF PROTEIN ENCODED BY GENE NO: 63
This gene is expressed primarily in human adipocytes, and to a lesser extent
in
spleen, 12-week old human, and testes.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: immune,
metabolic and
growth disorders. Similarly, polypeptides and antibodies directed to these
polypeptides
are useful in providing immunological probes for differential identification
of the
tissues) or cell type(s). For a number of disorders of the above tissues or
cells,
particularly of the immune system, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., adipocytes,
spleen, and testes and other reproductive tissue, and cancerous and wounded
tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for study, diagnosis and treatment of
immune,
developmental and metabolic disorders.
CA 02283299 1999-09-02
WO 98/39448 PCTIUS98/04493
43
FEATURES OF PROTEIN ENCODED BY GENE NO: 64
One translated product of this clone is homologous to the mouse zinc finger
protein
PZF. (See Accession No. 453376; see also Gene 152 (2), 233-238 ( 1995).)
Preferred
polypeptide fragments correspond to the highly conserved domains shared
between
mouse and man. For example, preferred polypeptide fragments comprise the amino
acid
sequence: LQCEICGFTCRQKASLNWHMKKHDADSFYQFSCNICGKKFEKKDSVVAHKAKSH
PEV (SEQ ID NO: 621 ); ITSTDILGTNPESLTQPSD (SEQ ID NO: 622); NSTSGECLLLEAEGM
SKSY (SEQ ID NO: 623); CSGTERVSLMADGKIFVGSGSSGGTEGLVMNSDILGATTEVLIEDSD
SAGP (SEQ ID NO: 624); IQYVRCEMEGCGTVLAHPRYLQHHIKYQHLLKKKYVCPHPSCGRLF
RLQKQLLRHAKHHT (SEQ ID NO: 625); DQRDYICEYCARAFKSSHNLAVHRMIHTGEK (SEQ
ID NO: 626); RSSRTSVSRHRDTENTRSSRSKTGSLQLICKSEPNTDQLDY (SEQ ID NO: 627);
PFKDDPRDETYKPHLERETPKPRRKSG (SEQ ID NO: 630); QYVRCEMEGCGTVLAHPRYLQ
HHIKYQHLLKKKYVCPHPSCGRLFRLQKQLLRHAKHHTD (SEQ ID NO: 629); or residues
151-182 of QRDYICEYCARAFKSSHNLAVHRMIHTGEKHY (SEQ ID NO: b28). Also preferred
are polynucleotide fragments encoding these polypeptide fragments.
This gene is expressed primarily in Rhabdomyosarcoma, melanocyte and colon
cancer tissue and to a lesser extent in smooth muscle, pancreatic tumor, and
apoptotic
T-cells.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to,. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the immune and hemopoetic, expression of this gene at significantly higher or
lower
levels may be routinely detected in certain tissues and cell types (e.g.,
striated muscle,
melanocytes, colon, smooth muscle, pancreas, and blood cells, and cancerous
and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for study, diagnosis and treatment of
cancer and
hemopoetic disorders.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98104493
44
FEATURES OF PROTEIN ENCODED BY GENE NO: 65
This gene is expressed primarily in human adipose and salivary gland tissue
and
to a lesser extent in human bone marrow and fetal kidney.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: metabolic and
immune
disorders. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the metabolic and hemopoetic systems, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., adipose,
salivary gland, bone marrow, and kidney, and cancerous and wounded tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for study, diagnosis of metabolic and
immune
disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 66
This translated product of this gene was recently identified as oxytocinase
splice variant
1. (See Accession Nos. 2209276 and d1010078.) Preferred polypeptide fragments
comprise the amino acid sequence: EMFDSLSYFKGSSLLLMLKTYLSEDVFQHAVVLYLHN
HSYASIQSDDLWDSFNEVTNQTLDVKRMMKTWTLQKGFPLVTVQKKGKELFIQQERFFLNMK
PEIQPSDTRYM (SEQ ID NO: 631 ). Also preferred are polynucleotide fragments
encoding
this polypeptide fragment.
FEATURES OF PROTEIN ENCODED BY GENE NO: 67
This gene is expressed primarily in hemopoetic cells, particularly apoptotic T-
cells, and to lesser extent in primary dendritic cells and adipose tissue.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of apoptotic T-cells, primary
denritic cells, and
adipose tissue present in a biological sample and for diagnosis of diseases
and
conditions: hemopoetic diseases including cancer and general immune disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
r ?
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
type(s). For a number of disorders of the above tissues or cells, particularly
of the oral
and intestinal mucosa as well as hemopoetic and immune systems, expression of
this
gene at significantly higher or lower levels may be routinely detected in
certain tissues
and cell types (e.g., hematopoietic cells, and cancerous and wounded tissues)
or bodily
5 fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
10 corresponding to this gene are useful for treatment of diseases of the
immune system,
including cancer, hemopoetic and infectious diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 68
This gene is expressed primarily in kidney cortex and to a lesser extent in
infant
15 brain, heart, uterus, and blood.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of kidney tissue present in a
biological sample and
for diagnosis of diseases and conditions: soft tissue cancer, inflammation,
kidney
fibrosis. Similarly, polypeptides and antibodies directed to these
polypeptides are useful
20 in providing immunological probes for differential identification of the
tissues) or cell
type{s). For a number of disorders of the above tissues or cells, particularly
of the
nervous and endocrines systems, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., kidney,
brain, and other nervous tissue, heart, uterus, and blood cells, and cancerous
and
25 wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
30 corresponding to this gene are useful for study and treatment of cancer and
fibroses.
FEATURES OF PROTEIN ENCODED BY GENE NO: 69
The translation product of this gene shares strong sequence homology with
vertebrate and invertebrate protein tyrosine phosphatases.
35 This gene is expressed primarily in endometrial tumors, melanocytes,
myeloid
progenitors and to a lesser extent in infant brain, adipocytes, and several
hematopoietic
stem cells.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
46
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of transformed hematopoietic and
epithelial cells
present in a biological sample and for diagnosis of diseases and conditions
which
include, but are not limited to, of skin and endometrium, leukemia. Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the nervous
and
hemopoietic systems, expression of this gene at significantly higher or lower
levels may
be routinely detected in certain tissues and cell types (e.g., endometrium,
melanocytes,
bone marrow, adipocytes, hematopoietic cells, and brain and other tissue of
the nervous
system, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma,
urine, synovial fluid or spinal fluid) or another tissue or cell sample taken
from an
individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution and sequence similarity with tyrosine phosphatases
indicate that polynucleotides and polypeptides corresponding to this gene are
useful for
study and treatment of cancer and hematopoietic disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 70
This gene is expressed primarily in osteoclastoma, breast, and infant brain
and
to a lesser extent in various fetal and transformed bone, ovarian, and
neuronal cells.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: degenerative
conditions
of the brain and skeleton. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the nervous and skeletal system, expression of this gene at
significantly
higher or lower levels may be routinely detected in certain tissues and cell
types (e.g.,
bone, mammary tissue, and brain and other tissue of the nervous system, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
1.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
47
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for study and treatment of degenerative,
neurological and skeletal disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 71
This gene was originally cloned from tumor cell lines. Recently another group
has also cloned this gene, calling it the human malignant melanoma metastasis-
suppressor (KISS-1) gene. (See Accession No. U43527.) Preferred polypeptide
fragments comprise the amino acid sequence: LEKVASVGNSRPTGQQLESLGLLA (SEQ ID
NO: 632); VHREEASCYCQAEPSGDL {SEQ ID NO: 633); RPALRQAGGGTREPRQKRWAGL
(SEQ ID NO: 634); and AVNFRPQRSQSM (SEQ ID NO: 635). Any frame shifts can
easily be
resolved using known molecular biology techniques.
This gene is expressed primarily in many types of carcinomas and to a lesser
extent in many normal organs.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues(s) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to, cancer particularly melanomas, and other hypeiproliferative
disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of
transformed organ tissue, expression of this gene at significantly higher or
lower levels
may be routinely detected in certain tissues and cell types (e.g., cancerous
and wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
fluid from an individual not having the disorder. As a tumor suppressor gene,
increase
amounts of the polypeptide can be used to treat patients having a particular
cancer.
The tissue distribution indicates that this gene and the translated product is
useful for diagnosing and study of cancer.
FEATURES OF PROTEIN ENCODED BY GENE NO: 72
This gene is expressed primarily in striatum and to a lesser extent in
adipocytes
and hemangioperiocytoma.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of striatal cells present in a
biological sample and
for diagnosis of diseases and conditions: neurological, fat and lysosomal
storage
CA 02283299 1999-09-02
WO 98/39448 PCT/LJS98104493
48
diseases. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the nervous and immune systems, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., striatal
tissue, adipocytes, and vascular tissue, and cancerous and wounded tissues) or
bodily
fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis, study and treatment of
neurodegenerative and growth disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 73
This gene is expressed primarily in bone marrow stromal cells and to a lesser
extent in smooth muscle, testes, endothelium, and brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of bone marrow present in a
biological sample and
for diagnosis of diseases and conditions: connective tissue and hematopoietic
diseases.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
skeletal and hematopoietic systems, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., bone
marrow, stromal cells, smooth muscle, testes and other reproductive tissue,
endothelium, brain and other tissue of the nervous system, and cancerous and
wounded
tissues) or bodily fluids {e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynueleotides and polypeptides
corresponding to this gene are useful for study, diagnosis, and treatment of
connective
tissue and blood diseases.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
49
FEATURES OF PROTEIN ENCODED BY GENE NO: 74
This gene is expressed primarily in brain, fetal liver and lung and to a
lesser
extent in retina, spinal chord, activated T-cells and endothelial cells.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of brain and regenerating liver
present in a
biological sample and for diagnosis of diseases and conditions: CNS and spinal
chord
injuries, immune disorders. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the nervous and immune system, expression of this gene at
significantly
higher or lower levels may be routinely detected in certain tissues and cell
types (e.g.,
brain and other tissue of the nervous system, liver, pulmonary tissue, blood
cells, and
endothelial cells, and cancerous and wounded tissues) or bodily fluids (e.g.,
serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for study and treatment of hematopoietic
and
neurological conditions.
FEATURES OF PROTEIN ENCODED BY GENE NO: 75
The translation product of this gene shares sequence homology with GTP
binding proteins (intracellular).
This gene is expressed primarily in bone marrow, brain, and melanocytes and to
a lesser extent in various endocrine and hematopoietic tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: hematopietic
and
nervous system conditions. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the nervous and immune, expression of this gene at
significantly higher
or lower levels may be routinely detected in certain tissues and cell types
(e.g., bone
marrow, melanocytes, brain and other tissue of the nervous system, and
cancerous and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to nucleotide binding factors indicate
that
polynucleotides and polypeptides corresponding to this gene are useful for
study,
5 diagnosis, and treatment of brain degenerative, skin and blood diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 76
This gene is expressed primarily in activated T-cells and to a lesser extent
in
retina, brain, and fetal bone.
10 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of activated T-cells and developing
brain present
in a biological sample and for diagnosis of diseases and conditions: immune
deficiencies and skeletal and neuronal growth disorders. Similarly,
polypeptides and
antibodies directed to these polypeptides are useful in providing
immunological probes
15 for differential identification of the tissues) or cell type(s). For a
number of disorders
of the above tissues or cells, particularly of the nervous, immune, and
skeletomuscular
sustems, expression of this gene at significantly higher or lower levels may
be routinely
detected in certain tissues and cell types (e.g., blood cells, brain and other
tissue of the
nervous system, retinal tissue, and bone, and cancerous and wounded tissues)
or
20 bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid}
or another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
25 corresponding to this gene are useful for diagnosis, study and treatment of
cancer,
urogenital, and brain degenerative diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 77
This gene is expressed primarily in fetal liver, activated monocytes,
osteoblasts
30 and to a lesser extent in synovial, brain, and lymphoid tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of myeloid and lymphoid present in a
biological
sample and for diagnosis of diseases and conditions: inflammation, immune
deficiencies, cancer. Similarly, polypeptides and antibodies directed to these
35 polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the immune system and skeleton, expression of this gene at
significantly
t r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
51
higher or lower levels may be routinely detected in certain tissues and cell
types (e.g.,
liver, blood cells, bone, synovial tissue, brain and other tissue of the
nervous system,
and lymphoid tissue, and cancerous and wounded tissues) or bodily fluids
(e.g.,
serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or
cell sample
taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for study, diagnosis, and treatment of
lymphoid
and mesenchymal cancers and nervous system diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 78
The translation product of this gene shares sequence homology with polymerase
polyprotein precursor which is thought to be important in DNA repair and
replication
This gene is expressed primarily in infant brain and to a lesser extent in
tumors
and tumor cell lines
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to, especially of the neural system and developing organs.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the neural
system
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain (e.g., brain and other tissue of the nervous system, and cancerous
and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to polymerase polyprotein precursor
indicate that polynucleotides and polypeptides corresponding to this gene are
useful for
diagnosis and treatment of cancers especially of the neural system and
developing
organs
FEATURES OF PROTEIN ENCODED BY GENE NO: 79
This gene is expressed primarily in muscle and endothelial cells and to a
lesser
extent in brain.
CA 02283299 1999-09-02
WO 98/39448 PCT/LTS98104493
52
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: vascular
diseases.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues}
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
vascular system, expression of this gene at significantly higher or lower
levels may be
routinely detected in certain (e.g., muscle, endothelial cells, brain and
other tissue of the
nervous system, and cancerous and wounded tissues) or bodily fluids (e.g.,
serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment and diagnosis of disorders
of the
vascular and neural system including cardiovascular and endothelial.
FEATURES OF PROTEIN ENCODED BY GENE NO: 80
This gene is expressed primarily in placenta and to a lesser extent in fetal
liver
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: developmental
disorders
and disorder of the haemopoietic system, fetal liver and placenta. Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissue{s) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of
developmental
disorders and disorder of the haemopoietic system, fetal liver and placenta,
expression
of this gene at significantly higher or lower levels may be routinely detected
in certain
tissues and cell types (e.g., placenta and liver, and cancerous and wounded
tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid} or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of
developmental
disorders and disorders of the haemopoietic system, fetal liver and placenta.
r ~
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
53
FEATURES OF PROTEIN ENCODED BY GENE NO: 81
This gene is expressed primarily in bone marrow, placenta and tissues and
organs of the hematopoietic system.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: disorders of
the bone
and haemopoietic system. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
IO of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the immune, bone and hematopoietic system, expression of this
gene at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., bone marrow, placenta, and hematopoietic cells, and cancerous and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
i 5 fluid) or another tissue or cell sample taken from an individual having
such a disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of disorders
of the
20 immune, bone and hematopoietic system
FEATURES OF PROTEIN ENCODED BY GENE NO: 82
The translation product of this gene shares sequence homology with secretory
carrier membrane protein which is thought to be important in protein transport
and
25 export. Any frame shifts in coding sequence can be easily resolved using
standard
molecular biology techniques. Another group recently cloned this gene, calling
it
SCAMP. (See Accession No. 2232243.)
This gene is expressed primarily in prostate, breast and spleen, and to a
lesser
extent in several other tissues and organs.
30 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: disorders of
the breast
prostate and spleen. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential
identification
35 of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly disorders of the breast prostate and spleen, expression of this
gene at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
54
types (e.g., prostate, mammary tissue, and spleen, and cancerous and wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synoviai fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
fluid from an individual not having the disorder.
The tissue distribution and homology to secretory carrier membrane protein
indicate that polynucleotides and polypeptides corresponding to this gene are
useful for
diagnosis and treatment of disorders of the breast, prostate and spleen.
FEATURES OF PROTEIN ENCODED BY GENE NO: 83
This gene is expressed primarily in developing organs and tissue like placenta
and infant brain and to a lesser extent in developed organs and tissue like
cerebellum
and heart.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: neurological
diseases.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
neural system, expression of this gene at significantly higher or lower levels
may be
routinely detected in certain tissues and cell types (e.g., placenta, heart,
brain and other
tissue of the nervous system, and cancerous and wounded tissues) or bodily
fluids
(e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue
or cell
sample taken from an individual having such a disorder, relative to the
standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment and diagnosis of diseases
of the
neural system including neurological disorders and cancer.
FEATURES OF PROTEIN ENCODED BY GENE NO: 84
The translation product of this gene shares sequence homology with ATPase 6
in Trypanosoma brucei which is thought to be important in metabolism.
This gene is expressed primarily in tumor and fetal tissues and to a lesser
extent
in melanocytes, kidney cortex, monocytes and ovary.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
CA 02283299 1999-09-02
WO 98139448 PCT/US98/04493
biological sample and for diagnosis of diseases and conditions: metabolism
disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the fetal
5 systems, expression of this gene at significantly higher or lower levels may
be routinely
detected in certain tissues and cell types (e.g., fetal tissues, melanocytes,
kidney, blood
cells, ovary and other tissue of the reproductive system, and cancerous and
wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
10 the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
fluid from an individual not having the disorder.
The tissue distribution and homology to ATPase indicate that polynucleotides
and polypeptides corresponding to this gene are useful for treatment and
diagnosis of
metabolism disorders, especially in fetal and tumor tissue growth.
FEATURES OF PROTEIN ENCODED BY GENE NO: 85
The translation product of this gene shares sequence homology with the
immunoglobulin superfamily of proteins which are known to be important in
immune
response and immunity.
This gene is expressed primarily in stromal cells, colon cancer, lung,
amygdala,
melanocyte and to a lesser extent in a variety of other tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: defects of
stromal cell
development and cancer. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the stromal cells, expression of this gene at significantly
higher or lower
levels may be routinely detected in certain tissues and cell types (e.g.,
stromal cells,
colon, lung, amygdala, and melanocytes, and cancerous and wounded tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution and homology to immunoglobulin indicate that
polynucleotides and polypeptides corresponding to this gene are useful for
treatment
and diagnosis of immune system disorders.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
56
FEATURES OF PROTEIN ENCODED BY GENE NO: 86
The translation product of this gene shares sequence homology with
transcription iniation factor eIF-4 gamma which is thought to be important in
gene
transcription.
This gene is expressed primarily in tumor tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: tumorigenesis.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
in tumor
tissues, expression of this gene at significantly higher or lower levels may
be routinely
detected in certain tissues and cell types (e.g., endometrium and lung, and
cancerous
and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid or
spinal fluid) or another tissue or cell sample taken from an individual having
such a
disorder, relative to the standard gene expression level, i.e., the expression
level in
healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to transcription iniation factor eIF-4
gamma indicate that polynucleotides and polypeptides corresponding to this
gene are
useful for gene regulation in tumorigenesis.
FEATURES OF PROTEIN ENCODED BY GENE NO: 87
The translation product of this gene shares sequence homology at low level in
prolines with secreted basic proline-rich peptide II-2 which is thought to be
important in
protein structure or inhibiting hydroxyapatite formation in vitro.
This gene is expressed primarily in endometrial tumor and fetal lung.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: endometrial
tumors.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell .
type(s). For a number of disorders of the above tissues or cells, particularly
of the
muscular/skeletal and reproductive systems, expression of this gene at
significantly
higher or lower levels may be routinely detected in certain tissues and cell
types (e.g.,
endometrium, and lung, and cancerous and wounded tissues) or bodily fluids
(e.g.,
serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or
cell sample
r r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98104493
57
taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
- The tissue distribution and homology to secreted basic proline-rich peptide
II-2
indicate that polynucleotides and polypeptides corresponding to this gene are
useful for
inhibiting hydroxyapatite formation or establishing celUtissue structure.
FEATURES OF PROTEIN ENCODED BY GENE NO: 88
This gene is expressed primarily in: amniotic cells inducted with TNF in
culture;
and to a lesser extent in colon tissue from a patient with Crohn's Disease;
parathyroid
tumor; activated T-cells; cells of the human Caco-2 cell line; adenocarcinoma;
colon;
corpus colosum; fetal kidney; pancreas tumor; fetal brain; early stage brain,
and anergic
T-cells.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: tumors.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the immune
system;
e.g., tumors, expression of this gene at significantly higher or lower levels
may be
routinely detected in certain (e.g., amniotic cells, colon, kidney, pancreas,
parathyroid,
brain and other tissue of the nervous system, blood cells, hematopoietic
cells, liver,
spleen, bone, testes and other reproductive tissue, brain and other tissue of
the nervous
system, and epithelial cells, and cancerous and wounded tissues) or bodily
fluids (e.g.,
serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or
cell sample
taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is
useful
for modulating tumorigenesis and other immune system conditions such as
disorders in
immune response.
FEATURES OF PROTEIN ENCODED BY GENE NO: 89
This gene is expressed primarily in fetal liver/spleen and hematopoietic cells
and
to a lesser extent in brain, osteosarcoma, and testis tumor.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
CA 02283299 1999-09-02
WO 98/39448 PCT/iTS98/04493
58
biological sample and for diagnosis of diseases and conditions: leukemia and
hematopoietic disorders. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the hematopoietic and immune systems, expression of this gene
at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., hematopoietic cells, liver, spleen, bone, testes, and other
reproductive
tissue, brain and other tissue of the nervous system, and cancerous and
wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of
hematopoietic and
1 S immune disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 90
The translation product of this gene shares weak sequence homology with
mouse Gcap 1 protein which is developmentally regulated in brain.
This gene is expressed primarily in infant and adult brain and fetal
liver/spleen
and to a lesser extent in smooth muscle, T cells, and a variety of other
tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: neurological
or
hematopoietic disorders. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the nervous, hematopoietic, immune, and endocrine systems,
expression
of this gene at significantly higher or lower levels may be routinely detected
in certain
tissues and cell types (e.g., brain and other tissue of the nervous system,
blood cells,
liver, spleen ,and smooth muscle, and cancerous and wounded tissues) or bodily
fluids
(e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue
or cell
sample taken from an individual having such a disorder, relative to the
standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
T
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
59
The tissue distribution and its homology to Gcap 1 protein indicate that
polynucleotides and polypeptides corresponding to this gene are useful for
treatubg and
diagnosis of disorders in neuronal, hematopoietic, immune, and endocrine
systems.
S FEATURES OF PROTEIN ENCODED BY GENE NO: 91
This gene is expressed primarily in brain and hematopoietic cells and to a
lesser
extent in tumor tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: disorder in
nervous,
hematopoietic, immune systems and tumorigenesis. Similarly, polypeptides and
antibodies directed to these polypeptides are useful in providing
immunological probes
for differential identification of the tissues) or cell type(s). For a number
of disorders
of the above tissues or cells, particularly of the in nervous, hematopoietic,
immune
systems, expression of this gene at significantly higher or lower levels may
be routinely
detected in certain tissues and cell types (e.g., brain and other tissue of
the nervous
system, and cancerous and wounded tissues) or bodily fluids {e.g., serum,
plasma,
urine, synovial fluid or spinal fluid) or another tissue or cell sample taken
from an
individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that the protein product of this clone is
useful
for diagnosis and treatment of disorders in the nervous, hematopoietic, and
immune
systems.
FEATURES OF PROTEIN ENCODED BY GENE NO: 92
The translation product of this gene shares sequence homology with
neuroendocrine-specific protein A which is thought to be important in
neurologic
systems.
This gene is expressed primarily in brain tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell typejs)
present in a
biological sample and for diagnosis of diseases and conditions: neural
disorders and
degeneration disease. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the central or peripheral nervous systems, expression of this
gene at
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., hematopoietic cells, and brain and other tissue of the nervous
system, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
5 such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to neuroendocrine-specific protein A
indicate that polynucleotides and polypeptides corresponding to this gene are
useful for
treatment or diagnosis of neural disorders and degeneration disease.
FEATURES OF PROTEIN ENCODED BY GENE NO: 93
The translation product of this gene shares sequence homology with collagen-
like protein and prolin-rich protein which are thought to be important in
connective
tissue function and tissue structure.
This gene is expressed primarily in fetal liver/spleen and brain tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: neuronal or
hematopoietic disorders. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the nervous and hematopoietic systems, expression of this gene
at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., liver, spleen, and brain and other tissue of the nervous system,
and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to collagen-like protein and proline-rich
proteins indicate that polynucleotides and polypeptides corresponding to this
gene are
useful for supporting brain and hematopoietic tissue function and diagnosis
and
treatment of disorders in these functions.
FEATURES OF PROTEIN ENCODED BY GENE NO: 94
This gene is expressed primarily in embryonic tissues and tumor tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
r i
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
61
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to,. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the immune system (e.g., tumors), expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., embryonic
tissue and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma,
urine, synovial fluid or spinal fluid) or another tissue or cell sample taken
from an
individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of cancer.
FEATURES OF PROTEIN ENCODED BY GENE NO: 95
This gene is expressed primarily in brain tumor, placenta, and melanoma.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: brain tumor or
melanoma. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the brain or melanocytes, expression of this gene at significantly higher or
lower levels
may be routinely detected in certain tissues and cell types (e.g., brain and
other tissue of
the nervous system, placenta, and melanocytes, and cancerous and wounded
tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that the translation product of this gene is
useful
in the diagnosis and treatment of brain tumors and melanoma.
FEATURES OF PROTEIN ENCODED BY GENE NO: 96
The translation product of this gene shares sequence homology with a yeast
membrane protein, SUR4, which encodes for APA 1 that acts on a glucose-
signaling
pathway that controls the expression of several genes that are
transcriptionally regulated
by glucose.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98104493
62
This gene is expressed primarily in fetal liver, and to a lesser extent in
placenta
and breast tissue.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: defects of
fetal liver or
defects of glucose-regulated ATPase activities in tissues. Similarly,
polypeptides and
antibodies directed to these polypeptides are useful in providing
immunological probes
for differential identification of the tissues) or cell type(s). For a number
of disorders
of the above tissues or cells, particularly of the fetal immune/hematopoietic
system,
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., liver, placenta, and mammary tissue,
and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to yeast SUR4 membrane protein indicate
that polynucleotides and polypeptides corresponding to this gene are useful
for
diagnosis and treatment of defects of fetal liver or defects of glucose-
regulated ATPase
activities.
FEATURES OF PROTEIN ENCODED BY GENE NO: 97
This gene is expressed primarily in fetal liver, brain, and amniotic fluid.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: defects of the
fetal
immune system and adult brain. Similarly, polypeptides and antibodies directed
to these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the fetal immune system and adult brain, expression of this
gene at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., liver, and brain and other tissue of the nervous system> and
cancerous and
wounded tissues) or bodily fluids (e.g., amniotic fluid, serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is
useful
for detecting defects of the fetal immune and hematopoietic systems since
fetal liver is
r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
63
the predominant organ responsible for hematopoiesis in the fetus. In addition,
the gene
product of this gene is thought to be useful for detecting certain
neurological defects of
the brain.
S FEATURES OF PROTEIN ENCODED BY GENE NO: 98
The translation product of this gene shares sequence homology with an yolk
protein precursor, Vitellogenin which is thought to be important in binding
lipids such
as phosvitin.
This gene is expressed primarily in amniotic cells and fetal liver.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: defects in
amniotic
cells, fetal liver development and the fetal immune system. Similarly,
polypeptides and
antibodies directed to these polypeptides are useful in providing
immunological probes
for differential identification of the tissues) or cell type(s). For a number
of disorders
of the above tissues or cells, particularly of the [insert system where a
related disease
state is likely, e.g., immune), expression of this gene at significantly
higher or lower
levels may be routinely detected in certain tissues and cell types (e.g.,
amniotic cells,
and liver, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma,
urine, synovial fluid or spinal fluid) or another tissue or cell sample taken
from an
individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution and homology to vitellogenin indicate that the protein
product of this clone is useful for treatment and diagnosis of defects in
amniotic cells,
fetal liver development and the fetal immune system.
FEATURES OF PROTEIN ENCODED BY GENE NO: 99
This gene is expressed primarily in placenta, endometrial tumor, osteosarcoma
and stromal cells.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: tumor of the
endometrium or bone, and osteosarcoma. Similarly, polypeptides and antibodies
directed to these polypeptides are useful in providing immunological probes
for
differential identification of the tissues) or cell type(s). For a number of
disorders of
the above tissues or cells, particularly of the obstetric system (e.g.
placenta,
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
64
endometrium) and the bones, expression of this gene at significantly higher or
lower
levels may be routinely detected in certain tissues and cell types (e.g.,
placenta,
endometrium, bone, and stromal cells, and cancerous and wounded tissues) or
bodily
fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of tumors
and
abnormalities of the endometrium, and the bones because of its abundance in
the
aforementioned tissues..
FEATURES OF PROTEIN ENCODED BY GENE NO: 100
This gene is expressed primarily in hepatocellular tumor.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: hepatocellular
tumor.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the liver,
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., liver, and cancerous and wounded
tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is
useful
for diagnosis and treatment of hepatocellular cancer because of its abundant
expression
in this tissue.
FEATURES OF PROTEIN ENCODED BY GENE NO: 101
This gene is expressed primarily in Corpus Colosum, fetal lung and infant
brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: defects of the
Corpus
Colosum or defects of the fetal lung. Similarly, polypeptides and antibodies
directed to
r r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
these polypeptides are useful in providing immunological probes for
differential
identification of the tissues) or cell type(s). For a number of disorders of
the above
tissues or cells, particularly of the Corpus Colosum and brain in general, and
fetal lung,
expression of this gene at significantly higher or lower levels may be
routinely detected
5 in certain tissues and cell types (e.g., lung, and brain and other tissue of
the nervous
system, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma,
urine, synovial fluid or spinal fluid) or another tissue or cell sample taken
from an
individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
10 disorder.
The tissue distribution indicates that the protein product of this clone is
useful
for diagnosis and treatment of defects of the Corpus Colosum and brain in
general, and
defects of fetal lung.
15 FEATURES OF PROTEIN ENCODED BY GENE NO: 102
This gene is expressed primarily in T cells and stromal cells, and to a lesser
extent in adrenal gland.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
20 biological sample and for diagnosis of diseases and conditions: defects of
T cell
immunity and stromal cell development. Similarly, polypeptides and antibodies
directed
to these polypeptides are useful in providing immunological probes for
differential
identification of the tissues) or cell type(s). For a number of disorders of
the above
tissues or cells, particularly of the immune system, expression of this gene
at
25 significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., blood cells, stromal cells, and adrenal gland, and cancerous and
wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
30 fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is
useful
for diagnosis and treatment of defects of T cell immunity and stromal cell
development
because of its abundant expression in these tissues.
35 FEATURES OF PROTEIN ENCODED BY GENE NO: 103
This gene is expressed primarily in infant brain and placenta.
CA 02283299 1999-09-02
WO 98/39448 PCT/LJS98/04493
66
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: defects of the
brain and
nervous system. Similarly, polypeptides and antibodies directed to these
polypeptides
are useful in providing immunological probes for differential identification
of the
tissues) or cell type(s). For a number of disorders of the above tissues or
cells,
particularly of the nervous system, especially brain, expression of this gene
at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., brain and other tissue of the nervous system, and placenta,
cancerous and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is
useful
for detecting defects of the brain, especially in young children.
FEATURES OF PROTEIN ENCODED BY GENE NO: 105
This gene is expressed primarily in human osteoclastoma and to a lesser extent
in human pancreas tumor.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to, cancer particularly osteoclastoma and pancreatic tumor.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly in transformed
tissues,
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., bone and pancreas, and cancerous and
wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is
useful
for diagnosis and treatment of some types of tumors, particularly pancreatic
cancer and
osteoclastoma.
r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
67
FEATURES OF PROTEIN ENCODED BY GENE NO: 106
This gene is expressed primarily in fetal liver/spleen, and to a lesser extent
in
activated T-Cells.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: immune
disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
immune system, expression of this gene at significantly higher or lower levels
may be
routinely detected in certain tissues and cell types (e.g., liver, spleen, and
blood cells,
and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,
urine,
synovial fluid or spinal fluid) or another tissue or cell sample taken from an
individual
having such a disorder, relative to the standard gene expression level, i.e.,
the
expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis or treatment of immune
disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 107
This gene is expressed primarily in human embryo and to a lesser extent in
spleen and chronic lymphocytic leukemia.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: leukemia.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the immune
or
hemopoietic systems, expression of this gene at significantly higher or lower
levels may
be routinely detected in certain tissues and cell types (e.g., embryonic
tissue, spleen,
and blood cells, and cancerous and wounded tissues) or bodily fluids (e.g.,
serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that the protein product of this clone is
useful
for the diagnosis and treatment of leukemia.
CA 02283299 1999-09-02
WO 98!39448 PCT/US98/04493
68
FEATURES OF PROTEIN ENCODED BY GENE NO: 108
This gene is expressed primarily in placenta, and to a lesser extent in early
stage
human brain and in lung.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: fetal
developmental
abnormalities. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly in
fetal and amniotic tissue, expression of this gene at significantly higher or
lower levels
may be routinely detected in certain tissues and cell types (e.g., placenta,
brain and
other tissue of the nervous system, and lung, and cancerous and wounded
tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this is useful
for
production of growth factors) associated with fetal development. Preferred
polypeptides comprise the full-length polypeptide shown in the sequence
listing,
truncated however, at the amino terminus and beginning with QTIE.
FEATURES OF PROTEIN ENCODED BY GENE NO: 109
This gene is expressed primarily in fetal spleen, and to a lesser extent in B-
Cell
lymphoma and T-Cell lymphoma.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: lymphoma.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissue{s) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the immune
system,
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., spleen and blood cells, and cancerous
and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
69
The tissue distribution indicates that the protein product of this clone is
useful
for the treatment and diagnosis of human lymphomas.
FEATURES OF PROTEIN ENCODED BY GENE NO: 110
The translation product of this gene shares sequence homology with sarcoma
amplified sequence (SAS), a tetraspan receptor which is thought to be
important in
malignant fibrous histiocytoma and liposarcoma.
This gene is expressed primarily in human osteoclastoma, and to a lesser
extent
in pineal gland and infant brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: malignant
fibrous
histiocytoma and liposarcoma. Similarly, polypeptides and antibodies directed
to these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the immune system, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., bone,
pineal gland, and brain and other tissue of the nervous system, and cancerous
and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to sarcoma amplified sequence (SAS)
indicate that the protein product of this clone is useful for treatment of,
osteosarcoma,
malignant fibrous histiocytoma and liposarcoma and related cancers,
particularly
sarcomas.
FEATURES OF PROTEIN ENCODED BY GENE NO: 111
The translation product of this gene shares sequence homology with 6.8K
proteolipid protein, mitochondria) - bovine.
This gene is expressed primarily in Wilm's tumor and to a lesser extent in
cerebellum and placenta.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: Wilm's tumor.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
type(s). For a number of disorders of the above tissues or cells, particularly
of the
immune or renal systems, expression of this gene at significantly higher or
lower levels
may be routinely detected in certain tissues and cell types (e.g., brain and
other tissue of
the nervous system, and placenta, and cancerous and wounded tissues) or bodily
fluids
5 (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or cell
sample taken from an individual having such a disorder, relative to the
standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution and homology to 6.8K proteolipid protein indicate that
10 the protein product of this clone is useful for diagnostic and therapeutics
associated with
tumors, particularly Wilm's tumor disease.
FEATURES OF PROTEIN ENCODED BY GENE NO: lI2
This gene is expressed primarily in embryonic tissue and to a lesser extent in
15 osteoblasts, endothelial cells, macrophages (GM-CSF treated), and bone
marrow.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: immune
disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
20 providing immunological probes for differential identification of the
tissues) or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
immune system, expression of this gene at significantly higher or lower levels
may be
routinely detected in certain tissues and cell types (e.g.> embryonic tissue,
bone,
endothelial cells, blood cells and bone marrow, and cancerous and wounded
tissues) or
25 bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid)
or another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
t7uid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
30 corresponding to this gene are useful for treatment or diagnosis of immune
disorders.
Preferred polypeptides encoded by this gene comprise the following amino acid
sequence: MITDVQLAIFANMLGVSLFLLVVLYHYVAVNNPKKQE (SEQ ID NO: 636).
FEATURES OF PROTEIN ENCODED BY GENE NO: li3
35 This gene is expressed primarily in hepatocellular tumor, and to a lesser
extent
in fetal liver/spleen.
? ~
CA 02283299 1999-09-02
WO 98/39448 PCT/US98104493
71
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: tumors,
particularly
hepatocellular tumors. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the hepatic system, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., liver, and
spleen, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma,
urine, synovial fluid or spinal fluid) or another tissue or cell sample taken
from an
individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that the protein product of this clone is
useful
for diagnosis and treatment of tumors, particularly hepatocellular tumors.
FEATURES OF PROTEIN ENCODED BY GENE NO: 114
The translation product of this gene exhibits a very high degree of sequence
identity with the human Pig8 gene which is thought to be important in p53
mediated
apoptosis. The sequence of this gene has since been published by Polyak and
colleagues (Nature 389, 300-306 ( 1997)). In addition, the predicted
translation product
of this contig exhibits very high sequence homology with a murine gene denoted
as
EI24 which is also thought to be important in p53 mediated apoptosis.
This gene is expressed primarily in infant brain and activated T-cells and to
a
lesser extent in bone marrow, fetal liver, and prostate.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to, and tissue damage by radiation and anti-cancer drugs.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the nervous
and
immune systems, expression of this gene at significantly higher or lower
levels may be
routinely detected in certain tissues and cell types {e.g., brain and other
tissue of the
nervous system, blood cells, bone marrow, liver, and prostate, and cancerous
and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
CA 02283299 1999-09-02
WO 98/39448 PCT/ITS98/04493
72
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to human Pig8 and murine EI24 genes
indicate that polynucleotides and polypeptides corresponding to this gene are
useful for
preventing apoptosis in patients being treated with anti-oncogenic drugs such
as
etoposide, hydroperoxycyclophosphamide, and X-irradiation, since this protein
product
is upregulated in cells undergoing such treatment where p53 was overexpressed.
It may
also be useful in the treatment of hematopoietic disorders and in boosting
numbers of
hematopoietic stem cells by interfering with the apoptosis of progenitor
cells. The
mature polypeptide is predicted to comprise the following amino acid sequence:
EEMADSV KTFLQDLARGIKDSIWGICTISKLDARIQQKREEQRRRRASSVLAQRRAQSIERKQES
EPRIVSRIFQCCAWNGGVFWFSLLLFYRVFIPVLQSVTARIIGDPSLHGDVWSWLEFFLTSIFSA
L W V LPLFV LS K V V NAI WFQDIADLAFE V SGRKPHPFPS V SKIIADMLFNLLLQALFLIQGMFV
SL
FPIHLVGQLVSLLHMSLLYSLYCFEYRWFNKGIEMHQRLSNIERNWPYYFGFGLPLAFLTAMQ
SSYIISGCLFSILFPLFIISANEAKTPGKAYLFQLRLFSLVVFLSNRLFHKTVYLQSALSSSTSAEK
FPSPHPSPAKLKATAGH (SEQ ID NO: 637). Accordingly, polypeptides comprising the
foregoing amino acid sequence are provided as are polynucleotides encoded such
polypeptides.
FEATURES OF PROTEIN ENCODED BY GENE NO: 115
This gene is expressed primarily in stromal cells and to a lesser extent in
multiple sclerosis.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: affecting the
nervous
system. Similarly, polypeptides and antibodies directed to these polypeptides
are useful
in providing immunological probes for differential identification of the
tissues) or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
nervous system, expression of this gene at significantly higher or lower
levels may be
routinely detected in certain tissues and cell types (e.g., stromal cells and
cancerous and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment and diagnosis of multiple
sclerosis
and other autoimmune diseases.
r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
73
FEATURES OF PROTEIN ENCODED BY GENE NO: 116
This gene is expressed primarily in the gall bladder
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: gall stones or
infection
of the digestive system . Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the digestive system or renal system, expression of this gene
at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., gall bladder and tissue of the digestive system, and cancerous
and wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for possible prevention of digestive
disorders
where there may be a lack of digestive enzymes produced or in the detection
and
possible prevention of gall stones.
FEATURES OF PROTEIN ENCODED BY GENE NO: 117
The translation product of this gene shares sequence homology with dystrophin
gene which is thought to be important in building and maintenance of muscles.
This gene is expressed primarily in placenta and to a lesser extent in fetal
brain
and fetal liver, and spleen.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: muscular
dystropy,
Duchenne and Becker's muscular dystropies. Similarly, polypeptides and
antibodies
directed to these polypeptides are useful in providing immunological probes
for
differential identification of the tissues) or cell type(s). For a number of
disorders of
the above tissues or cells, particularly of the skeletal muscle system,
expression of this
gene at significantly higher or lower levels may be routinely detected in
certain tissues
and cell types (e.g., placenta, brain and other tissue of the nervous system,
muscle,
liver, and spleen, and cancerous and wounded tissues) or bodily fluids (e.g.,
serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
CA 02283299 1999-09-02
WO 98/39448 PCTILTS98/04493
74
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution and homology to the dystrophin gene indicate that
polynucleotides and polypeptides corresponding to this gene are useful for
diseases
related the degenerative myopathies that are characterized by the weakness and
atrophy
of muscles without neural degradation; such as Duchenne and Becker's muscular
dystropies.
FEATURES OF PROTEIN ENCODED BY GENE NO: 118
This gene is expressed primarily in olfactory tissue and to a lesser extent in
cartilage.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: connective
tissue
diseases; chondrosarcoma. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the connective tissue, expression of this gene at
significantly higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., olfactory
tissue and cartilage, and cancerous and wounded tissues) or bodily fluids
(e.g., serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for tumors of connective tissues,
osteoarthritis
and the treatment and diagnosis of chondrosarcoma.
FEATURES OF PROTEIN ENCODED BY GENE NO: 119
This gene is expressed primarily in Activated Neutrophils and to a lesser
extent
in fetal spleen, and CD34 positive cells from cord blood.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: allergies,
defects in
hematopoiesis and inflammation. Similarly, polypeptides and antibodies
directed to
these polypeptides are useful in providing immunological probes for
differential
r . ?..
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
identification of the tissues) or cell type(s). For a number of disorders of
the above
tissues or cells, particularly of the immune system and hematopoiesis system
the,
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., blood cells, and spleen, and
cancerous and
5 wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
10 corresponding to this gene are useful for reducing the allergic effects
felt by allergy
suffers by neutralizing the activity of the immune system, especially since
neutrophils
are abundant in persons suffering from allergies and other inflammatory
conditions.
FEATURES OF PROTEIN ENCODED BY GENE NO: 120
15 The translation product of this gene shares sequence homology with poly A
binding protein II which is thought to be important in RNA binding for
transcription of
RNA to DNA
This gene is expressed primarily in colon and to a lesser extent in brain and
immune system.
20 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: colon cancer.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
25 number of disorders of the above tissues or cells, particularly of the
immune and
digestive system, expression of this gene at significantly higher or lower
levels may be
routinely detected in certain tissues and cell types (e.g., colon, tissue and
cells of the
immune system, and brain or other tissue of the nervous system, and cancerous
and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
30 fluid) or another tissue or cell sample taken from an individual having
such a disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to poly A binding protein II indicate
that
polynucleotides and polypeptides corresponding to this gene are useful for
detection
35 and treatment of colon cancer and other disorders of the digestive system..
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
76
FEATURES OF PROTEIN ENCODED BY GENE NO: 121
The translation product of this gene shares sequence homology with thymidine
diphosphoglucose 4.6 dehydrase which is thought to be important in the
metabolism of
sugar.
This gene is expressed primarily in fetal liver and spleen and to a lesser
extent in
infant brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: diabetes.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the
endocrine system,
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., liver, spleen, and brain and other
tissue of the
nervous system, and cancerous and wounded tissues) or bodily fluids (e.g.,
serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution and homology to thymidine diphospoglucose 4.6
dehydrase indicate that polynucleotides and polypeptides corresponding to this
gene are
useful for treatment of persons with diabetes since it appears that this
protein is needed
in the metabolism of sugar in to its more basic components.
FEATURES OF PROTEIN ENCODED BY GENE NO: 122
The translation product of this gene shares sequence homology with
ceruloplasmin which is thought to be important in the metabolism and transport
of iron
and copper. Ceruloplasmin also contains domains with homology to clotting
factors V
and VIII. Defects in the circulating levels of ceruloplasmin
(aceruloplasminemia) have
been associated with certain disease conditions such as Wilson disease, and
the
accompanying hepatolenticular degeneration.
This gene is expressed primarily in brain and retina and to a lesser extent in
endothelial cells.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: diseases
marked by
defects in iron metabolism; aceruloplasminemia not characterized by defects in
the
r r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
77
known ceruloplasmin gene locus; nonclassical Wilson disease; movement
disorders;
and tumors derived from a brain tissue origin. Similarly, polypeptides and
antibodies
directed to these polypeptides are useful in providing immunological probes
for
differential identification of the tissues) or cell type(s). For a number of
disorders of
S the above tissues or cells, particularly of the brain, retina, and nervous
system,
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., brain and other tissue of the nervous
system,
retinal tissue, and endothelial cells, and cancerous and wounded tissues) or
bodily
fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
The tissue distribution and homology to ceruloplasmin indicate that
polynucleotides and polypeptides corresponding to this gene are useful for
treatment of
patients with aceruloplasminemia, or other defects in iron and/or copper
metabolism.
Mutations in this locus could also be diagnostic for patients currently
experiencing or
predicted to experience aceruloplasminemia.
FEATURES OF PROTEIN ENCODED BY GENE NO: 123
This gene is expressed primarily in brain and B cell lymphoma and to a lesser
extent in fetal liver and spleen.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: B cell
lymphoma;
tumors and diseases of the brain and/or spleen; hematopoietic defects.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the brain
and
hematopoietic system, expression of this gene at significantly higher or lower
levels
may be routinely detected in certain tissues and cell types (e.g., brain and
other tissue of
the nervous system, blood cells, liver, and spleen, and cancerous and wounded
tissues)
or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid)
or another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment of disorders in neuronal,
CA 02283299 1999-09-02
WO 98!39448 PCT/US98/04493
78
hematopoietic, and immune systems. It could potentially be useful for
neurodegenerative disorders and neuronal and/or hematopoietic cell survival or
proliferation.
FEATURES OF PROTEIN ENCODED BY GENE NO: 124
This gene is expressed primarily in osteoclastoma, dermatofibrosarcoma, and B
cell lymphoma and to a lesser extent in endothelial cells.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to, cancer in particular osteoclastoma, dermatofibrosarcoma, and B
cell
lymphoma. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the bone, immune, and circulatory system, expression of this gene at
significantly
higher or lower levels may be routinely detected in certain tissues and cell
types (e.g.,
bone, epidermis, blood cells, and endothelial cells, and cancerous and wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of cancers
and
lymphoma; osteoporosis; and the control of cell proliferation and/or
differentiation.
FEATURES OF PROTEIN ENCODED BY GENE NO: 125
This gene is expressed primarily in immune tissues and hematopoietic cells,
particularly in activated T cells and neutrophils, spleen, and fetal liver,
and to a lesser
extent in infant adrenal gland.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: defects in T
cell
activation; hematopoietic disorders; tumors of a hematopoietic and/or adrenal
gland
origin. Similarly, polypeptides and antibodies directed to these polypeptides
are useful
in providing immunological probes for differential identification of the
tissues) or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
hematopoietic and/or endocrine systems, expression of this gene at
significantly higher
T
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
79
or lower levels may be routinely detected in certain tissues and cell types
(e.g., cells and
tissues of the immune system, hematopoietic cells, blood cells, liver, and
adrenal gland,
and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,
urine,
synovial fluid or spinal fluid) or another tissue or cell sample taken from an
individual
having such a disorder, relative to the standard gene expression level, i.e.,
the
expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for immune and/or hematopoietic
disorders;
diseases related to proliferation and/or differentiation of hematopoietic
cells; defects in T
cell and neutrophil activation and responsiveness; and endocrine and/or
metabolic
disorders, particularly of early childhood.
FEATURES OF PROTEIN ENCODED BY GENE NO: 126
This gene is expressed primarily in placenta and endothelial cells and to a
lesser
extent in melanocytes and embryonic tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: tumors of an
endothelial
cell origin; angiogenesis associated with tumor development and metastasis.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the
vascular system
and developing embryo, expression of this gene at significantly higher or
lower levels
may be routinely detected in certain tissues and cell types (e.g., placenta,
endothelial
cells, melanocytes, and embryonic tissues, and cancerous and wounded tissues)
or
bodily fluids {e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment of developmental
disorders;
inhibition of angiogenesis; and vascular patterning.
FEATURES OF PROTEIN ENCODED BY GENE NO: 127
This gene is expressed primarily in endothelial cells and hematopoietic
tissues,
including spleen, tonsils, leukocytes, and both B- and T-cell lymphomas.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: tumors of an
endothelial
cell and/or hematopoietic origin; leukemias and lymphomas. Similarly,
polypeptides
5 and antibodies directed to these polypeptides are useful in providing
immunological
probes for differential identification of the tissues) or cell type(s). For a
number of
disorders of the above tissues or cells, particularly of the immune and
vascular systems,
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., endothelial cells, hematopoietic
cells, spleen,
10 tonsils, and blood cells, and cancerous and wounded tissues) or bodily
fluids (e.g.,
serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or
cell sample
taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
15 The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the manipulation of angiogenesis;
the
differentiation and morphogenesis of endothelial cells; the proliferation
and/or
differentiation of hematopoietic cells; and the commitment of hematopoietic
cells to
distinct cell lineages.
FEATURES OF PROTEIN ENCODED BY GENE NO: 128
This gene is expressed primarily in kidney medulla and to a lesser extent in
spleen from chronic myelogenous leukemia patients, prostate cancer, and some
other
tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: tumors of a
kidney
origin; chromic myelogenous leukemia; prostate cancer. Similarly, polypeptides
and
antibodies directed to these polypeptides are useful in providing
immunological probes
for differential identification of the tissues) or cell type(s). For a number
of disorders
of the above tissues or cells, particularly of the kidney and spleen,
expression of this
gene at significantly higher or lower levels may be routinely detected in
certain tissues
and cell types (e.g., kidney, spleen, and prostate, and cancerous and wounded
tissues)
or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid)
or another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
T r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
81
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the diagnosis and treatment of
kidney
disorders and cancer, particularly chromic myelogenous leukemia and prostate
cancer.
It may also be useful for the enhancement of kidney tubule regeneration in the
treatment
of acute renal failure.
FEATURES OF PROTEIN ENCODED BY GENE NO: 129
This gene is expressed primarily in adult and infant brain and to a lesser
extent
in mesenchymal or fibroblast cells, as well as tissues with a mesenchymal
origin.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: tumors of a
brain andlor
mesenchymal origin; neurodegenerative disorders; cancer; fibrosis. Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the brain
and of
mesenchymal cells and tissues, expression of this gene at significantly higher
or lower
levels may be routinely detected in certain tissues and cell types (e.g.,
brain and other
tissue of the nervous system and cancerous and wounded tissues) or bodily
fluids
(e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue
or cell
sample taken from an individual having such a disorder, relative to the
standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the diagnosis of tumors of a brain
and/or
mesenchymal origin; neurodegenerative disorders; cancer; and fibrosis, based
upon the
expression of this gene within those tissues. Fibrosis is considered as
mesenchymal
cells and fibroblasts are the primary cellular targets involved in this
pathological
condition.
FEATURES OF PROTEIN ENCODED BY GENE NO: 130
This gene is expressed primarily in hepatocellular cancer and to a lesser
extent in
fetal tissues as well as testes tumor.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: liver cancer.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
82
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the
digestive system,
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., liver, fetal tissue, and testes and
other
reproductive tissue, and cancerous and wounded tissues) or bodily fluids
(e.g., serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of liver
cancer.
FEATURES OF PROTEIN ENCODED BY GENE NO: 131
This gene is expressed only in infant early brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: development
and
diseases of the nervous system. Similarly, polypeptides and antibodies
directed to these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the brain and nervous system, expression of this gene at
significantly
higher or lower levels may be routinely detected in certain tissues and cell
types (e.g.,
brain and other tissue of the nervous system and cancerous and wounded
tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treating diseases of the brain in
children and in
treating nervous system disorders such as Alzheimer's disease, schizophrenia,
dementia, depression, etc.
FEATURES OF PROTEIN ENCODED BY GENE NO: 132
This gene is expressed primarily in brain and to a lesser extent in
glioblastoma.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: Alzheimer's
disease,
CA 02283299 1999-09-02
WO 98/39448 PCT/L1S98/04493
83
schizophrenia, depression, mania, and dementia. Similarly, polypeptides and
antibodies
directed to these polypeptides are useful in providing immunological probes
for
differential identification of the tissues) or cell type(s). For a number of
disorders of
the above tissues or cells, particularly of the brain and nervous system,
expression of
this gene at significantly higher or lower levels may be routinely detected in
certain
tissues and cell types (e.g., brain and other tissue of the nervous system,
and cancerous
and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid or
spinal fluid) or another tissue or cell sample taken from an individual having
such a
disorder, relative to the standard gene expression level, i.e., the expression
level in
healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treating brain.disorders such as
Alzheimer's
disease, schizophrenia, depression, mania, and dementia.
FEATURES OF PROTEIN ENCODED BY GENE NO: 133
The translation product of this gene shares sequence homology with ribitol
dehydrogenase of bacteria which is thought to be important in metabolism of
sugars.
This gene is expressed primarily in macrophage and to a lesser extent in T-
cell
lymphoma and lung.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: tissue
deswction in
inflammation. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the immune system, expression of this gene at significantly higher or lower
levels may
be routinely detected in certain tissues and cell types (e.g., blood cells and
lung, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to ribitol dehydrogenase indicate that
polynucleotides and polypeptides corresponding to this gene are useful for
altering
macrophage metabolism in diseases such as inflammation where macrophages are
causing excess tissue destruction.
CA 02283299 1999-09-02
WO 98/39448 PCTIUS98/04493
84
FEATURES OF PROTEIN ENCODED BY GENE NO: 134
This gene is expressed primarily in pancreatic tumor and to a lesser extent in
synovial sarcoma.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to,. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the endocrine and connective tissue systems, expression of this gene at
significantly
higher or lower levels may be routinely detected in certain tissues and cell
types (e.g.,
pancreas, and synovial tissue, and cancerous and wounded tissues) or bodily
fluids
(e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue
or cell
sample taken from an individual having such a disorder, relative to the
standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treating and diagnosing various
cancers.
FEATURES OF PROTEIN ENCODED BY GENE NO: 135
This gene is expressed primarily in T cell lines such as Raji and to a lesser
extent in infant brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: immune system
disorders and inflammation. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the immune system, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., blood
cells, and brain and other tissue of the nervous system, and cancerous and
wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treating and diagnosing inflammatory
diseases
r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
such as rheumatoid arthritis, sepsis, inflammatory bowel disease, and
psoriasis, as well
as neutropenla.
FEATURES OF PROTEIN ENCODED BY GENE NO: 136
5 The translation product of this gene shares high sequence homology with SAR
1
subfamily of GTP-binding proteins which is thought to be important in
vesicular
transport in mammalian cells.
This gene is expressed primarily in serum-stimulated smooth muscle cells and
to
a lesser extent in a T-cell lymphoma.
10 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: diseases
affecting
vesicular transport. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing imrnunological probes for differential
identification
15 of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the muscular system, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., blood
cells, and smooth muscle, and cancerous and wounded tissues) or bodily fluids
(e.g.,
serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or
cell sample
20 taken from an individual having such a disorder, relative to the standard
gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution and homology to GTP-binding proteins indicate that
polynucleotides and polypeptides corresponding to this gene are useful for
gene therapy
25 in treating the large number of diseases involved in defective vesicular
transport within
cells..
FEATURES OF PROTEIN ENCODED BY GENE NO: 137
The translation product of this gene shares sequence homology with a protein
30 found in C. elegans cosmid F25B5.
This gene is expressed primarily in a fetal tissues and to a lesser extent in
rnelanocytes.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
35 biological sample and for diagnosis of diseases and conditions: abnormal
fetal
development, especially of the pulmonary system. Similarly, polypeptides and
antibodies directed to these polypeptides are useful in providing
immunological probes
CA 02283299 1999-09-02
WO 98/39448 PCT/LTS98I04493
86
for differential identification of the tissues) or cell type(s). For a number
of disorders
of the above tissues or cells, particularly of the fetal pulmonary system,
expression of
this gene at significantly higher or lower levels may be routinely detected in
certain
tissues and cell types (e.g., fetal tissue, pulmonary tissue, and melanocytes,
and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment and diagnosis of diseases
affecting
the pulmonary system, such as emphysema.
FEATURES OF PROTEIN ENCODED BY GENE NO: 138
This gene is expressed primarily in gall bladder and to a lesser extent in
smooth
muscle.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: digestive
system disease
and gall bladder problems. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the digestive system, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., gall
bladder and tissue of the digestive system, and smooth muscle, and cancerous
and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treating diseases of the digestive
system.
FEATURES OF PROTEIN ENCODED BY GENE NO: 139
This gene is expressed primarily in placenta and to a lesser extent in brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue{s) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: abnormal fetal
development. Similarly, polypeptides and antibodies directed to these
polypeptides are
~, fi
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
87
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
developing tissues, expression of this gene at significantly higher or lower
levels may
be routinely detected in certain tissues and cell types (e.g., placenta, and
brain and other
tissue of the nervous system, and cancerous and wounded tissues) or bodily
fluids
(e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue
or cell
sample taken from an individual having such a disorder, relative to the
standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treating and diagnosing abnormal
fetal
development.
FEATURES OF PROTEIN ENCODED BY GENE NO: 140
This gene is expressed primarily in smooth muscle and to a lesser extent in
ovary, prostate cancer, and activated monocytes.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: hypertension
and
atherosclerosis. Similarly, polypeptides and antibodies directed to these
polypeptides
are useful in providing immunological probes for differential identification
of the
tissues) or cell type(s). For a number of disorders of the above tissues or
cells,
particularly of the circulatory system, expression of this gene at
significantly higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., smooth
muscle, ovary and other reproductive tissue, prostate, and blood cells, and
cancerous
and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid or
spinal fluid) or another tissue or cell sample taken from an individual having
such a
disorder, relative to the standard gene expression level, i.e., the expression
level in
healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treating diseases of the circulatory
system,
such as hypertension, atherosclerosis, etc.
FEATURES OF PROTEIN ENCODED BY GENE NO: 141
This gene is expressed primarily in fetal spleen and to a lesser extent in
placenta
and bone marrow.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98J04493
88
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: anemia and
other
- diseases affecting blood cells. Similarly, polypeptides and antibodies
directed to these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the circulatory and pulmonary systems, expression of this gene
at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., spleen, placenta, bone marrow, and blood cells, and cancerous and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the generation of red and white
blood cells and
for the diagnosis of disease of these cells.
FEATURES OF PROTEIN ENCODED BY GENE NO: 142
The predicted translation product of this contig is a human homolog of the
marine tetracycline/sugar transporter molecule recently reported by Matsuo and
colleagues (Biochem. Biophys. Res. Commun. 238 (1), 126-129 (1997)).
This gene is expressed primarily in synovium and to a lesser extent in
endothelial cells.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: rheumatoid
arthritis and
inflammation. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the immune and lymphatic systems, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., synovial
tissue, and endothelial cells, and cancerous and wounded tissues) or bodily
fluids (e.g.,
serum, plasma, urine, synovial fluid or spinal fluid) or another tissue or
cell sample
taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
r r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
89
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment and diagnosis of
inflammatory
diseases, such as rheumatoid arthritis, leukemia, neutropenia, inflammatory
bowel
disease, psoriasis, sepsis, and the like.
FEATURES OF PROTEIN ENCODED BY GENE NO: 143
This gene is expressed primarily in placenta and to a lesser extent in
melanocyte,
fetal liver and spleen, and bone marrow.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: abnormal early
development. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
lower levels
may be routinely detected in certain tissues and cell types (e.g., placenta,
melanocytes,
liver, spleen, and bone marrow, and cancerous and wounded tissues) or bodily
fluids
(e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue
or cell
sample taken from an individual having such a disorder, relative to the
standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the treatment and diagnosis of
abnormal early
development phenomena and diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 144
This gene is expressed primarily in fetal liver and spleen.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: anemia and
neutropenia.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
immune and blood systems, expression of this gene at significantly higher or
lower
levels may be routinely detected in certain tissues and cell types (e.g.,
liver and spleen,
and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,
urine,
synovial fluid or spinal fluid) or another tissue or cell sample taken from an
individual
having such a disorder, relative to the standard gene expression level, i.e.,
the
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful in hematopoeisis and bone marrow
regeneration
5 as it is most abundant in fetal tissues responsible for the generation of
hematopoeitic
cells.
FEATURES OF PROTEIN ENCODED BY GENE NO: 14S
The translation product of this gene shares sequence homology with protein
10 tyrosine phosphatase which is thought to be important in transducing signal
to activate
cells such as T cell, B cell and other cell types.
This gene is expressed primarily in T cells and tissues in early stages of
development and to a lesser extent in cancers.
Therefore, polynucleotides and polypeptides of the invention are useful as
15 reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: immuno-related
diseases and cancer. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
20 particularly of the immune system expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
{e.g., embryonic
and fetal tissue, undifferentiated cells, and blood cells, and cancerous and
wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
25 the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
fluid from an individual not having the disorder.
The tissue distribution and homology to the protein tyrosine phosphatase
family
indicate that polynucleotides and polypeptides corresponding to this gene are
useful for
modulating the immune system.
FEATURES OF PROTEIN ENCODED BY GENE NO: 146
This gene is expressed primarily in T cell and to a lesser extent in B cell,
macrophages and tumor tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell type{s)
present in a
biological sample and for diagnosis of diseases and conditions: immuno-
disorders.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
91
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
immune system, expression of this gene at significantly higher or lower levels
may be
routinely detected in certain tissues and cell types (e.g., blood cells, and
cancerous and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for regulating the immune system
therefore can be
used in treating diseases such as autoimmune diseases and cancers.
FEATURES OF PROTEIN ENCODED BY GENE NO: 147
This gene is expressed primarily in placenta and to a lesser extent in
endothelial
cells, testis tumor, ovarian cancer, uterine cancer.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not linuted to cancer. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the immune system, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., placenta,
endothelial cells, testis and ovary and other reproductive tissue, and
cancerous and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of cancers.
FEATURES OF PROTEIN ENCODED BY GENE NO: 148
This sequence has significant homology to mouse torsin A. Recently, another
group cloned the human Torsin A gene. (See, Accession No. 2358279; see also
Nature
Genet. 17, 40-48 ( 1997).)
This gene is expressed primarily in osteoclastoma, T-cell, and placenta and to
a
lesser extent in fetal lung, fetal liver, fetal brain, adult brain and tumor
tissues
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
92
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: disease
conditions in
hematopoiesis and cancers. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the hematopoiesis system, expression of this gene at
significantly higher
or lower levels may be routinely detected in certain tissues and cell types
(e.g., blood
cells, bone, placenta, lung, liver, and brain and other tissues of the nervous
system,
and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,
urine,
synovial fluid or spinal fluid) or another tissue or cell sample taken from an
individual
having such a disorder, relative to the standard gene expression level, i.e.,
the
expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treating blood related diseases such
as
deficiencies in red blood cell, white blood cell, platelet and other
hematopoiesis cells.
FEATURES OF PROTEIN ENCODED BY GENE NO: 149
This gene is expressed primarily in T cell, prostate and prostate cancer,
endothelial cells and to a lesser extent in monocyte, dendritic cell, bone
marrow,
salivary gland, colon cancer, stomach cancer, pancreatic tumor, uterine
cancer, fetal
spleen and osteoclastoma.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: immuno-related
diseases and cancers. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the immune system, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., blood
cells, prostate, endothelial cells, dendritic cells, bone marrow, salivary
gland, colon,
stomach, pancreas, uterus, spleen and bone, and cancerous and wounded tissues)
or
bodily fluids (e.g.> serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
93
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment of cancers.
FEATURES OF PROTEIN ENCODED BY GENE NO: 150
This gene was recently cloned by another group, calling it eIF3-p66. (See
Accession No. 2351378.) This gene plays a role in RNA binding and
macromolecular
assembly, and therefore, any mutations in this gene would likely result in a
diseased
phenotype. Preferred polypeptide fragments comprise the amino acid sequence:
MAKFMTPVIQDNPSGWGPCAVPEQFRDMPYQPFSKGDRLGKVADWTGATYQDKRYTNKYSS
QFGGGSQYAYFHEEDESSFQLVDTARTQKTAYQRNRMRFAQRNLRRDKDRRNMLQFNLQILP
KSAKQKERERIRLQKKFQKQFG VRQKWDQKSQKPRDSS VE VRS DWEV KEEMDFPQLMKMRY
LEVSEPQDIECCGALEYYDKAFDRITTRSEKPLRXXKRIFHTVTTTDDPVIRKLAKTQGNVFATD
AILATLMSCTRS V YS WDIV V QRV GS KLFFDKRDNSDFDLLTVSETANEPPQDEGNSFNSPRNL
AMEATYINHNFSQQCLRMGKERYNFPNPNPFVEDDMDKNEIAS V AYRYRSGKLGDDIDL1V RC
EHDGVMTGANGEVSFINIKTLNEWDSRHCNGVDWRQKLDSQRGAVIATELKNNSYKLARWTC
CALLAGSEYLKLGYVSRYHVKDSSRHVILGTQQFKPNEFASQINLSVENAWGILRCVIDICMKL
EEGKYLILKDPNKQVIRVYSLPDGTFSS (SEQ ID NO: 638), as well as N-terminal and C-
terminal deletions of this polypeptide fragment.
This gene is expressed primarily in T cell, bone marrow, embryo and
endothelial cells and to a lesser extent in testis tumor and endometrial
tumor.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: immune
diseases and
tumors. Similarly, polypeptides and antibodies directed to these polypeptides
are useful
in providing immunological probes for differential identification of the
tissues) or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
immune system and reproductive system, expression of this gene at
significantly higher
or lower levels may be routinely detected in certain tissues and cell types
(e.g.,
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for immune disorders and cancers.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
94
FEATURES OF PROTEIN ENCODED BY GENE NO: 151
This gene is expressed primarily in testis and to a lesser extent in T cell,
spinal
cord, placenta, neutrophil and monocyte.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: male
reproductive and
endocrine disorders. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the reproductive, immune and endocrine systems, expression of
this
gene at significantly higher or lower levels may be routinely detected in
certain tissues
and cell types (e.g., testis and other reproductive tissue, blood cells,
tissue of the
nervous system, and placenta, and cancerous and wounded tissues) or bodily
fluids
(e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue
or cell
sample taken from an individual having such a disorder, relative to the
standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for regulating immune and reproductive
functions.
FEATURES OF PROTEIN ENCODED BY GENE NO: 152
The translation product of this gene shares sequence homology with tyrosyl-
tRNA synthetase which is thought to be important in cell growth.
This gene is expressed primarily in brain, liver, keratinocytes, tonsils, and
heart.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to, cancer autoimmune diseases. Similarly, polypeptides and
antibodies
directed to these polypeptides are useful in providing immunological probes
for
differential identification of the tissues) or cell type(s). For a number of
disorders of
the above tissues or cells, particularly of the brain, liver, keratinocytes,
tonsils, heart
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., brain and other tissues of the
nervous system,
liver, keratinocytes, tonsils and heart, and cancerous and wounded tissues) or
bodily
fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
The tissue distribution and homology to tyrosyl-tRNA synthetase indicate that
polynucleotides and polypeptides corresponding to this gene are useful for
modulating
5 cell growth.
FEATURES OF PROTEIN ENCODED BY GENE NO: 153
This gene is homologous to the Drosophila transcriptional regulator dre4. (See
Accession No. 2511745.) Dre4 is a gene required for steroidogenesis in
Drosophila
10 melanogaster and encodes a developmentally expressed homologue of the yeast
transcriptional regulator CDC68. Preferred polypeptide fragments comprise the
amino
acid sequence: KKRHTDVQFYTEVGEITTDLGKHQHMHDRDDLYAEQMEREMRHKLKTAFKN
FIEK V EALTKEELEFEV PFRDLGFNGAPYRSTCLLQPTS SAL V NATEWPPFV VT'LDEVELIHFXR
VQFHLKNFDM V IV YKDYSKKVTMINAIPV ASLDPIKEWLNSCDLKYTEG V QSLNWTKIMKTIV D
15 DPEGFFEQGGWSFL (SEQ ID NO: 639), as well as N-terminal and C-terminal
deletions of
this fragments. Also preferred are polynucleotide fragments encoding this
polypeptide
fragment.
This gene is expressed primarily in fetal liver, spleen, placenta, lung, T
cell,
thyroid, testes.
20 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: brain tumor,
heart and
liver diseases. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
25 or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the fetal liver, spleen, placenta, lung, T cell, thyroid, testes expression of
this gene at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., liver, spleen, placenta, lung, blood cells, thyroid, and testes
and other
reproductive tissue, and cancerous and wounded tissues) or bodily fluids
(e.g., serum,
30 plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
35 FEATURES OF PROTEIN ENCODED BY GENE NO: 154
This gene is expressed primarily in brain and to a lesser extent in fetal
heart,
testis, spleen, lung.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
96
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: heart, liver
and spleen
diseases, immunological diseases. Similarly, polypeptides and antibodies
directed to
these polypeptides are useful in providing immunological probes for
differential
identification of the tissues) or cell type(s). For a number of disorders of
the above
tissues or cells, particularly of the brain, fetal heart, testis, spleen, lung
expression of
this gene at significantly higher or lower levels may be routinely detected in
certain
tissues and cell types (e.g., brain and other tissue of the nervous system,
heart, testes
and other reproductive tissue, spleen, and lung, and cancerous and wounded
tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
FEATURES OF PROTEIN ENCODED BY GENE NO: 155
Activation of T cells through the T cell antigen receptor (TCR) results in the
rapid tyrosine phosphorylation of a number of cellular proteins, one of the
earliest being
a 100 kDa protein. This gene is the human equivalent of murine valosin
containing
protein (VCP). VCP is a member of a family of ATP binding, homo-oligomeric
proteins, and the mammalian homolog of Saccharomyces cerevisiae cdc48p, a
protein
essential to the completion of mitosis in yeast. Both endogenous and expressed
murine
VCP are tyrosine phosphorylated in response to T cell activation. Thus we have
identified a novel component of the TCR mediated tyrosine kinase activation
pathway
that may provide a link between TCR activation and cell cycle control.
This gene is expressed primarily in brain, liver, spleen, placenta.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue{s) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to, cancer immunological disorders. Similarly, polypeptides and
antibodies
directed to these polypeptides are useful in providing immunological probes
for
differential identification of the tissues) or cell type(s). For a number of
disorders of
the above tissues or cells, particularly of the brain, liver, spleen, placenta
expression of
this gene at significantly higher or lower levels may be routinely detected in
certain
tissues and cell types (e.g., brain and other tissue of the nervous system,
liver, spleen,
and placenta, and cancerous and wounded tissues) or bodily fluids (e.g.,
serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
t
CA 02283299 1999-09-02
WO 98/39448 PCT/LJS98/04493
97
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution and homology to VCR indicate that polynucleotides and
polypeptides corresponding to this gene are useful for treating cancer.
FEATURES OF PROTEIN ENCODED BY GENE NO: 156
The translation product of this gene shares sequence homology with rat growth
response protein which is thought to be important in cell growth. A group
recently
cloned the human homolog of this gene, calling it insulin induced protein 1.
(See
Accession No. 2358269, see also, Genomics 43 (3), 278-284 ( 1997).) Preferred
polypeptide fragments comprise the amino acid sequence: RSGLGLGTI'IAFi.ATLITQF
LVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMGVPEKPHSD (SEQ ID NO: 640),
as well as N-terminal and C-terminal deletions of this polypeptide fragment.
Also
preferred are polynucleotide fragments encoding these polypeptide fragments.
This gene is expressed primarily in brain, liver, placenta, heart, spleen,
lymphoma.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to, cancer immunological disorders. Similarly, polypeptides and
antibodies
directed to these polypeptides are useful in providing immunological probes
for
differential identification of the tissues) or cell type(s). For a number of
disorders of
the above tissues or cells, particularly of the brain, liver, placenta, heart,
spleen.
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., brain and other tissue of the nervous
system,
liver, placenta, heart, spleen, and lymphoid tissue, and cancerous and wounded
tissues)
or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid)
or another
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution and homology to growth-response protein indicate that
polynucleotides and polypeptides corresponding to this gene are useful for
modulating
cell growth.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
98
FEATURES OF PROTEIN ENCODED BY GENE NO: 157
This gene is expressed primarily in Glioblastoma, endometrial tumor,
lymphoma and pancreas tumor.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: Glioblastoma,
Endometrial tumor, lymphoma and pancreas tumor. Similarly, polypeptides and
antibodies directed to these polypeptides are useful in providing
immunological probes
for differential identification of the tissues) or cell type(s). For a number
of disorders
of the above tissues or cells, particularly of the immune, expression of this
gene at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., endometrium, lymphoid tissue, pancreas, and tissue of the nervous
system,
and cancerous and wounded tissues) or bodily fluids {e.g., serum, plasma,
urine,
synovial fluid or spinal fluid) or another tissue or cell sample taken from an
individual
having such a disorder, relative to the standard gene expression level, i.e.,
the
expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
FEATURES OF PROTEIN ENCODED BY GENE NO: 158
The translation product of this gene shares sequence homology with IGE
receptor which is thought to be important in allergy and asthma.
This gene is expressed primarily in T cell, and fetal liver.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: allergy and
asthma and
other immunological disorders. Similarly, polypeptides and antibodies directed
to these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the immune, expression of this gene at significantly higher or
lower
levels may be routinely detected in certain tissues and cell types (e.g.,
blood cells, and
liver, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma, urine,
synovial fluid or spinal fluid) or another tissue or cell sample taken from an
individual
having such a disorder, relative to the standard gene expression level, i.e.,
the
expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
1 I
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
99
The tissue distribution and homology to IgE receptor indicate that
polynucleotides and polypeptides corresponding to this gene are useful for
allergy and
asthma.
FEATURES OF PROTEIN ENCODED BY GENE NO: 159
The translation product of this gene shares sequence homology with
immunoglobin heavy chain which is thought to be important in immune response
to the
antigen.
This gene is expressed primarily in activated neutrophil and to a lesser
extent in
activated T cell, monocyte and heart.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: infection ,
inflammation
and cancer. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the immune, expression of this gene at significantly higher or lower levels
may be
routinely detected in certain tissues and cell types (e.g., blood cells, and
heart, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to immunoglobin heavy chain variable
region indicate that polynucleotides and polypeptides corresponding to this
gene are
useful for making the ligand to block specific antigen which cause certain
disease.
FEATURES OF PROTEIN ENCODED BY GENE NO: 160
The translation product of this gene shares sequence homology with mouse X
inactive specific transcript protein which is thought to be important in X
chromosome
inactivation.
This gene is expressed primarily in HSA 172 cell and to a lesser extent in
normal
ovary tissue, ovarian cancer, frontal cortex and brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: ovarian tumor,
schizophrenia and other neurological disorders. Similarly, polypeptides and
antibodies
directed to these polypeptides are useful in providing immunological probes
for
CA 02283299 1999-09-02
WO 98/39448 PCT/ITS98/04493
100
differential identification of the tissues) or cell type(s). For a number of
disorders of
the above tissues or cells, particularly of the immune and neural system,
expression of
this gene at significantly higher or lower levels may be routinely detected in
certain
tissues and cell types (e.g., ovary and other reproductive tissue, and brain
and other
tissue of the nervous system, and cancerous and wounded tissues) or bodily
fluids
(e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue
or cell
sample taken from an individual having such a disorder, relative to the
standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution and homology to X inactive specific transcript protein
indicate that polynucleotides and polypeptides corresponding to this gene are
useful for
diagnosis and treatment of reproductive system tumors and CNS tumors.
FEATURES OF PROTEIN ENCODED BY GENE NO: 161
This gene is expressed primarily in adipose cell and to a lesser extent in
liver
and prostate.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: obesity and
liver
disorder. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the adipose cell, expression of this gene at significantly higher or lower
levels may be
routinely detected in certain tissues and cell types (e.g., adipose cells,
liver, and
prostate, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma,
urine, synovial fluid or spinal fluid) or another tissue or cell sample taken
from an
individual having such a disorder, relative to the standard gene expression
level> i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for treatment of obesity and liver
disorder.
FEATURES OF PROTEIN ENCODED BY GENE NO: lb2
The translation product of this gene shares sequence homology with yeast
ubiquitin activating enzyme homolog which is thought to be important in
protein
posttraslation processing.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
101
This gene is expressed primarily in stromal cell and to a lesser extent in
retina,
H. Atrophic Endometrium, colon carcinoma and myeloid progenitor cell.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: defects of
stromal cell
development, neuronal growth disorders and tumors. Similarly, polypeptides and
antibodies directed to these polypeptides are useful in providing
immunological probes
for differential identification of the tissues) or cell type(s). For a number
of disorders
of the above tissues or cells, particularly of the immune and neural system,
expression
of this gene at significantly higher or lower levels may be routinely detected
in certain
tissues and cell types (e.g., retinal cells, endometrium, colon, and bone
marrow, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to ubiquitin-activating enzyme homolog
indicate that polynucleotides and polypeptides corresponding to this gene are
useful for
diagnosis or treatment of some type of tumors , fucosidosis and neuronal
growth
disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 163
This gene is expressed primarily in primary breast cancer and
hemangiopericytoma and to a lesser extent in adult brain and cerebellum.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: breast cancer,
leukemia
and cerebellum disorders. Similarly, polypeptides and antibodies directed to
these
polypeptides are useful in providing immunological probes for differential
identification
of the tissues) or cell type(s). For a number of disorders of the above
tissues or cells,
particularly of the immune system and neural system , expression of this gene
at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., mammary tissue, brain and other tissue of the nervous system, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
102
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis or treatment of various
tumors and
disease involved in neural system.
FEATURES OF PROTEIN ENCODED BY GENE NO: 164
The translation product of this gene shares sequence homology with proline
rich
proteins. Recently, another group has also cloned this gene, calling it CD84
leukocyte
antigen, a new member of the Ig superfamily. (See Accession No. U82988, see
also,
Blood 90 (6), 2398-2405 ( 1997).)
This gene is expressed primarily in Weizmann olfactory tissue and
osteoclastoma and to a lesser extent in anergic T-cell.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: ostsis and
immune
disease. Similarly, polypeptides and antibodies directed to these polypeptides
are useful
in providing immunological probes for differential identification of the
tissues) or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
immune system, expression of this gene at significantly higher or lower levels
may be
routinely detected in certain tissues and cell types (e.g., olfactory tissue,
bone, and
blood cells, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma,
urine, synovial fluid or spinal fluid) or another tissue or cell sample taken
from an
individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy-tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution and homology to the Ig superfamily indicate that the
protein product of this clone is useful for treatment of osteoporosis,
autoimmune
disease, and other immune disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 165
This gene is expressed primarily in atrophic endometrium and colon cancer and
to a lesser extent in some fetal tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: tumors.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the immune
system,
T
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
103
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., endometrium, colon, and fetal tissue,
and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis and treatment of tumors,
specifically
endometrium and colon tumors.
FEATURES OF PROTEIN ENCODED BY GENE NO: 166
This gene is expressed primarily in human primary breast cancer and to a
lesser extent
in activated monocyte. Although the predicted signal sequence is identified in
Table 1,
other upstream sequences are also relevant. Preferred polypeptide fragments
comprise
the amino acid sequence: VTQPKHLSASMGGSVEIPFSFYYPWELAXXPXVRISWRRGHFHG
QSFYSTRPPSIHKDYVNRLFLNWTEGQESGFLRISNLRKEDQSVYFCRVELDTRRSG (SEQ ID
NO: G41 ), as well as N-terminal and C-terminal deletions. Also preferred are
polynucleotide fragments encoding these polypeptide fragments.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: breast cancer.
Similarly,
polypeptides and antibodies directed to these poiypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the immune
system,
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., mammary tissue, and blood cells, and
cancerous
and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid or
spinal fluid) or another tissue or cell sample taken from an individual having
such a
disorder, relative to the standard gene expression level, i.e., the expression
level in
healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for diagnosis of breast cancer.
FEATURES OF PROTEIN ENCODED BY GENE NO: 167
This gene is expressed primarily in fetal tissues and to a lesser extent in
adult
lung. This gene has also been mapped to chromosomal location 9q34, and thus,
can be
used as a marker for linkage analysis for chromosome 9.
CA 02283299 1999-09-02
WO 98/39448 PCTlUS98/04493
104
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample. Similarly, polypeptides and antibodies directed to these
polypeptides
are useful in providing immunological probes for differential identification
of the
tissue{s) or cell type(s). For a number of disorders of the above tissues or
cells,
particularly of the embryo tissues, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., fetal
tissues, and lung, and cancerous and wounded tissues) or bodily fluids (e.g.,
serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
FEATURES OF PROTEIN ENCODED BY GENE NO: 168
The translation product of this gene shares sequence homology with Ig Heavy
Chain which is thought to be important in immune response.
This gene is expressed primarily in prostate cancer tissue specifically
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue{s) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: prostate
cancer.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
prostate, expression of this gene at significantly higher or lower levels may
be routinely
detected in certain tissues and cell types (e.g., prostate, tissue and cells
of the immune
system, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma,
urine, synovial fluid or spinal fluid) or another tissue or cell sample taken
from an
individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
FEATURES OF PROTEIN ENCODED BY GENE NO: 169
The translation product of this gene shares sequence homology with cytosolic
acyl coenzyme-A hydrolase, which is thought to be important in neuron-specific
fatty
acid metabolism. The gene represented by this contig has since been published
by Hajra
and colleagues (GenBank Accession No. U91316).
r. T
CA 02283299 1999-09-02
WO 98/39448 PCT/US98104493
105
This gene is expressed primarily in human pituitary gland and to a lesser
extent
in colorectal cancer tissue. This gene has also been observed in the LNCAP
cell line.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell type{s)
present in a
biological sample and for diagnosis of diseases and conditions:
hyperlipidemias of
familial and/or idiopathic origins. Similarly, polypeptides and antibodies
directed to
these polypeptides are useful in providing immunological probes for
differential
identification of the tissues) or cell type(s). For a number of disorders of
the above
tissues or cells, particularly blood, expression of this gene at significantly
higher or
lower levels may be routinely detected in certain tissues and cell types
(e.g., pituitary
and colon, and cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma,
urine, synovial fluid or spinal fluid) or another tissue or cell sample taken
from an
individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution and homology to rat cytosolic acyl coenzyme-A
hydrolase indicate that polynucleotides and polypeptides corresponding to this
gene are
useful for the detection or treatment of hyperlipidemia disease states by
virtue of the
ability of specific drugs to activate the enzyme.
FEATURES OF PROTEIN ENCODED BY GENE NO: 170
The translation product of this gene shares sequence homology with a
Caenorhabditis elegans gene which is thought to be important in organism
development.
This gene is expressed primarily in human synovial sarcoma tissue, bone
marrow, and to a lesser extent in human brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to, of bone, specifically synovial sarcoma. Similarly,
polypeptides and
antibodies directed to these polypeptides are useful in providing
immunological probes
for differential identification of the tissues) or cell type(s). For a number
of disorders
of the above tissues or cells, particularly of the bone, connective tissues
and possibly
immune system, expression of this gene at significantly higher or lower levels
may be
routinely detected in certain tissues and cell types (e.g., synovial tissue,
bone marrow,
brain and other tissue of the nervous system, and cancerous and wounded
tissues) or
bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or
another
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
106
tissue or cell sample taken from an individual having such a disorder,
relative to the
standard gene expression level, i.e., the expression level in healthy tissue
or bodily
fluid from an individual not having the disorder.
The tissue distribution and homology to Caenorhabditis elegans indicate that
polynucleotides and polypeptides corresponding to this gene are useful as a
diagnostic
and/or therapeutic modality directed at the detection and/or treatment of
connective
tissue sarcomas or other related bone diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 171
The translation product of this gene shares sequence homology with betal-
6GlcNAc transferase which is thought to be important in the transfer and
metabolism of
betal-6, N-acetylglucosamine. This gene product has previously been shown to
suppress melanoma lung metastasis in both syngeneic and nude mice, decreased
invasiveness into the matrigel, and inhibition of cell attachment to collagen
and laminin
without affecting cell growth.
This gene is expressed primarily in human testes and prostate tissues, and to
a
lesser extent in kidney, medulla, and pancreas.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to, cancer particularly melanoma. Similarly, polypeptides and
antibodies
directed to these polypeptides are useful in providing immunological probes
for
differential identification of the tissues) or cell type(s). For a number of
disorders of
the above tissues or cells, particularly of the immune system, expression of
this gene at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., testes and other reproductive tissue, prostate, kidney, pancreas,
brain and
other tissue of the nervous system, and cancerous and wounded tissues) or
bodily
fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
The tissue distribution and homology to betal-6GlcNAc transferase indicate
that
the protein product of this clone is useful for the development of diagnostic
and/or
therapeutic modalities directed at the detection and/or treatment of cancer,
the metastasis
of malignant tissue or cells. Defects in this potentially secreted enzyme may
play a role
in metastasis.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
107
FEATURES OF PROTEIN ENCODED BY GENE NO: 172
This gene is expressed primarily in fetal spleen and liver,
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: immune
disorders,
Wilm's tumor disease, hepatic disorders, and hematopoietic disorders.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the
hematopoiesis and
immune systems, expression of this gene at significantly higher or lower
levels may be
routinely detected in certain tissues and cell types (e.g., spleen and liver,
and cancerous
and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial
fluid or
spinal fluid) or another tissue or cell sample taken from an individual having
such a
disorder, relative to the standard gene expression level, i.e., the expression
level in
healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that polynucleotides and polypeptides
corresponding to this gene are useful for the treatment and identification of
fetal defects
along with correcting diseases that affect hematopoiesis and the immune
system.
FEATURES OF PROTEIN ENCODED BY GENE NO: 173
The translation product of this gene shares sequence homology with ret II
oncogene which is thought to be important in Hirschsprung disease and many
types of
cancers.
This gene is expressed in multiple tissues including the lymphatic system,
brain,
and thyroid.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for identification of the tissues) or cell types) present in a
biological sample
and for diagnosis of diseases and conditions: Hirschsprung disease and
multiple
cancers. Similarly, polypeptides and antibodies directed to these polypeptides
are useful
in providing immunological probes for identification of the tissues) or cell
type(s). For
a number of disorders of the above tissues or cells, particularly of the
immune and
central nervous system, expression of this gene at significantly higher or
lower levels
may be routinely detected in certain tissues and cell types (e.g., lymphoid
tissue,
thyroid, and brain and other tissue of the nervous system, and cancerous and
wounded
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
108
the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
fluid from an individual not having the disorder.
The tissue distribution and homology to ret II oncogene indicate that
polynucleotides and polypeptides corresponding to this gene are useful for
diagnosis
and treatment of various cancers. It would also be useful for the diagnosis
and treatment
of Hirschsprung disease. Preferred polypeptides of the invention comprise the
amino
acid sequence: MEAQQVNEAESAREQLQXLHDQIAGQKASKQELETELERLKQEFHYIEEDLY
RTKNTLQSRIKDRDEEIQKLRNQLTNKTLSNSSQSELENRLHQLTETLIQKQTMLESLSTEKNSL
VFQLERLEQQMNSASGSSSNGSSINMSGIDNGEGTRLRNVPVLFNDTETNLAGMYGKVRKAAS
SIDQFSIRLGIFLRRYPIARVFVIIYMALLHLWVMIVLLTYTPEM HHDQPYGK (SEQ ID NO:
642).
FEATURES OF PROTEIN ENCODED BY GENE NO: 174
The translation product of this gene shares sequence homology with testis
enhanced gene transcript which is thought to be important in regulation of
human
development.
This gene is expressed primarily in infant brain and to a lesser extent in a
variety
of other tissues and cell types, including the prostate, testes, monocytes,
macrophages,
dendritic cells, keratinocytes, and adipocytes.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: neurological,
developmental, immune and inflammation disorders. Similarly, polypeptides and
antibodies directed to these polypeptides are useful in providing
immunological probes
for differential identification of the tissues) or cell type(s). For a number
of disorders
of the above tissues or cells, particularly of the brain and immune systems,
expression
of this gene at significantly higher or lower levels may be routinely detected
in certain
tissues and cell types (e.g., brain and other tissue of the nervous system,
prostate,
testes and other reproductive tissue, blood cells, keratinocytes, and
adipocytes, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution and homology to testis enhanced gene transcript
indicate
that the protein product of this clone is useful for diagnosis and treatment
of disorders
involving the developing brain and the immune system.
r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98104493
t09
FEATURES OF PROTEIN ENCODED BY GENE NO: 175
This gene is expressed primarily in prostate and to a lesser extent in various
other tissues, including placenta.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to, cancers, especially of the prostate. Similarly, polypeptides
and antibodies
directed to these polypeptides are useful in providing immunological probes
for
differential identification of the tissues) or cell type(s). For a number of
disorders of
the above tissues or cells, particularly of the prostate, expression of this
gene at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., prostate and placenta, and cancerous and wounded tissues) or
bodily fluids
(e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another tissue
or cell
sample taken from an individual having such a disorder, relative to the
standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid
from an
individual not having the disorder.
The tissue distribution indicates that the protein product of this clone is
useful
for diagnosis and treatment of prostate disorders and cancer. It may also be
useful for
the diagnosis and treatment of endocrine disorders.
FEATURES OF PROTEIN ENCODED BY GENE NO: 176
The translation product of this gene shares sequence homology with
Sacchromyces cerevisiae YNT20 gene which is thought to be important in
mitochondrial function.
This gene is expressed at a particularly high level in muscle tissue.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases related to such tissues and
cell types
including: muscle wasting diseases. Similarly, polypeptides and antibodies
directed to
these polypeptides are useful in providing immunological probes for
differential
identification of the tissues) or cell type(s). For a number of disorders of
the above
tissues or cells, particularly of the neuromuscular system, expression of this
gene at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., muscle and cancerous and wounded tissues) or bodily fluids (e.g.,
serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
CA 02283299 1999-09-02
WO 98/39448 PCT/US98104493
I10
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution and homology to the YNT20 gene indicate that this
protein is useful for treatment and detection of neuromuscular diseases caused
by loss
of mitochondria) function. For example this gene or its protein product could
be used in
replacement therapy for such diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 177
This gene is expressed primarily in the brain and to a lesser extent in
kidney,
placenta, smooth muscle, heart and lung.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: neuromuscular
diseases, degenerative diseases of the central nervous system, and heart
disease.
1 S Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
neuromuscular system, central nervous system, and heart, expression of this
gene at
significantly higher or lower levels may be routinely detected in certain
tissues and cell
types (e.g., brain and other tissue of the nervous system, kidney, placenta,
muscle,
heart and lung, and cancerous and wounded tissues) or bodily fluids (e.g.,
serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
This gene or its protein product could also be used for replacement therapy
for
the above mentioned diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 178
The translation product of this gene shares sequence homology with caldesmon
which is thought to be important in the cellular response to changes in
glucose levels.
This gene is expressed primarily in multiple tissues including brain and
retina.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for identification of the tissues) or cell types) present in a
biological sample
and for diagnosis of diseases and conditions: central nervous system disorders
and
retinopathy. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for identification of the tissues) or
cell
T
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
type(s). For a number of disorders of the above tissues or cells, particularly
of the CNS
disorders and retinopathy, expression of this gene at significantly higher or
lower levels
may be routinely detected in certain tissues and cell types (e.g., brain and
other tissue of
the nervous system, and retinal tissue, and cancerous and wounded tissues) or
bodily
fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
The tissue distribution and homology to caldesmon indicate that
polynucleotides
and polypeptides corresponding to this gene are useful for treatment of
retinopathies.
FEATURES OF PROTEIN ENCODED BY GENE NO: 179
The translation product of this gene shares sequence homology with mouse
fibrosin protein which is thought to be important in regulation of
fibrinogenesis in
certain chronic inflammatory diseases.
This gene is expressed primarily in amniotic cells and breast tissue.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of breast cancer and abnormal embryo
development. Similarly, polypeptides and antibodies directed to these
polypeptides are
useful in providing immunological probes for differential identification of
the tissues)
or cell type(s). For a number of disorders of the above tissues or cells,
particularly of
the reproductive system, expression of this gene at significantly higher or
lower levels
may be routinely detected in certain tissues and cell types (e.g., amniotic
cells, and
mammary tissue, and cancerous and wounded tissues) or bodily fluids (e.g.,
serum,
plasma, urine, synovial fluid or spinal fluid) or another tissue or cell
sample taken from
an individual having such a disorder, relative to the standard gene expression
level, i.e.,
the expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The tissue distribution and homology to fibrosin indicate that the protein
product
of this clone is useful for treatment of breast cancer. This gene or its
protein product
could be used in replacement therapy for breast cancer. In addition the
protein product
of this gene is useful in the treatment of chronic inflammatory diseases.
FEATURES OF PROTEIN ENCODED BY GENE NO: 180
This gene is expressed several infant tissues including brain and liver and
various adult tissues including brain, lung, liver, testes, and prostate.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
112
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions which include,
but are
not limited to, brain cancer, lung cancer, liver cancer and cancers of the
reproductive
system. Similarly, polypeptides and antibodies directed to these polypeptides
are useful
in providing immunological probes for differential identification of the
tissues) or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
central nervous system, hepatic system, and reproductive system, expression of
this
gene at significantly higher or lower levels may be routinely detected in
certain tissues
and cell types (e.g., brain and other tissue of the nervous system, lung,
liver, testes and
other reproductive tissue, and prostate, and cancerous and wounded tissues) or
bodily
fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
The tissue distribution of this gene product indicates that the protein
product of
this clone is involved in growth regulation and could be used as a growth
factor or
growth blocker in a variety of settings including treatment of cancers.
FEATURES OF PROTEIN ENCODED BY GENE NO: 181
This gene is expressed primarily in activated monocytes and to a lesser extent
in
melanocytes and dendritic cells.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of immune system diseases and cancer.
Similarly,
polypeptides and antibodies directed to these polypeptides are useful in
providing
immunological probes for differential identification of the tissues) or cell
type(s). For a
number of disorders of the above tissues or cells, particularly of the immune
system,
expression of this gene at significantly higher or lower levels may be
routinely detected
in certain tissues and cell types (e.g., blood cells, melanocytes, and
dendritic cells, and
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,
synovial
fluid or spinal fluid) or another tissue or cell sample taken from an
individual having
such a disorder, relative to the standard gene expression level, i.e., the
expression level
in healthy tissue or bodily fluid from an individual not having the disorder.
The tissue distribution indicates that the protein product of this clone could
be
involved in growth regulation and could be used as a growth factor or growth
Mocker
in a variety of settings including treatment of cancers.
r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
113
FEATURES OF PROTEIN ENCODED BY GENE NO: 182
This gene is expressed primarily in placenta and several tumors of various
tissue
origin and to a lesser extent in normal tissues including liver, lung, brain,
and skin,
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of cancers of all kinds. Similarly,
polypeptides and
antibodies directed to these polypeptides are useful in providing
immunological probes
for differential identification of the tissues) or cell type(s). For a number
of disorders
of the above tissues or cells, particularly of the central nervous system,
respiratory
system and skin, expression of this gene at significantly higher or lower
levels may be
routinely detected in certain tissues and cell types {e.g., liver, lung, brain
and other
tissues of the nervous system, and skin, and cancerous and wounded tissues) or
bodily
fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
The high expression of this gene in multiple tumors indicates that the protein
product of the clone may be involved in cell growth control and therefore
would be
useful for treatment of certain cancers. Likewise molecules developed to block
the
activity of the protein product of this clone could be used to block its
potential role in
tumor growth promotion.
FEATURES OF PROTEIN ENCODED BY GENE NO: 183
The translation product of this gene shares sequence homology with the mouse
Ndr I gene which is thought to be important in cancer progression.
This gene is expressed multiple cell types and tissues including brain, lung,
kidney, bone marrow, liver, and spleen.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of all types of cancers. Similarly,
polypeptides and
antibodies directed to these polypeptides are useful in providing
immunological probes
for differential identification of the tissues) or cell type(s). For a number
of disorders
of the above tissues or cells, particularly of the nervous, immune, and
endocrine
systems, expression of this gene at significantly higher or lower levels may
be routinely
detected in certain tissues and cell types (e.g., brain and other tissue of
the nervous
system, lung, kidney, bone marrow, liver and spleen, and cancerous and wounded
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
114
tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or
spinal fluid) or
another tissue or cell sample taken from an individual having such a disorder,
relative to
the standard gene expression level, i.e., the expression level in healthy
tissue or bodily
fluid from an individual not having the disorder.
The tissue distribution and homology to Ndrl gene, which is thought to be
involved in cancer progression, indicate that polynucleotides and polypeptides
corresponding to this gene are useful for treatment of certain cancers.
Likewise
molecules developed to block the activity of the protein product of this clone
could be
used to block its potential role in tumor growth promotion.
FEATURES OF PROTEIN ENCODED BY GENE NO: 184
This gene is expressed primarily in early stage human brain and liver and to a
lesser extent in several other fetal tissues.
Therefore, polynucleotides and polypeptides of the invention are useful as
1 S reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of diseases and conditions: brain and
liver cancers.
Similarly, polypeptides and antibodies directed to these polypeptides are
useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
central nervous system and immune system, expression of this gene at
significantly
higher or lower levels may be routinely detected in certain tissues and cell
types (e.g.,
brain and other tissue of the nervous system, liver, and fetal tissue, and
cancerous and
wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid
or spinal
fluid) or another tissue or cell sample taken from an individual having such a
disorder,
relative to the standard gene expression level, i.e., the expression level in
healthy tissue
or bodily fluid from an individual not having the disorder.
The expression of this gene in embryonic tissues indicates that the protein
could
be involved in growth regulation and could be used as a growth factor or
growth
blocker in a variety of settings including treatment of cancers.
FEATURES OF PROTEIN ENCODED BY GENE NO: 185
This gene is expressed primarily in infant and embryonic brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of degenerative nervous system disorders
and brain
cancer. Similarly, polypeptides and antibodies directed to these polypeptides
are useful
in providing immunological probes for differential identification of the
tissues) or cell
T
CA 02283299 1999-09-02
WO 98/39448 PCT/US98104493
115
type(s). For a number of disorders of the above tissues or cells, particularly
of the
central nervous system, expression of this gene at significantly higher or
lower levels
may be routinely detected in certain tissues and cell types (e.g., embryonic
tissue, brain
and other tissue of the nervous system, and cancerous and wounded tissues) or
bodily
fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) or another
tissue or
cell sample taken from an individual having such a disorder, relative to the
standard
gene expression level, i.e., the expression level in healthy tissue or bodily
fluid from an
individual not having the disorder.
The expression of this gene in embryonic tissues indicates that the protein
could
be involved in growth regulation and could be used as a growth factor or
growth
blocker in a variety of settings including treatment of cancers.
FEATURES OF PROTEIN ENCODED BY GENE NO: 186
This gene is expressed primarily in multiple tissues including placenta, fetal
lung, fetal liver, and brain.
Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissues) or cell types)
present in a
biological sample and for diagnosis of all types of cancers including liver,
brain and
lung. Similarly, polypeptides and antibodies directed to these polypeptides
are useful in
providing immunological probes for differential identification of the tissues)
or cell
type(s). For a number of disorders of the above tissues or cells, particularly
of the
central nervous system, pulmonary system, and hepatic system, expression of
this gene
at significantly higher or lower levels may be routinely detected in certain
tissues and
cell types (e.g., placenta, lung, liver, and brain and other tissue of the
nervous system,
and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,
urine,
synovial fluid or spinal fluid) or another tissue or cell sample taken from an
individual
having such a disorder, relative to the standard gene expression level, i.e.,
the
expression level in healthy tissue or bodily fluid from an individual not
having the
disorder.
The expression of this gene in embryonic tissues indicates that the protein
could
be involved in growth regulation and could be used as a growth factor or
growth
blocker in a variety of settings including treatment of cancers.
CA 02283299 1999-09-02
WO 98/39448 PCTIUS98/04493
116
00
O O N N N M N N
.r O ,_,
O N 0. O~ Ov M N N
~'' 00 00 O
o ~ o
M ~' M ~ M V7
z ~ ~. O ~ ~ I~ ~ p'-"p O~ ~' M
~L ~~ d'
z o ~b ~ N
0
U
E..,. ~ Q, N o ~ M ~t ~'
z ~ p ~ 00 M ~D
V7 00
M
z o o ~ ~, ~ .-. N ~"
~n U ~ N N
0
.n
I~ ~ M
z d ~ O ~ .--~ N Ov ..., O
L~.v L
Q Q Q d ti W
N N
y ~ ~ M ~ I~ ~ M Q~ t~ ~ M OWE O~ ~ O~ l~ O~ ~ O~ l~ ~ ~ Q~
U~oN '° ~'~o n °'~o n °'~o n °'~o~n
°Wco~n °'~o n
~' ~zb ~N~~~N~~~N~o~o°o~o°o
O N O O N O O N N O
N N
Q~ N N
z ~ w w cA as u., w
a
"U
o x x ~ x x x
N N M M
~z
r r
CA 02283299 1999-09-02
WO 98139448 PCT/US98/04493
117
~
N t M 00 N
~1
a ~ ~ _
b~O~"'~ M ~
N N cY N
i. ~ O
H
w b_p L1, .-
O Cn M 00 N N N
Gr
w GU N,
N ~
O ~ . ~ .-~ .--~ .-.i ..,
~r
O
N
M M M M M M
w
~
~
~
.~. f3w N Q1 ~
w ~ O
~
.'~
~ 0, N N
G
z N O M 1~~
~ b
~ ~-~ M N N r'
C/~ U
,~,, G p~ 00 M_ ~O '~ U O
N vD cVi d' d' ~n
zo
o
""
~r M ~ ~r o, o
M
z~~o~c
0
a
W W W W >Q
N
N N N N
y
U'~N s ~~~~ ~~~~ ~~~~ ~oyo. ~ay~, ~~~~
Ll ~~o~n yoo~n ~~o~n yoom ~ 00
a ( Ov N CT N ~ N ~ N ~ N ~ N
z ~ ~ ~ ~ ~ ~ V\1 ~ N ~ V1' j
~ O O O O ) y
O p p O O O O O
N . --. O ~ M
~
a a > Q ~
x
00 ~ ~ ~ ~ a
~ ""'
" U x x x
x x x
z
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
118
w ~ v-, ~ ~r o, ' a ov
O v D --~ ~ N
O . ~ N
.b
~
~
v
_ r... . -.
w ~ 01 M M
~
~~' ~ G,
~ 00 ~ O
0 ~ .
w
b
_ ~ ~ , .
0 .,
w ~ Q.
N
~
M M M V7
O O
t1
O
' Oy y 0
p
z
o ~ ~ ~ o
~ O
U
p ~ ~ M M
z
o
o M I~- ~ ~ V1
M "~
Z w C Q' v~ ., N r..
O O N ~ v~ ~ N
~n U ~
'~ E~ a' ~" -" ~ ~ oho
z~ M
~
,
,
..., --~ N N
~'~ ~ ~C O O N O N O
Z
O
Q Q d O CL
p,
N N N N
a a
N t~ (~ C~~ h l'~ I~ C~ I~ M I~ M
U'~N s ~ov.~ l~ ~a'~' ~'~a' I~ l~
' ~o'~o' ~'~t' ~oyov
G~ ~no~ wootn ~o~ ~o~n ~o~n mom
U o
b ~' ~ ) N ~ ~ N O~ N
~ \' v7 ~ ~ ~ ~
N ~ N ~ O~ N O~ ~ O O O
V V y O
1 1 O
O O O O O O
G~ o
Q 3 3
x
x ~ ~ Q Q
w ~ z z w w
x x x x x x
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
119
~ ~ o y~7 N ~n o 0 00 ~ err'
O N y. ~-~ N vp M 00
M M N N M
'~
0..
C/
u.
~
4~ CQ Q. _
O C%~ N OM M N N
~
p
,r
O O O N O
r
c~
O ~ O p O O
~ ~ ~ p ~ N O
w
G
.b N I~ O ~ M
O o N o 0
O ~ ~ N M
~t ~ ~ M O N
M - N
M
O ~ a~ ~ ~-~ r. V7 O ~'
~ "' .,...,
v'~ U _..,
O" 00 ~ M 00
d' ~ M M M
C~ -, ~ ~ ~D
, .--~N .-.
'X N O O
'
z~~
~, O
,
N N
' N N N N N
~
...,
G ~~ p C C G C
N h C"~ (~ l'~ (~. l',-
~ i~ (T t"'. l~ ~ I~ Q~ I~ Q~ ~~-
M Q1 Q~ l~ pv ~ M O~ M Qy p~
~' M O~ M Ov ~tw '~T- M pv
~ ' d'
p (~ 1 ~~0~ 1 N~ "" ~~ ~,,~
~~Ov ~~OV ~ ~ w
o ~ N ~ N ~O O
0 ue O
O'
f-' ~ z '.d ' v ~ N ' G~ y O I\
~ ~ W ~ y w .. y y N~~
N Ov Ov ~ C ~ N ~
Ov N ~ V1 ~ cT cT O~ v1
~ ~n O~ ~ yn 0 ~ O
~ v~
O N N O ( N y
O O O
O O O O O O O O
d- ~ ~Y ~p
>
~ ~ ~ ~ a
x ~ x
O M M M M ~' d'
CA 02283299 1999-09-02
WO 98!39448 PCT/LTS98/04493
120
w ~ pW p M N V1 M
O ~ M ~ M M N
O
Q ~ C
d ~n o
N
w Ov ..~ ~., N N N
. -~ N M M
b ~ O V ~
c~ ~ ~ O
ur
w bA Q.
0 O O M N
L ~ ~ ~ ~ r1 r-1 ~ rl ~--1 rl
~~~o~. O N N ~ OM M
M M ~ M M
~ d' O ~D
~ vD N M M
CL W
~
~
O t~ ~ ~O
'Z O
~
O V~ N M M
U
N
M
zoos- N ~ N
W U~
Q" ~ ~ t~ c~ ~n
z /~ ~ r~ ~ N N ~ N N
Q Q Q ~ Q a
N N N N N N
U ~N ~ ~'~'Q' ~~' ~~.~'s ~'.~' ~o'MVs ~~~~
U L1 ~ ~ ~o~n ~ov~ ~o~n ~o~n
vo~~n mow
Z"O ~NO~ ~NO~ ~ ~NO~ ~NOv~1 ~NO~
~NO i
N NO v NO NO ONO
1
NO
O O O O O
O
~O M O
z~ '~ w ~ ~ ~ a
~
coo ~ x o o o
~
x x x x x
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
121
O ~ N O ~ N
O .....~
O ~ _. _
~
~ ~p .--, oo N .-~ ~D
U Q ,,."
a .O
%b ~ O ~-' M M N N M N
~
4_-' N 4Y
'~ ~,,_,
bD t3. M M N N ~ N
O ~ ~
H
w ~ G
N M -_ ~ v7 N_
M M t!1 M M ~!'~
O ~
b_O O l~ 00 ~ M 00
~ M
~
V7
C~
O f'~ h ~O
~
z
o
~
z M ~ M
o
o a,
z
o
o N
in U ~
E~ a'
z~
~
,
~ O
c N M M
rt
~r
O ~C
Q
N
~ ~ ~ N N
c. a. U y y
U'~N ~ ~o~~' ~a'MV' ~a'~' ~Q'~' ~a'~' ~o,''''o~
~'~
U o Ll oo~o~n oO~co~nyoo~n ~~o~n ~~aov~~
~n
~ cV p~1 ~ ~ Q\ N O~ G~ N
y j N ~ ~ i ~ ~n N 'C~'N
t j ~ V'1
~n
O O O O O O O O O O O O
c~ O O
w w
a ~ ~
U U O O O
U
x x x x x x
a~ _ _
ON N N N N N
CA 02283299 1999-09-02
WO 98139448 PCT/CTS98/04493
122
~' ~
O
a ~' ef' M ~ M
Q O
w ~ v .-~ .-. v~ .~ .-. ~.
%Zj ~ O ~-' M M N N M N
~
N 4_..~ ~
O
~~w
O O N O O O
p
~ M
~ M M r. ~-~ M
~0,~'"
M M V7 M V7 M
w
O
C ~. ~ 01 N I' ~ O
z "-' s.'i'..
O ..: dp 00 .-.r l~ M - N
C~
O vp v~
z
~
o ~ ~, ~ M
~
M ~ M o 0
f O~ V1 ~O V~ M
H
z w ~ -~ -.
~'
p ..-~ .-, .~ . .
O ~,
'v~
~ H ~"
M
~ ~ ~ ~ ~
z~
,
,
N
M M
M N N M
Q" ~, ~ ~ ~ r
O U GL G, ~. fy G-i
N N N N N
c~
.
a
~ ~ ~ ~ ~ c~ ~ ~. ~ ~. r t-
U'~N i ~o~ oo~~ov oooyo~ ooo,~o~~ oooyo~
~ ooo~~~
U o p ~ ~~om ~~o~n ~ oo~n yoo~n yoo~n
~~om
zb ~ ~N ~ ~ j i ~N~V'
i ~ j ~
l
Q~ N~~ yn ~ yn c 1
O yN O
O
O O O O O O O O O
N ~ 41 00 00
o ~
y N
z
~ z w w w w
~ W W W W a
V r
n
x x x x x x
N N N N N N
CA 02283299 1999-09-02
WO 98!39448 PCT/US98/04493
123
N ~O ~O ~ M O
' ~
J O ct N N V
Q
..-~ O_ _ _
a O ~ ~~ M N N M N
U
0
~
~
~ w ~-0 ~ 00
O N ~ N
~ M N .-.
O ~ ~
~_~ ~
M M M M V7
w
N N O ~t' N M
~
~ w M ~i' t,-
O
O N O~ I~ h l~
p ~ U N O ch N~ N
00 M M
z
o
o
m
N
M cT
O O ~ .-, M ~n O
~n
~n U ~
CT N O ~ ~
O
'
, o ' N N
O
~ M ~ V
x x x
x ~ ~ ~ ~ x
o ~ o~ ~ ~ ~ ~,
j N N " ' " N
a o a
. . ,
y
~rn~o~ o~~Q. oyv~ ~~~o~ ~
U oovo ~ oo~ ~ ~ ~~ov~ ~
L1 yoov~ ~~ov, y0
o ~ O ~ ~'' O 1 O v ~
z ~ ~ O ~ ~ O ~
~
Q C~ N N N V N N N
~ N O O
~
O O O O O O O O O O
M
Q x U
L7 > ~ ~ ~ W
UU x x x
x x
a~
O O 00 Q\ O ~-~ ~' N
U
Z N N M M M M
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
124
M ~ 1 M ~ ~
O N
~a
O M
:b a p V ~ .-. O~ N M
~j~,-' M .-.
N i_, ~ O
Ar
~
a ~ c,.., Ov O o~0 O~
~0 ~ M
O ~
~
N
' o~ ~ ~ ~ h
V1 M M ~ M
z w. 4 o o. ~r M
~ o M
~ o .-, h ~ o0
o f
~ G.~
~n
i.
z w. ~ b Wit'
o ....~
p U h 00
h ~ M ~ G\
O U1 d'
M
z~.~~-
N
00 00 h h
~O .--~ ~' O~ .-,
Z ~ M
~ M ~r
' C/7
j ~ d j ~' N
O (3. f~. 0.. GL O. C.
N N N N N N
a
h h h h h
U O ~ ~ ~p ~ ~p yo o ~ ~p yc o yp o
~ ~n o ~n ~n o v~ ~n ~n
O Z b N O ~ O N O N O O~ N ~ N
~ ~ ~ ~ O ~ O ~
h i
Ov 1 O~ G~ NO ONO
pN O N NO
N
O O O O O
O O
x x
3 z Q Q
~ ~ ~ ~
a . ..,
a u u
x x x x x x
O N M ~ ~h
U,. z M M M M M M
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
125
~~ o~ ~ ~ N ._ ''
,
O
-v
'~
ar
~
y O oo ON c M
O
y_.. ~
i"~ ur ~
Ar
~,_, b0 CL
~ O~ M a1 OM p
c,., b_D
p. .-. .~ .-, ..-~ .....
s.. O ~
M ~ O
( M V~ M
4r
O C
Cs. N .... ..... t~ 00 ..-,
z cw. ~ ~ ~, ~D ~ ~O
O
~
~
~
~
z o ~ -d N ~ --~ h ~.,
os- ~ ~ g
z
o ~ M M V7
,~ ,~
zw~~ ~ ~ ~ o
O o a~ ~ ~
c~ oo .., ..,
~" ~' M
~-. .~
V7
~~ ~ o
o~c ~ ~ ~ N
z
x x x x x
x ~ x
~
Q ~ d Q a
j N ~ N N N N
c ~~ ~c
a
.r a~ ~ ~ ~ r- r, ~ r. c~. ~ ~ ~ r-
U'~N ~ ~~~' ~~' a'~' a'~c' ~Q'~' ~,~'~.o~
U O ~ ~~o~n ~ ~ ~ ~ oo~ ~
~~oo~n ~.DO~n yco~n yoom
z "L~ 7 ~ ~ ~ O ~ ~
~ 1 ~ O ~ ~' O ~
O O
Q ~ ~t ~ N N N ~ N N
N N O O O
O O
O O O O O O O O
Q
c U U
O
V x ~ GCa CA
x x x x x x
O M M
M M M
~z
CA 02283299 1999-09-02
WO 98/39448 PCT/US9S/04493
126
N ~h
~ O O M M - O
r.~ Vl d
O
'b
~ ~ ' O C~ ~'
~ v
w N V ~D N M
b ~ O ~ N 1
~ N
~ G
V
O ~ ~ N N ~ N O
v w a0 A~
O ~ .-~ .-., ~. .--. .-.
M M M ~ M
_w
vp
G.~ N .-~ ~, ~
~ ~ N - M
~
O N N M O~ ~D
Z '-' ~
~
~ ~ N .~ O~ O
b ..." N ..-. ~t M ...,
v~ U
z w G p~ ~. ~ Wit' O~
U ~j N O N ~t ~O
ct
z w O ~ ~ O ~
N
O ~. a> N
i
n
.-~ o o~
o '~ o
c 0
-
V~ ~n V~ v~
N
~ x x x
x
~.
d a ~ Q Q
N N ~ N N N
N
U ~N ~ ~~~a~ oo~~rno~ov,~.ovovoy~ o~a.~~ ovoy~
U '~O~ '~oo~nQ'~o~n '~o~n a'~o~n '~o~n
G~ o
Qoz~ ~ ~ v ~NN WNN~ ~N~u1
~ ~ ~N \'
N~ N~ ~ V O O
~ O
p O p O C7 O O O O
,~ O ~n rt ~ oMo
M
o ~ x ~ z z
vU x
x x x x
a
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
127
w N
N
~N ~ C
U w ~ ' ~ O~ ~ Q\ ~D
b ~ O ~' ~~ M -~ N M
~
y ,_.. ~
O
~ per" 00 <M 00 Y> O
N M
N
V M v'~ M N
't
z w ~ O ~ ~ O ~ N O~
~
O ~ N O
~"Q~Q. N Wit' V1
C
z o ~ "O ~ O Wit' N
~
~ U N tt
__.
M
~o h ~ O .
c
~,.., a\ .o ~n ~r o N
a ~'
O o a~
~
U ~
n
H ~
~ N o0 (w D N -
~
!
N t N
x ~ x
' N N N N
'~ 'c 'c ~~ U U
c. a.
h h h h h h h h h h
~ ovov'r'~ova~'~'o,ow'r'ovovov'~'ovo~~'r'o~Q.~'r'~
~'~ . ~'~ ~r,. ~~. ~t
~t~
~~ l ~~ ". ,. ~~
U ~ ap vD ~ yp O Q,~ ~~ ~
O v' yp O V7 op yp yp yp O
v~ O ~n O ~n
~n
"~ C~ N 01 N ~ N 4\ N Ov Ov N
Z b O ~ O V~'1 O N O ~ N O V1o
1 N
~
O O O Q O O O p O O O O
O
00 h M M V1 V1
G1 a o o h h
Q ~
~
~ x
o
_ x x
x x x
~ o ~t ~n w o h h
CA 02283299 1999-09-02
WO 98/39448 PCT/US98J04493
128
ue ~ Q N
d V
-
U ',-. ~ d~ --~ Q\ N --,
v M M ~ N M
O
O
~
w b4 Cl.
O oo N O o0
M
~ ~ O V'1
~ ~ Or M 00 ~ ...r Ov Ov
O Gl M .--n
e
C
z ~ ~ b M 00
O M -~ .-
U
O~ I~ M o0 t~
~
t~ ~ o ~n
o
C/~ ~-~ --~ ~~ N N
M
Q1 ~D M 00
O z O ~ C'
E-.. .--~ N
C/~
~
N V1 N ~O
y
Q Q a
;x a a
N N N ~~ N N
' '
U ~~~~ ~~ r ~o~~~ ~o~~o yo~~a~ ~oyo~
~N a ~
U yco~n ~~o~n ~~ov~ yoo~n ~~om ~
~ o
z ~ ~ ~ ~' V
a ~ Ov N Ov N ~ N O~ N Ov N Ov N
~ ~ ~ ~ ~ v ~ ~ ~
1 1
O O p O p O p O p O p O
M M
U a a
z~ a ~ ~ pq U U
U
x x x x x
~ n u
v ~ ~ ,
~z
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
129
~~ orx ~ -
".~ M N ~' M M
O
'-' O ~ ~'~ M ~ N M N M
y O
H
c,~, 04 C3,
O~~ O ~ ~ O N O
b
0 ~,
_ ~ rr .~-w ~ ~.r
rj
M t M M V7 M
M O ~ N M M
C, .-. V1 O~ N ~t N
C
b M N M
Ov N ~t N
M ~ N
00
Cn
~~ N M
00
z ,~" C p~ ~ Ov M I~ N
O ~ N 00 N N
v -'
U w
~
E"' O' ~h N ~ ~ 0~0 '~t
E- z v~ N M
~
~
a Q a Q a
j N N ~ N N N
v v a v v
N
UyN
U G~ ~~ov- y~ ~n ~~ ~n ~~o~n ~~ao~ ~~n
~O ov-,
[~ I~-yOy ~NOv I~NOW ',-NOv ~NQI I,..yOy
'C ~ O~ O~ O~ CT O O~
<C ~ z
~ O N O N O N O N N O O N
O O O O O
W W U
c Q
0. ~ x ~ ~ 4
x x x x x x
C O N N M ~t
c~
CA 02283299 1999-09-02
WO 98139448 PCT/US98/04493
130
, O ~. _
O ~ N N
'b
:p ~ O L N ~ N ON M
~~
py_.. ~
O
C1,
~ ~
00 O O~ O
~ 4.
~'~~ ~ ~ M
z
_w
~n O ~ N~ ~ ~ ~D ~ N ~ N
V N N N Q~ N
N
O ~O M N
z
~
O ~ ~ N N Q\ N
U
H ~O pp ~D ~ ~O '~ 00
z
o
o ~ ~ ~ ~ ~ ~ o
s
M
f'-. p" ~-~ M ~
4-~
z
O ~ ~ ~ ~'_' ~, N M
in
E'" Q' M M d' N ~ 'n
O
~
z~
,
z ~ ~ z N ~ N vp N vp ~D
,'X~,
x x
x x x ~
0
N N N N ~~' w
N
N
ar ~ ~ ~ ~ ~ ~ ~ ~ ~ [n ~ [(~ ~ [n
U ' ~ N ~ cy ow ~ ov oy ~ ~ ~ av oy
i ov ov o~ ~., oy. ay ~. o,
o~ av o,
~' '~ ' ' ' o~n
U W o~ 'v
o ~ ~o~n o~n ~o~n ooo n ~ o
.o n
Q ~ z ~ ~ N ~ j ~ N O ~ j Ov j Q\ N
O ~ O N O ~ ~ O n O n O ~n
N N N N N N N O
p O O O O O O
O O O O O
M V~ ~ M ~ ~D O~
C7 x z
w
~ ~ Q Q ~ W w 3
o
_ x
x x x x ~ x
o ~n ~ ~o ~ t~ oo a\
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
131
O ~
f ~n ~O ~D d' M
a'
U N N M ~ M N
~ ~'.~
~.
~ f ~" CJ7
,_, O I~' O N
M M ~! M 41
z c,.., M O Ov Ov
y~
~
~
G ~"
, ~ ~ N ~ M
"
~
~ G.,
Lt
.i
c
z~. ~b M
o ~
v~ rr~ N .-. M
U
M OpO
N M ~' t'~ V1
~n U ~
00 ~n .- c~ ~ o
z~~~ N O ~ N ~ N
~
N ,~C, x ~C x
N
G, Q, G, 0.
Q Q Q Q
N N N N
N ~ ~ j
c~- ~ r- ~ ~ c,
U'~N i ~~~~ ~ov.'~~.o,ooo~~o y~~ov goyov c~~~ov
U 0~1 NO~n ~~o~n ~~oo~n woo~n yoo~ yoo~n
~ O~ j O~ j ~ N ~ j CT j ~ j
~ v1'~ ~ i ~ in ~ ~ ~ i y!
i
O O O O O O p O O O O O
~ ~
_
3 ~ ~ ~
x w w Q Q
x x x x x
c~
CA 02283299 1999-09-02
WO 98/39448 PCT/U598/04493
132
M
' N O ~ N M
O O ct
~
b N O H M M N N M
~
f.., ~ O
H
O O O N N O
C/~ p.,
.-.
z
M V'I V7 M M
w
2 w v O c~ r' O ~ N M
G ~, ~..
Q ~O o M .-
O O (~ ~
~ N
LL N
''
v7
C/~
z ~
~b
o ~ N l~ N
N ~ N M
O O 000 ~ ~ N
%
C
ih
zw ~ o" ~ ~ O
n
;,.~
V c
p F" ~ M 0
0
~ ~ ~ N
z 04 O~ ~'
E"~ ~ N ~.,
~
x x x
x x
~.
Q Q ~ ~ a a
N N N N N N
.r a~ t~ ~ t~ ~ r- ~ t~ ~ t~
U'~N ~ ov.~' o go'~' o'~' g'~' c~o~~av
a'~' o
p yao~ p ~~o~n o o,~o~n o~~o
yoo~ ycoln n
~zb ~ ~ jO~ n ~NO~ ~NOin ~ jO
O~ ~NO i
a n N ~ n NO NO
N NO NO
N
O O O O O O
p O
a~ ~ ~ W a
~
~
O O
x
x x x x x
~z
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
133
N N
'b
O ~
0 M M N N
'~ L~ ~ j
L1.
w b_U O.
M O O N
p"
~_~~~
M M V7 M M
O C
Q' ~D d' ~U "" t'~ N
z w w
~ N t~ N N N N
C
O ~ ..... ~ N
p N f N N N N
' ~
~ U
o _ _ _
O O C% ~ N t~- ~ N
M
N ~ __
~' .~ M M
N ~
O
y ~ ~ N
O
Zi~~~C N ~ ~ N 000
x
O 0.. fl. U U O-~ Gh
N N N
~ ~ N
a ~ Q a'
a~
U'~N ~s g'o~ g~o g con o~~~ g~~~ g~~.~
i
E~ ~ ~ ~ ~ ~N ~N ~N
~N ~
zb O vOv vO~ O O~ O~
~ON ~ON ~ONO ~pNO ~pN ~pNO
O O O
Ov Ov Q\
~
d ~ a. ~ ~ U
~ W
E ~ ~C p
-~
x x x x x x
~z
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
134
00 -~ !w 0
O O M ~ .-. ~ 00
~
r. I
.l
b d '~ c
... O _
~~j 4 O ~ ('NV _ _ ~ N M
~ M M
y _~.. y
O
N
~ ~
w ~
O N O O Ov N O
V7 G.
.-.,
~ L1~
M M M V1 M M
w
E-' O c'~ ~-~ O\ O d.
O
N 00 vp
O O~ O
o 0 0
U
z o ~ ~ ; M o
o
o
z w ~ cT' ~ o ~"' ~t Ov
v~
~
U ~
n
O ~ N
~ ~ pp O N M 00
~O O~
N ~"
~
x 00 00 00 N O 00
O
a
x
N
N N N N N
a a
U'~N ~s o~~.o' g~~ov oov.d.o~oa~~y ooyov ooyo~
U o ~ ovoo~n ~o~n voov~ o.nov, ~~o~n ~~o~n
~' ~zb
p N p N p N p N O N O N
O O O O O O
00
~
d x ' ~ a t7
A w a w
~ x x x
x x
x
-i N M M
c~
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
135
O O N M
O
~ M ~ V~'1 '~' M
w ~
~ M ~--~ V7 ~ M
~~~~r~'~ ~ ~ ~ M
~1
E"'
O c~ ~
'i'
~ ~.. N ~ O
p w
~ ~ ~
z ~ ~ o
~b
o M
W,., c v~ ~r ~t oo ~ 0 0
~ 00 N
O O ~ M O~ .~ 0
' ~
~n U ~'
M
E-~ o" M
O
E.., z V1 t~ 00
.-~ N .-
za~
x
O N N ~ ~ N N
N
~ N N N N N
y
U ~N ~a $o, c~o~ oo~.~.o~ooya~ go,~.o~oo~.~a.
U a, a~ o~n o oo~ om
~ o~~n wc'~~n
o
y ~ ~~ y ~ yo
O yo
QLWZ ~ ~ ANON ~NO~ ~NO~ ~NO~ ~NO~
~N O O O
O
O O O O O O O O
M
M M ~ ~ N
'
N V
J
~ x x
x x
~
z
c~
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
136
O a\ ~ a\ ~ p
'
rY v0 M C M
~
O _ _
O M ~ fV M M M
V
O
~
Gr
~ ~
4., b4 O
O V ~ ~~d' N O M O
7 G,
~-.a
w
M
M M M
z~.~o~~ ~ ~ o
w Q ~ G, vo ~n N ~ M
z ~ ~ M ~ o ;
U ~o ~n ~n ~ M
zw~~ ~ ~ ~ ~; N
M ~ 00
V~ M M N M
,~
00 ~' N
O
z O ~O O~
~.
~
z~~ ~ ~ N
x
o
x
~. ~. x
.
o ~ ~ Q
Q Q ~
N ~ ~ N N N
A o
. ~ ~ a
U'~N ~s o~~' gQ'd-o'oQ'd.' ga'~' oa'~' oo,~o~
U O ~ ~ov~ ~o~n ~o~n ~o~n tom ~o~n
~ Ov N ~ N O~ N Ov N O~ N ~ N
~ ~ ~ ~ N ~ ~ ~ ~ ~ V~'1 ~ ~
O O
c O O p O O O O O p O
~O l~ N V7
z~ ~' w w ~
z a
w
~
U
x x x x x
c~
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
137
N ~ v'7M
G
V ~.. N v M N M
~ O ~ ~ M N M N M N
O ~ ~ O
c,., by a. ~,
~ M N M ON OM N
~. -~ -,
. .
~
M M M M
O
N
N
C
,," O o0 I~ w D ~t vo
cT ~ O O~ N N
O Cn N 00 ,_, ~ I
M V1 f~ O M
O 0 ~ N l~- i~ ,_, 00
C/~ ~
,-, ~. N
~
,, ~ N N o_O
0' ~ .~
O
O N ~ I' Ct
N
~
U ~
n
00 ~ O N O c~r1
O M 00 I~ ~ V'7 00 ~f 1
E-. V7 .-, .-, ~.. N .~ N
za~
x
O N ~ ~ ~ N ~ N
N
N N N N ~~ N N
'
a
a
a~ ~ ~ ~ ~ _~ ~ ~ _~ ~ _~ ~ _~
~ l
N
U ~o~ Wo~ OvpO ~c 0 D~~ Ov'00 O~o
~ i n v n n
~
z ~ ~ ! i ~ N ~' 1
~ ~ ~ N i ~ ~
~ N ~ n ~ ~ ~ ~ ~ v N N ~
d ~ N ~ ~ ~ ~
O
O O O O O O O O O O O O O
C~ ~ M ~- N
d ~ ~C
~ ~ w N n a ~ a
o
_ x x x x x
UU
x x
O O N M ~t v~ ~ ~O ~D
c~
CA 02283299 1999-09-02
WO 98/39448 PCT/I1S98/04493
138
M
~ ~ ~h ON
O ~ l~ I h
'b
:r O
p V .~; N N M ~ N
N C
a ~ w ~ ~ M N o0
O ~ N M
~
ii, v'
~
m
z ~ ~ N
~
~~
o ~
~
z w cd ~ M
..-. o
O O V' M
U r.
~r a~ ~ oo t~
M ~
oc, ~ o a~ ~. O
V7 ~ o
M (/7 .-, .-. N
z~,~o~
p O y ~ N ~ 00
U~
O O ~. M 00
z ~ ~ ~~ N
E-. .-. ~
C~
O
O
k ~ ~ ~ ~ k
Q Q ~ d Q
N N N N N N
N = ,' ""o'~' ""a'~ '-"'a'~o'""'a'~'""'Q,~ov
U' "'~,~ '
~ ~ ~no~n ~ o~o~n ~o n ~~o~n
U o ~ ~o n o.flo~n
Q ~ ~ ~ ~ N ~ N ~ N ~
Z ~ ~ ~ N ~ N ~ ~ ~ ~
~
~ N ~ ~ ~ O O O O O
O
O O O O O
M M
d d
~ Ca
~ ~ Q Q x x x
x x x
o r- o0 0o a. o. o
CA 02283299 1999-09-02
WO 98/39448 PCT/LJS98/04493
139
O ~
o0 ~ ~ N N
O_
.
_ _
b ~ a" N M M ~ M
~
i_.. ~ O
V ur
4r ~
O O 00
y
Qr
~'
~
w
~
a
~
(3; 01 N
.
,
,~
~
C
O N o0 \O ~ 00
U V7 M
z
~ M ,
M
Z w ~ N f~'
~ ~"
p O ~-" ~' ~ o0
'
~H o" ~ ~ ~
z'~ox O O N N O O
a" ,'~' ~C ~C ~C ~C
U G-i G~, O.r C, Cl,
N
N N N N N
y y ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
U ' ~ N ~ ~ ~ ~ ~ h .-~
-~ ov .--~ ~., .-~ -~ ov ov
ov ov ov ov ov a,
o~ ov o~ '
U C~ ~~~n ~oon Q,,~on ~~on ~~c ~on
~n
~NO~I ~NOt~'~1~NO~ ~NO~ ~NO~ ~NOV~1
O O O O O O O O O p O
p
~ M
Q H
A
x x x x x
x
~z
c~
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
140
opo ~ ~ ono
N N N
O _
b O ~ ~~ ON N N ~ ~ ~t M
~ ~ 0
~ ~ ~
O N N V1 ~t
C/] (~,
~
~. .--~ .... -
~ G.
z
_w
' O O ~ ~ ~ N N M N
~O
Q. N ~ 00 ~ ~D ~ Wit'
z ''" ~ ~ N
b ~ N N ~
N ,~ 00 00
~n
U
C pm n ~t ~ ~ oNO ~ N
M
O ~ ~ ~ O O V~ ~' M
00 d' ~
N --. N
C p ~ N ~O 00
O O ~ ~ ~-~ O O
~n U
0
za~ox O O O N O
N N
~1. Qr
d a d Q Q W a
N N N N N ~ N
N
~
~ ~~on aon ~~on ~on p~on c ~oon
~
z ~ N ~ ~ ~N ~ ~N~~
\' ~ ~ ~
~ N~~ N~ N~ N~ ~~ 0 O O
Q~ 1 O ~0
O
O O O O O O O O O
Q
H
a a
V W
x x
O ~ ~ a\ Q~ O~ D\ O~
~z
CA 02283299 1999-09-02
WO 98/39448 PCT/LTS98/04493
141
t'~ I~ I_~~ N N
,...a N N
'b
C
O
Qv ~ .-r M
w ~1'
V ~ N M M ~
O
,,,,., pp
~L O OM N d'
LL, ~ L~
~
~
~o~.
O
0
w
C
O N M ~O
r-
o
H C Q"
00 N .-. ~ 00 ...,
O ~~ ~ p ~ ~ N t
M N N N
O~ h
~ o v~
o '-'
in U ~'
~E"~Q' O ~ M ~ ~ V1
z ~
E.r ~-~ N N N
C/~
ZI~~~C," N O O
Q Q Q Q
' N N N N N
. .
~ C
r.~ r~ r-~ r.~
C~ ~ ~ ~ ~ n ~ ~
U'~N rd ~'~ ~'~ ~ ~ ~ C
a' a' ""~ ~"~ -'~ ~o,
c' Q' ov cT
U L7 o~ i ~con ~~on a,~on oon ~~on
Z 'b ~ ~ ~ ~ ~
~ ~'" j ~ ~
Q Q N N N ~ N ~ N ~ ~ j
v ~
~
O O O O O O O O O O O O
~ w
Q w w w as
s as
a a W w w a
x x x x x x
' O
z
CA 02283299 1999-09-02
WO 98/39448 PCT/~JS98104493
142
. ... O N
O N ~ ~ v~ M
O Ow 1
'b
4-. ~ O O~ O~ O ~ M C ~1
O N N
A
V
w
M
~ ~ ~ ~ " -",~, ~ ~
~ Ar
a ~
o
~
~
~
d
~.
~ a,
~ O
~ ,~ N -~ N N t
~ , r
-y
d M
_D
CL
LT
V7
r C~
D1
Z ~ N M O
~ b
0 M N N
U
M ~ ~ cn N
in U ~ 'O N ~
.n U ~
~ ~ M ~ ~O V7
~
0 ~ ~ ~ M N
..
~ ~, ~ ~ ~
~
~ ~ N ~~ N
N
x
~ ~
~. ~ ~ Q
'""' N N
~ N p . . .
a. .~ ~ a c
~t~~ ~~~~ .~~~~
U ~ ~ p n
N ~ ~ ~
p
o o ~N 0~~ ~N 0~~~ ~ o
o~ ~ o'~ ~
b ~NO~ O~ _ _ N~~ ~N~~ ~'NONO
~N~ N O~ (~
~
N N O O O O O O O
O
p O
O
N ~ O O
Z ~ W N
r~ a ~
U ~ x x x
~
x x x
~ ,-,N N M
O 0 O 0 0
o o ~
~ ~ ~
r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
143
M M 00 r1' M
1p
O O N .-. f~ f".
.-. O _ _
O M M v0 c~~'1
N~ ~
w ~D A.
M
w
N~ ~ ~ M
M M -~
L,~ ~ G, M M O~ ~ .-
p ~'b
M M ~ O
U M M 01
Zw ~ v' y 0 M O ~
O
.-. .--m -" p I~ I',
p
~ p O ~O Ov M O ~U
v~'1 ~ ~ M N _
s '~t
U ~
n
N N ~ M
~
N ~ .- ~ ~f' M 00
-~
N ~_ M
za~ N N
~
O ~ N .--~
w. 4.
G~ 0~ Ar
w w w
a a a
N N N
a a a r v v
N N N
a~
U oN ~ ~'o, .-.a,~o'.-.o~~~-.~~ov .-.oy"o~--~~~ov
o, 0\"~\ ~\~\ ~\, 0\'~'\ p\~t'\
0\'~\ \
N ~N ~N ~N O
-~ '
,
~zb Ov O Ov ~NOI Ov NO~
aG~ Ov \ Q' a, O~ ~
O~ C'~
~ ONO ONO ONO ONO ONO ONO
~ ~ ~
a U U U ~. w G
i.. z"
z ~ oa m a~ a a a
a a
o ~ > > >
U x x
x x x x
a 0 0 0 0 0 0
CA 02283299 1999-09-02
WO 98/39448 PCT/ITS98/04493
144
~O O O ~ M
O N
G
.-. O_
U c,.., U .~ ~, y-~ Q1 ~ d'
.
~b ~ O U M M N N M N
C
y_., U O
s"' ~Ir C~
''' CL
p ~ ~ ~ ~ N N ~ N
~ ~_ A~
O U .-. .-, .-~ .-.
~ Ar
z ~", ~ ~ ' . ~ o cw
~ '
~ v~ ~ , ~ M N
~ G, ~
"~
~~....,, .-~ pv o0
O
U N ~ due' N
o ~n oo ~ a. o
~ ~ 0 0
M
t~ ~ 00 00
O ~ U ~ ~ ~ ~ N N
~n U ~
N O
z~~~ ~ N N ~ '
N
x x
x ~ x ~
Q
Q Q a Q a
N N N N N N
U ~' ~ a'~' a'~Q' ' ~ '~tQ'
N ~ ~'
~ o~ v o o o o
oo
~ N ~ N ~ N ~ N ~ N ~ N
~ ~-~ p~ ~ ~'' ~ ~ ~-~ O~
~' .-,
b ~ ~ ~ ~ ~ j ~ j ~ N ~ N
O ~n O n O n O ~n O tn O ~
p N p N N N N O N O
0 0 O O O O
O O
~,
W W
x ~ x x x x
z 'o o ~o ~o o o
.,. r ,
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
145
~ pLx N O M p ~ N
~ ,-. .--~ .~r N ~O M
O
O
v
4... ~ .--n
O 47 M N M M N
w ~D ~
M N M ~ N
o_p G~. ..." .-, .-.
w
O ~
w ~ 0.,
H
v
~
G. ~ ~!1 N o0 O l~
~ (~ ~~
~
~ M M ~ M
O .-.. .-.~ N .-. M
pp
p~
~
~
~n
'
' cil
O V'1 Y1 N 00 I
O
O l~ ~~ M M M
N ..-~ N M
z ~, ~ ~. ~, M ~ ~ ~.
o g o ~
z
o
o
~n U
O M 00 ~
N ~ l~
O N l~ ~O V7
~, a ~. ~ ~ o ~ o
z~~x
x x x x x x
x x x x ~ x
p
N N N N N N
. . .
~ ~ ~
"a'
U o.,. yoo~n o~'r~" o"~~~ o o..",~1
~O ~'l
E" t~~OW ~-vOW ~vOW ~NOW ~NOv tINO.-.~
"L7 Ov Ov CT Ov cT O~
~
z
~ ONO ONO QNO ONO ONO ONO
~
A o 0 0
Q
Q O
x x x x x x
~ o o ~ '~ ~'
z o
CA 02283299 1999-09-02
WO 98/39448 PCT/LTS98/04493
146
a\ 00
O O N N ~-~ O~
p
U Q c,., N .--~ p~ ~O M
~ . p
'-d ~ O ~ N M ~ --~ N
~
w
~ N O ~ ~ N
_~
u.
M ~ y n o
~ ~ ~ ip t~
p .~ bpi ~t
p
z
b
o ~ ~ ~
rn U .~ oo ~, N
zw~~ ~ ~
p ~ ~ m o~ ~o ~o
.....
o ~ ~ ooo ~ c
w
sn
U
'~ E-~ Q" ~ o M ~ O
~
z~
,
,
z~~~~
x x x x
x x
Q a Q Q
N N N N
'c c ~c
~ ~ ~ ~ ~ ~ ~ ~ t~ ~ r~
U'~N ~ oy' ~~' a'~' o'~' oa'~' o~~ov
U o y o o o woo~n yoo~n ~~o~
oo~n ~ov woo~
Q ~ z ~ ~ j j O ~ j ~ N ~ j ~ N O
O v i O O ~ O ~ i
i i
N n NO ONO NO ONO
O~
N
O O O O
O O
.-~ O O ~n M M
~
z a
p ~ ~ ~
~~ O E- 0 0
~ ~
x x x x x x
N M M ~t
CA 02283299 1999-09-02
WO 98/39448 PCT/LTS98/04493
147
o O o. o
pO 'd' M M N M N
U 4.. ~ ~ C O~ .-r .-.,
t'_~. p V ~ M N M ~-
a-'~ ~Cl.
~~4. ao~
~00000~0
o a,
w
n ~ n
v ~ '~ f.~. 00 Wo
in N .-.
w
p C~ r1' ~ ~ ~ N
in V N
....., ,r, N v, ~ O
M~~0~1~~OMO
ef in M N --r
V1 00 ~ tt
z p p ~, .... .-, ~ ~ ~ N
M N 'o
~E-.v'~v~~~~°
M
~z~ ~. ~ N ~ 00
,'~ N N ~ N ~ N
p Q "~ d' 'd Q Q
j N N N N N N .
.C .~
r.. N l~ r' I~ ~' I~- ~'~' l~ ~ I~ (~ ('~ l~
~ N GT ~ Ov N Ov ~ ~ N Ov ~ Cv N ~ ~ Ov N Ov ~ ~ N U ~ CT
U ~ ° c ~ n ~ c~ n ~~o n ~~~ n °~~~ n ~~~ n
apz ~ ~cV~ n~c~°N n~N° n~cy~V"~'~ ~ i~ n~N~ n
O O O O O O O O O O O O
N
z~ ~ c~ ~ ~ a
a
x x x x x x
CA 02283299 1999-09-02
WO 98/39448 PCTJUS98/04493
148
~ M OM
O~ (
G
-p ~ O V ~ M ~~ N N N
.~
O~~ c~ M ~ N N N
~'
..,
Ar
v O Q, ~ N V'
ad ~
~ p '~' ~ '-"' ~ N
,,
w
N ch
O ~ ~ ~ ~ Q1 N
'~ U
~-~ rt 00 ~ N V'1
z w '~t N 00 M v0
O 0 ~ I~ N ~ O~ ~O v7
M
~ ~ ~ i
p 0 p ~ N
"" p
E-~ a" ~ t ~
z~ ~ ~ o
~ o
N M cf
M M l~ M M M
.
Q
Q Q d a fix
N N N N
a,
.r a~ ~~~ ~~~ ~~--~ ~ ~ c~~c~ c~~t~
U Wn N e"d N Oy. N py. N py. N Oy. N ~ N O~
Ov O~ ~ O~ ~ ~ ~.
O~
O A U o~o~n o coin o~aO~n ~~0~ ~~o~
WoO~
b ~ N ~ N ~ j ~ N ~ ~I ~ N
~ ~n ~ i ~ i ~ in ~ i ~ i
O O O O O O O O O
O O O
'~ ~, ~, M ..-. M
L ~ ~O ~O ~' M N
N ~ Q
z~ c m aa u o
7 a
~ ~ ~ N
U ~ U" Q Ar
x x x x
x
O N N N
N N N N
..-. ~. ~.
r ~.
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
149
~ '
vi7 ~ ~ M
'~7
:j O
~
_ _
b ~i' M M ~ N
O V .~
~_ ~ O
~"'
C1
ur ~
~
O O c0
0
z~ ~b N
O y .-, O o0 N ,~ 00
O .-. ..~ t' W 1
C/7 .-, .-.
'~ U
zw~~ '' o
O ~ ~ .-. 01 d' C'~ M
C/~ N .~ ..~ N
z o
o
o 'r' ~n
U v~ ,~ -"
o~ ~
O N ~ N Ov
~
x M M M ~ M
-. N .-r -
.. .
o ~ a. N N ~ G.
d -~ x -d x d
' c ~ ~ ' c
a
a~ ~ ~ t~ ~ r~ ~ c~ c~ ~ c~ t1
U'~N i o~ o~ o~ o~~' ' o,
~ ~' ,~ Q' ~ oa' o~
~ .~' ~ ~ ~
~
~
H Q,O ~ GTN C~N -~ O~N O~N
Z G~N ~ ~ G~N~. ~ ~
~ ., ~ O ~ O ~ ~
~ 1 ~ ~ ~ O ~
O ~
~' O
~ O N N O N (~ N
d A 'v (~ ~ O O O
j O
v
'1
O
O O O O O O O
M ~h d' O~ ~D
a~ ~ x x x x >
~ x
~ w ~ ~
x x x x x x
z N N N N N N
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
150
O y ~ Q '
D M 00 ~i
.
'b a O V N M M N
~
N t_-~ ~
O
,a._, d4
Cs. N ~ M N
O ~ ~
~ ,'''~'J. .-~ .-,
~ ~'
~~~o~.
z
_
~"' i- '~ i '~' o
~ ~ ~ (3r \D ~ ~ ~ M
C
z o ~b
'O M
Y
7
O~ ~, N
w
o '
O "'_' ~' N (~ ~ 00
j
~
v-, U
~
~ d' N t~ ~ 41
(%
'~t ~f' d'
x x x x ~ x
O a~ r~ Q. a.
_ Q
N N N ~
' N ~ N
~
C C C C C
N t~ I~ I~ !'~ I~ I~ ~ I~ [~ C'~ [~ (~
U'~nN ~ Np~~~ NOV~O~ NOv~C~ Np~~~ NOv~Ov NOv~~
U Ll ~~o ~~oo ~o~ ~~o ~~o ~~o
n n n n n
~ N N i N ~ N
N i ~ N N
j ~ O~ ~ ~ 01 O~ N ~
~ N N O
~ O
~
C O O O O O p O O C
~
d ~ Q j ~ U
d
Gl o m ~1 ~ C7
~U
x x
x ~ x
G
O -~ N N M ~t
M M M M M M
CA 02283299 1999-09-02
WO 98/39448 PCT/US98104493
151
o~o o ~- o ff ..."
,_, M N
~ O
_ _ _ _
~ L~ M N M N M N
~ 0.
ur
a ~ 4~
O~ ~ N ~ N OM N
~
' b4 ~
._.
O ~ ~
vp ~D
"b ~ ~ N
~ v0
~n .-~ M ....
z~.=~ N ~ N ~ o
O ~ N ~ N N
M
z
~
~
~n U
~ E-' o- '_'~ -- ~ oo vo t~
z v o cue. ~ ~ ~ M
~
i
za~ox ~ N ~ N dI~'
z
~, ~, ~ x
. .
U U U U
N N
U
U
~
GG ~ a7 C~G1 C C
Q. Cw LL Q.
...~ U f~~ L.- I~.
l'"~ f~ h N Qv N ~ N ~
N Q1 N O~ N O~ ~ O~ ~ O~ ~ ~
~ O~ ~ Ov ~ O~
~~o ~~o~ ~o n ~ ~o ~o n ~ oo
n n n
~ z ~ O ~ O N O O N O O ~
i
Q O~ N tn y ~n ~ Q1 N
N O~ N Ov ~ N 01 N
N N N N
O O O O O O
O O O O O O
O O ~ ~ ~ 'n
~
z
> > z z
C 3 3
'
"
U
x x
x ~ x x
W n v~
M M M M M M
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
152
..-_ ~ N ~ O~
CJ ("~ '~t V~ M M
~ O_
a
'
_
'Z7 ~ M --~ N M c'~
O s""
~
~.L
'+. ~ ~'' 00 M N --~ O N
O (% M --~ N M M
~ ~
O C!) ~
~t ~' N d'
O ~
Gr t~ N N ~' ~ N
C
z ,~, ~ O ~ -. ~ ~ ~r
O ~ U I~~ N ~t ~' N
z ~, ~ ~- ~ ~ ~ ~
O ~ ~ O oo y n vo
M N
~ ~ ~ O
~ N ~ .~ v~ N
U v' t~
n
F~ a'
O z ~ O oo y n ~n
E-a C/~ ~
N .-., -- N
za~ v ~ N o
O~C
z N
Q, T1.
Q
N
N N N
'c ~c ~c
U'~N s o~~~ o~~~ o~~a' o~~' oo'~' o~~~
U G Woo~n ~o~n .noon ~o~n ~o~n ~o~n
1 n i ~ ~ N
n
Ov N Q\ N O~ N Ov N av 01
~ ~ ~ ~ ~ N ~
~
O O O O O O O O p O p O
N O O ~ O O
3
UU
x x x x x x
00 0~ ~ o
M M M ~1' Wit' d'
CA 02283299 1999-09-02
WO 98139448 PCT/US98/04493
153
_.
,_",, N
'~
M I N
N N N N
N
~
4. 04 G.
~ ~ ~1 N N N NO
..-., .--~ ~.
~a~''
H
o
w
w
z~~
v~ V ~ ~ ~ ~' r o~"o
M ~ N M
O C~
O
z 4. c a. o ~ o~
V~ ~ ~ cw
E-' ~' ~ ~ 00 O M M
Hz~ ~ ~ ~ o
x
~ ~ x
. ,
. .
0 0 ~ ~ ~.,
~ ~ ..~
j
.
~ A
. .
'
U
~ N ~
U ~ ycov~ yoo~n ~~o~n ~~o~n ~~o~n ~~o~n
Q ~ z b ~ N Ov N O~ ~ Ov N ~U N
~ V~"'t~ ~ ~ ~ ~ ~ ~ ~
1
O O O O O O O O
p p O O
t~ I~
z~ ~ ~ ~ ~
n x
H ~ ~ w w
x ~ x x x x
N M M ~ v~ 4n
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
154
'-' ,n ~ N
V7 ~ ~ M V7
O M
~a
_ ~ O_ _
a O V .~ N M N M N N
s_.. ~ O
G
~
.
~~w
O ~ ~ N M N ~ N N
O ~ ~
'
.
~
~
~
E" N N
n O c~ a
c ~ ~ N M
,
O
~ ~ ~ ~ N N
~
C
O
M
N N N ~,'
O ~ ~ 00 ~_ N oNo
U o0 ~ ~
N
M
" ~ ~
O ~ O
"_'
' V ~' w V~
H Q' 00 O~ ~ 00
0~ 00 ~
N N
za~ N
~
O' N N N
>C >C x ~. N
o A, G, .~ .~ Q
~ ~
U Q Q O O Q a~ 'O ~
N N ~ ~ N
s3., n. y
p"
U'~nN c~ ~~~r' ~a'~t'MpQ'~t'~a'~t' M' oQ'rt, o\'
~
U ~ L1 ~~o~ ~~o~n ~~om ~~o~n ~r, yoo~ ~~c
~
O z ~ ~ N ~ N N O N O O j O Ov N
O ~ O ~ ~ i O ~ O v~
O
Q N v7 1 O~ NO v NO
~ N D\ NO NO
N
c O O 0 O O O
O O p
I1 M M M N
O O
C7
~
o z z w w x a
~
_ x x x x z x x
c~
~r
r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
155
N o0 M cf'
~ C
N
U '~ ,
~
~
+, ~" ,_, (~ .-r
. M M ~~ M
b ~ O ~'
LJ
W _-. ~
O
A
~
"'
~L V1
w
O O O ~O O
~ ~
4 ~.
G
_ ""' "'
O ~
Ar
E"'' v O v N o0
a3 G O
, _ '
'
ct ~ O N N vp
C
w
0
w C Q' ~ O h- MO
Z
0 o a, O
~ ~ O
V7 N .-, N
M (~
N
~ ~ N
v~, U 'r~ --~
Q_\
Z V7 00
~-' N Ov N
C/~
vp N ~L7 N v0
x x x x
x x x x x
Q Q a Q d
' N N N N N
v ~. ~ W~- ~ r- c, ~ ~ r. ~
U~ ~ Mp MQ Mp MQ M~~Q~
~ M~~O ~~O ~ ~~O T
~ 1~0 ~ 1~C
~nN _ _ _ _ _ 1 ~
_ _ _ _ \
~ ~ L ~ ~ yD O ~ ~D yD O yD O ~
V7 ~n O ~n ~ vo
z .b O ~ O N 1' O O ~ O ~
O ~
'~ L ~ N CT N V Q, N O~ N Ov N
O p t ~ p p
Q, N 1
p p
O O O O O O
z~ v w w
n x a
o
_ x ~ x
~U
x x x
--~ --~ N N M
c~
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
156
ocL ~ ~ ~ o
~,] O M M N
~ _O _
b a O ~-' lp ~' M ~' M
t'.
c~ L_ y O
Or
~ ~ ~
O ~ ~ ~ M
O ~ ~
O
~ N ~
Ov ~t 0
G. N M N V'~ M 0
N
z orb
N M N N
O 00 ~ 00 ~-W D
z 4-. ~ Q' ~ f~- M N
M
N N N
C ~' ~ Q' ~D M O
~ M
0 O l~ I~ 00 00 ~
N N W t' M
V1 O M ~ M ~_O
M N
N
x ~ x x x x
x x x x x x
d Q Q d Q d
N N N N N N
' a'
U'~N ~ oa~~' oo'~' v' oQ'~Q' oa'v o~~av
oo' '
yoo~ ~~o~n yoo~n yoom ~~o~n yoo~n
O ~ O ~ ~' ' N O N O
N O N O ~
pv N O~ N V V O~ O~
N N 1 Q~ NO ~
Ov ~ NO
N NO
O O O O O O
O O O
00 ~ ~ ~
~ 0
N r-~ '.~ ~ LZ,
x x
x x x x x x
' ~ ~t v, Tw o t~
r r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
157
O N M
N ~ N
~ O_
.
b a s" ~ N '~t N
~
N V~' N
~_ p
N ~ M
w~ _
z~.~ o ~ . ~ N
_~ O
_ M N ~7
~ f1.
LL
,
G _
O 0 ~ p ~ N
opU ~, N o ,n
f-~ ~.,... w o o' .~ o
c a~ 0 0
z
o~ ~ ~
M N
G ~ 00 00
\o
o v ~ v
E"" ~ O~ ~ N 00 O
t,-
x .~ x x
k a x ~C
O ~ U U
v..
Q Q Q" ~r
j N ~ ~ N N urn
a~ o Q
. ~ ~ .
a~ r~ 4., c~ o~ ~. a~ ~ o~ ~ c~ r- a~
U ~ v~ N ~ c, c~ ~ c~ ~
~ M O~ M (T M (7~ M ~ tr1 M p~
01 ~ O~ a1 ~ ~ O'~
Uo ~ ~~on ~~,~n ~~on ~oon ~~on ~c>on
Q O~ N Q1 N Ov N Ov N Qv N O~ N
' z O ~ O ~ O ~ O ~ O ~ O ~
L O O N O O O O O N O O
~
O O O
00
A N N N N N
Q
c ~
~ ~ 2 U
o
~ U d
x x x x x
v c~ oo ~ O O
. .
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
158
N
N o0
V7 M M
~ .~ N
U Q c
j
. ...., . N
i., M M
~
~
'J c,._,
D~ Q. O O
~ ~
Q
~'~~.
z w ~ ~n M N ~ .~ o
c a
~ ~ ~ ~~ ~ ~ M
~ Gr
LZ
r
Z ''-" ~ ~ M N ~ '~ O
b
~ U ~ '~t Ov ~ M
H a~ ' -. 00
O M O N
0~~ ~ ~ ~ N oNo
cn
z c~-. C l~ M N ~ N
p'
00 00 ~ ~ N ,n
o ~ o
,_, N
'~ o0
--~ .-, N .-. .-., M
rl7
za~~x ~ N ~ N ~ N
p. O. D., C1.
U U U U
~ ~ ~
~v~ ~cn ~v~ av~ N N
o o o Wi
. . . n.
V N I~ ~ I~ I~ ~ h I~ ~ t~ ~ f~
"' M ~ M ~ M p1 M O~ M O~ M ~
~ O~ ~ CT ~ O~ ~ O~ ~ G~ ~ O~
~ ~
on ~~p ~~on ~ oon ~~'pon ~~on
~~ o~n
Z ~ h ~ N N ~
~ ~ ~ N
~ N ~ Ov N Ov N ~ ~ 0 V
Q ~ V ~ ~ Ov ~ O~
o O O 1
O
O O O O O O O O O
a
a a w Q Q
UU
x
x x ~ x
N N M M ~i'
~ r
CA 02283299 1999-09-02
WO 98139448 PCT/US98/04493
159
w ~ ~ N N ~ t~
O O ~ N U1 ~D N N
Q
U d w N V'7 Ov \p M N N
.O N ~ N N N N
O
4
~ ~
w b,0 d.
O ~ ~ N N N N N
~ LL~
~t' v~~ 'd. ~t.
w
z
~
~'
o
~
E" M
O M .-.
U
v" O M ~ ~ U V1
N N ~ V1
M
w C p d~ o~o Q\
-, .-.. ....
O O ~ ~ M ~ .
in U
~N
~
~
z
,
~,
z,~ox ~ N
x x
x x ~.
.
Q Q a ~x Q
N N N ,~v~ N N
'c 'c
a
a
U in N ~ M ~ M Q~1 M ~ M ~ M Q1 C'~
~ ~ ~ O~ ~ ' ~ O~ ~ O~ O~
~ ~
O ~ ~ N O~ N ~ N ~ N ~ N ~ N
U p ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
, . ~ ! ~N~ ~N~~ ~Ny1
~ ~ ~N V
~
~ N~ vN~ ~~ 1 O O O
O O O
c p O p O O O p
m_ n vn
M M
x O N N
w Q
~
A O ~ x N
0. G.
x x x x
CA 02283299 1999-09-02
WO 98139448 PCT/US98l04493
160
N
~D M ct
U Q c,..,
-~ L O V M N N M N OM
O
cue, by
L1~ ~ N N ~ N N
O rj~ ~
~'i'.. ~ ....
O G4C3r
Cn
z~,~O~tl. N N V1 ~ O
V1 O LL O\ ~ ~ ~ O -,
Q
Cl
V~
C
4.. O N N
'r, o, ~ ate.
U
M V1 N
Q\
N M ~ N
~" O" Ov O ~D
tn M ~ O~ O~
z~~ox ~ ~ ~ o
N r.. --~ M
G3. Q, L~..
Q a Q
N N ~ N N N
U.oN i ~O~Ov pOvO~~ p~0~0~ pOvO~Ovp~O,~s pO~O,~s
~
U p O ~~oo~n ~~oo~n ~~o~n ~~oo~n ~~o~n
~~o~n
<C 0 z O Ov N ~ N O~ N O~ N Ov ~
O~ O ~ O N O i O ~ O ~
j
~ O O O O O O p
O
O O O O
Oy Y d'
~r
v
Q ~ ~
~ ~ ~ ~
v
x x x x x x
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
161
~4.,~ ~ ~ cT r
~ fJ N
U _.
O
'~
U _
c._, N N ~ M ~ M
q~
.
b
v
O
i'
~
U
i_..
~
O
'~
LL
(/~
L1..
~_
O V O N ~ O O~ O
l (Z, J
~W
O
~
~
'"
0
r
G1, r M M ~ ~ N
~!7 N
r
r~ ~ M M ~ N
U N
z~~~ o ~ ~ ~ _.
H
O ~ In M N ~ .-.
~ "
U
V7
M ~ ~r N N .-~ .-.
__ .
r r
~
~'
n
U
off o ~ ~ o
~
E-' ~ N N
z
~
N N
z'~o~ ~ ~ o ~ o
M -~ M
~' C1' '~ ~v
y0 Ar U ~ U ~ G, C, Qr
N ~ x N N N
~ ~r
n
U'~N ~~p~ d~~~~ ~t~~~ ~~~ ~ror\,~~~~~
~
U yoo~n yoo~n ~~ov, yoo~ voo~n o
o ~
L1 ~N
.~
E_"
C
U rvOv rvOv rvOv rNO~ r'O\ O
~'O ~ O ~ p ~ p ~ O ~ p ~ p
N O N O N N O N O N O
O
N N
z Q ~ m as as
~
w w
x x x x x z
M ~t ~ V'1
r r r r r r
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
162
o ~n
M M M N N N
.-~ O
_ _
Lj a O V N trt ct M ~'
, i~
~ O
N
Ar
~ ~
~_~' N O M O oO
~
G4 ~.
G ~ ~
da~
~"
z
0
z~-~ ~ ~ ~ ~ o
=~
~ ~P ~-~ l~ ~ ~ rt'
LL
z
~
o
v
z ~. ~ ~- ~ ~ ~ '
O 0 ~ t/W 1 ~ N
z
a ~
o ~t ~. c~ a, N
U ~
E"'~ ~ 00 O M ~ O~
~z~
0 0~0 0 0 0 0~0
~ x
x x x
Q Q Q Q Q d
N N N N N N
~o~ ~o~ ~o~ ~o~'' ~o~ ~o~
U'~N ~ o~~n' ~~n' oa'm' ~a',n' o~inv' o~v~o~
(~ ~p o ~ o ~ o ~p o ~ ~p
v> ~p o W p ~n ~n o n
~ o ~n
z b ~ ~ N N ~ Ov N O~ N
O v ~ ~ ~ ~1
Q ~ O~ N O~ N ~ 7 O O O
~ ~ O~ Ov
O O
p O p O O O O
~ ~ v Q
z m Q a
~ w Q Q
x u x x x x
.~
x
T
CA 02283299 1999-09-02
WO 98/39448 PCT/US98/04493
163
cat ~ p ~ v7 ~ ~ M ~ O~
N N M -
'~
w c~ .... ..-.~
V M M M M M
~d V O V
~
_i.. v O
''W ~G~
"~ w bD ~L
0 O ~ M M
t .--~ .-r
.~.. ~
_ . .-,
O C/~ Gr
LT.
o
LL N M d
O
~ M ~ o
z ~
~
o M N M
b
C~
U
O ~ ~ - N
O ,~
M
o' o
z
o ~ N ~" N M
~
V7 U
h ~ O ~ M
n
~z~ o ,~ ~ o
o
N N
a ~ o 0
x x ~. .~ .. x
x ~ ~. ~ x
O Clr G.i U ~ U ~ U ~ G.
' ~ ~ ~
N N ~ ~ ~ N
j
' ,''o~ r.oc~ ,r~or" nor""' ~o~ r..
U'N ~ oyna' oo~v.,ayv~,~,oyo,",o~oo~,~o~oQ.".,ov
U o D ~~o~n yoov~ ~~oov, ~ c ~ oaf ~~o~n
o~n
~ N O~ N O~ N ~ N ~ N ~ N
~ ~ ~ ~ N tr ~ ~ ~ ~ Q V1
O O O O O O O
O O O O O
00 00 00 00 00
Q O O
0 p W W ~.t, G.t, ti.
U x
x x x
O O ~~ ~ ~ N
CA 02283299 1999-09-02
WO 98/39448 ~ PCT/US98/04493
164
OO ~ ~ ~ N
~ N
Q
Q
O
~+. a ~ ~ O~ N ~-~ O~
~p ~ O V M ~~ M
~
N L ~ ~O
L
O oo O o0
4r ~_
4..n rr ...w
~
O
N ~ M_
~D V' ~O '~t ~G
~ O
~ ~ ~ d' N
O
LL N
in
C%~
z
b
o ~ ~ c= ~ ~ o
Q\ ~Y N .-.
Z ~+. ~ 0~0 N ~ N
O"
O ~ ~ N O O O
M
F-' C Q" O O d. ~D N
O U ~ ~ ~ O Ov
O ~
~ M O O O O
N N M M
a o ate.
M
Q Q Q d Q Q
N N N N N N
. .
~ c
U'~N c"d o~~n' oyn' ~~~n' oo'mQ' oa'm' oyno~
A ~ N ~ O~ N Ov CT N O~ N O~ N
U G ~ ~ ~ N ~ ~ ~ ~ ~ ~
~
~
. O ~ N ~ N ~ Ov N Q~ N
z N N ~ ~ ~ ~ ~
1
~ Ov N N ~ O~ O O
Q; ~ ~ O~ ~ O
O
O O O O O O O O
,n ~ N N O O
M M M M 00 00
~1 ~ ~ G~, C~., CG1 ~Cl
O
_ x x x x x
M M ~ cf
00 00 00 00 00 00
~z
CA 02283299 1999-09-02
WO 98/39448 PCT/LTS98/04493
165
s~
o o ~ o
...
O
~ a
U Q c,.., ~.,
~ .
U
M N
~ u.
w
~ OM N
~y
O G_A ~. .-,
G. N O~
G
z 'a-' ~
b
N N
U N CT
~," c a- ov
o\
z
o o ci~ o00
M
H
'
i
U
n
N N
ox
M
N
N
U'~N ~ 'a'~"~,~~ro~~,,~.,~
U L1 ~ oo~ oo~n
.
Q ~
z b
L~ ~ NO NO
O O
~t d'
~ Q Q
O
_ x x
UU
z
s
DEMANDES OU BREVETS VOLUMtNEUX
LA PRESENTS PARTIE DE CETTE DEMANDS OU CE BREVET
COMPREND PLUS Di'UN TOME.
CECI EST LE TOME ~ DE
NOTE: Pour les tomes additionels, veuillez contacter le Bureau canadien des
brevets
JUMBO APPLlCATIONS/PATENTS
THiS SECTION OF T1~IE APPLICAT10N/PATENT CONTAINS MORE
THAN ONE VOLUME
THIS IS VOLUME _~_ OF
NOTE: Far additional vo~iumes-pl~ase.cantact the Canadian Patent Office .
